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Abstract 
Niemann-Pick type C disease (NPCD) is a ruinous condition that mostly affects children.  Although 
stemming from a single genetic error its pathology involves dysfunction of multiple organs especially 
liver, spleen and brain.  Life expectancy is dramatically reduced. 
NPCD is usually caused by a mutation in NPC1 a protein located in the lysosome, the cell’s recycling 
centre, and believed to export cholesterol from there for use elsewhere in the cell.  Consequently 
NPCD patients accumulate cholesterol in their lysosomes.  Extensive research has found that mutation 
of this single protein restricted to one organelle has effects that encompass almost every aspect of 
cellular function.  This is rather surprising so chapter 1 attempts to piece together what we know to 
give as coherent and complete an account as possible of the cellular pathology of this disease 
including insights gathered from the various treatment approaches tried to date. 
Using a combined docking-molecular dynamics approach Chapter 2 supports the idea, previously 
advanced from in vitro experiments, that NPC1 and its partner NPC2 may also bind sphingosine, the 
simplest sphingolipid.  This chapter also uses docking to understand some previously observed, but 
not fully explained, aspects of lysosomal dysfunction in NPCD including reduced big potassium 
channel activity, annexin mislocalisation and impaired SNARE recycling.  These errors are traced 
ultimately to cholesterol accumulation but pathological roles are found for other lipids which also 
accumulate in this disease 
Chapter 3 finds that lysosomal pH is increased in fibroblasts from NPC1-deficient patient fibroblasts; 
inhibtion of glucocerbrosidase 2 (GBA2), the only clinically approved NPCD treatment, corrects this 
error.  The same treatment is not effective in other Niemann-Pick variants.  Only limited and 
preliminary success was encounted when GBA2 inhibition was examined as a potential treatment for 
related diseases. 
Chapter 4 finds that the mitochondrial defect in NPCD is not responsive to GBA2 inhibition nor to 
manipulation of sphingolipids more widely.  Attempts at correcting this error by manipulating 
mitochondrial cholesterol, widely believed to be elevated to levels toxic to this organelle, were not 
clearly effective. 
Chapter 5 draws the various threads of this thesis together and combines them with very recent work 
published elsewhere to sketch an integrated cellular pathology of NPCD. 
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Whilst this thesis will range widely over neurodegenerative diseases of children and 
adults the focus will be on Niemann-Pick type C disease (NPCD) which will serve 
as an exemplar of the complexity of these conditions.  First described in 1914 and 
affecting approximately 1 in 150,000 live births,1 NPCD is characterised by diverse 
symptoms affecting liver, spleen, motor control and brain; premature death 
invariably results.2,3  Its molecular origins were traced, as late as 1997, to a protein 
of late endosomes and lysosomes which was named NPC1.4,5 
 
NPC1 
 
Behold, I show you a mystery. 
Paul the apostle 
First letter to the Corinthians 
 
Despite years of research the functions of NPC1 still resist simple definition.  It has 
been proposed as an exporter of lipophilic molecules6 and amines,7 and to bind 
sphingolipids8 and mycolic acids.9  However the emphasis has been on this protein 
as a cholesterol exporter following the recognition that it possess a sterol sensing 
domain (SSD).4  Mutations in the SSD were found to impede cholesterol export from 
the lysosome10 and to reduce labelling of the protein by a fluorescent cholesterol 
analogue.11  The developing view of the pathogenesis of NPCD was complicated 
somewhat by the discovery that a second lysosomal protein, termed NPC2, was also 
involved in the disease.12  However this molecule was swiftly established as capable 
of binding cholesterol13,14 and subsequent studies confirmed this.15,16  The idea that 
NPC1 and -2 act together was put forward17,18 and has been confirmed and refined 
by later work.  Thus within the lysosome NPC2 collects cholesterol19 and conveys it 
to NPC1 in the limiting membrane.  This account has been refined and developed 
though it retains its difficulties to which we shall return in subsequent chapters.  
Beyond controversy (eg4) is that mutant NPC1 or -2 lead to accumulation (often 
termed storage) of cholesterol in late endosomes and lysosomes of NPCD patients.  
This condition thus constitutes a member of the class of lysosomal storage disorders 
(LSDs) but is unusual in that category as most such diseases derive from failure of 
catabolism rather than from failure of export.  Cholesterol in the lysosome is mostly 
derived from low density lipoprotein (LDL) via the process of endocytosis. 
NPC1 serves to 
export cholesterol 
from lysosomes; 
mutation leads to 
cholesterol storage 
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Endocytosis 
Endocytosis is a constitutive process by which cells internalise nutrients and turn 
over their outer membranes.  There are at least three varieties known to modern 
biology (Figure 1).  The best studied depends on the protein clathrin which 
accumulates in regions of the plasma membrane and forms pits (Figure 1, ❶). These 
pits contain certain receptors such as that for LDL and the iron-binding protein 
transferrin.  Clathrin induces a curvature in the membrane that eventually becomes 
so pronounced that the pit is almost separated from the membrane; the protein 
dynamin completes the separation and an approximately spherical, clathrin-coated 
vesicle forms.  The coat is soon shed and the resulting vesicle proceeds to carry its 
cargo into the cell.  A less well understood mechanism uses the protein caveolin to 
induce membrane curvature and form structures known as caveolae (Figure 1, ❷); 
the insulin receptor is internalised in this way.20  Once a caveola has been pinched 
off it too forms a vesicle.  Similarly the protein galectin-3 can form structurally 
distinct vesicles known as clathrin-independent carriers (CLICs, Figure 1, ❸).21  This 
process depends on glycosphingolipids,21 a class of compound we will meet much 
more extensively later in this chapter.  Once the vesicles are generated by whichever 
mechanism they eventually fuse with bodies known as early endosomes (Figure 1, 
❹).  From here some material is recycled to the cell surface while other is 
progressed along the endocytic pathway to late endosomes (Figure 1, ❺).  The 
regulation of this process is not fully understood but involves both rab proteins and 
phosphoinositide lipids.22,23  Late endosomes are also known as multi-vesicular 
bodies (MVBs) as they feature intra-luminal membranes which is where the original 
endocytic cargo resides (Figure 1, ❻). 
 
Further processing requires the late endosome to fuse with a lysosome.  This in turn 
necessitates them being close in space meaning both organelles must be mobile.  
The small GTPase rab7 attached to the membrane of each organelle contacts motor 
proteins that attach to the cytoskeleton24–26 and allow the requisite movement.  (As 
rab7 is present on both late endosomes and lysosomes it is not possible to distinguish 
the two sets of organelles precisely so the term ‘late endolysosome’ (LEL) will be 
used here to include both).  Merging of endocytic vesicles may also require annexin 
A2 (AnxA2),27,28 possibly through its ability to mediate membrane fusion events.29  
The definite requirements are the initial formation of a tether between rab7 and a 
cognate effector, probably the HOPS complex30 (Figure 1, ❼), release of calcium 
ions31 (Figure 1, ❽) and finally formation of a SNARE complex (Figure 1, ❾) from 
.  
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Figure 1  Schematic of endocytosis  For details see text   
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proteins on the surface of each partner.  For endocytosis these SNAREs are syntaxin 
7 (Stx7) and VAMP8.32–34   
 
Once the hybrid organelle has formed from an endosome and a lysosome catabolism 
of the contents is performed by an array of enzymes; the pH optima of many of 
these enzymes are low35 thus an acidic  environment is necessary.   Acidity is 
achieved by the activity of the vacuolar ATPase pump (vATPase, Figure 1, ❿)36 
inhibition of which is reported by some studies to lead to widespread failure of 
endocytosis.37,38  Metabolites generated in the LEL are exported (Figure 1, ⓫) by a 
variety of proteins including NPC1, the lysosome reforms (Figure 1, ⓬) while the 
rab and SNARE proteins are removed from the membrane to be reused (Figure 1, 
⓭). 
 
In addition to the failure to export cholesterol from the LEL a variety of experiments 
have detected multiple transport defects in Niemann-Pick cells39–45 including a 
slowing of the entire endocytic process.40,43  How can an accumulation of a single 
metabolite have such wide-ranging effects?  As we have already seen (Figure 1) 
endocytosis relies on an extensive, complex set of protein machines to function.  
There is a growing appreciation of the interaction of lipids, especially cholesterol 
(eg46,47), with proteins and that this interaction has functional consequences.  Could 
the origins of the endocytic defect in NPCD result from protein dysfunction induced 
by cholesterol accumulation? 
 
Successive investigations have indeed found it to be so.  Thus under conditions of 
high cholesterol content such as pertain in NPCD the endolysosomal protein ORP1L 
undergoes conformational change.24,48  Through a complex of proteins, including 
rab7, this associates the motor protein dynein with the organelle.  Dynein is 
responsible for movement to the minus-end of microtubules, which is to say toward 
the cell interior.  In NPCD the endolysosomal cholesterol content is permanently 
high so dynein remains associated and the organelles become immobilised24–26,49,50 
away from the cell periphery24,26,51 and therefore unable to fuse with early 
endosomes  This mechanism also keeps them away from the ER.  This is important 
as the ER is believed to replenish52 endolysosomal calcium stores which have been 
used up in vesicle fusion (Figure 1, ❽) but are needed if the lysosome is to fuse 
with and therefore process the next wave of incoming vesicles.  Indeed lysosomal 
calcium was found to be low in NPCD cells53–55 while blocking the IP3 receptor, a 
channel plausibly implicated in endolysosomal calcium refilling, led to a proliferation 
of endocytic vesicles,56 a characteristic of lysosomal storage diseases (see chapter 
3). 
Accumulating 
cholesterol interacts 
with proteins needed 
for endocytosis; these 
interactions have 
functional 
consequences. 
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Cholesterol accumulation also makes a more direct contribution the endocytic 
defect.  Annexins A227,57 and A658,59 both associate with cholesterol-rich areas of 
membrane and so in NPCD mislocalise to late, rather than early, endosomes;60,61 this 
defect is recapitulated in cells treated with a small molecule blocker of NPC1.27  
Whilst the function(s) of annexins in endocytosis have only been partially 
elucidated27–29 their tendency to associate with cholesterol-rich membranes renders 
likely some role in the NPCD endocytic defect.  Other proteins found in membrane 
subfractions with high cholesterol content include rab7,62 syntaxin762,63 and 
VAMP8.64  As shown above (Figure 1, ⓭) the successful continuation of the 
endocytic cycle requires their removal from membranes for re-use.  This removal is 
retarded for all these proteins when they are present in cholesterol-rich 
membranes,26,50,65 such as those present in NPCD endolysosomes, and so endocytosis 
as a whole is slowed down.26,50  (A similar defect affects NPCD synapses.66)  
Consistently this transport defect can be rescued by over-expression of rab7.41  
(Experiments involving rab7 should be interpreted with caution as this protein has a 
plethora of functions,67 many of which such as cathepsin D maturation,68 
autophagy69,70 and lysosome-mitochondrion contacts71 are likely to be relevant to 
NPCD.  Controlling adequately for all these factors is necessarily challenging.) 
 
It is, however, questionable whether the vATPase proton pump through which these 
organelles acquire the requisite acidic pH is similarly affected by cholesterol.  The 
pH of lysosomes in NPCD cells has been reported as elevated,43,72 though other 
studies find it normal.54,73,74  This issue will be revisited in chapter 3.  Acidification 
will generate an electrical potential52,75,76 and there is debate whether ion fluxes 
mediated by other ion channels in the endolysosomal membrane are necessary to 
balance this.  The debate has been wide-ranging77–79 and will not be entered here, 
though the association of calcium,80 chloride81–83 and potassium84,85 channels with 
neurodegeneration may well be significant.  Indeed even the absence PIKfyve, the 
protein responsible for synthesising the ligand for some calcium channels, results in 
neurodegenerative disease86 perhaps through impaired acidification and consequent 
inhibition of autophagy.87 
 
Autophagy 
Autophagy is the process by which cells degrade worn out organelles and toxic 
proteins.  It begins with the formation of a double-membraned organelle termed the 
phagophore which seals to become an autophagosome.88  This fuses with a lysosome 
to become an autolysosome wherein the necessary degradation occurs and 
metabolites are exported.   
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Given the resemblance of this process to endocytosis we might expect similar 
requirements to pertain, particularly to the organelle fusion step.  Indeed correct 
acidification,89–91 rab7,69,70,92 Ca2+ efflux through the TRPML1 channel,93 Stx1794 
(though not -795) and VAMP796 or -895 have all been reported as necessary.  The 
additional dependence on the correct proportion of membrane cholesterol90,92 raises 
the expectation that autophagy will be slowed in NPCD, just as endocytosis is, and 
that this deficiency may have similar molecular origins.  Such an error would be 
expected to appear as a proliferation of autophagosomes (visualised as positive for 
marker protein LC3-II) as they fail to fuse with lysosomes.  This has indeed been 
repeatedly reported in NPCD (eg97–99). 
 
Nonetheless alternative accounts, only partially consistent, are available.  Work in 
NPC neurones (derived from embryonic stem cells, ESCs) found the autophagic 
pathway not stalled but rather over-active,100 a result echoed in NPC fibroblasts.74,98  
On this model the proliferation of autophagic vesicles (eg98,99) derives from reduced 
clearance of autolysosomes and not from impaired fusion of their precursors.  In 
turn clearance may be slowed by reduced activity of lysosomal proteases the 
cathepsins which was attributed, after elimination of more conventional causes, to 
direct enzyme inhibition by stored lipids.74  
 
From cholesterol storage to protein misregulation 
It is becoming increasingly apparent that lysosomes, rather than being merely waste 
processing units, are fully integrated into the life of the cell.101  Accordingly failure 
of lysosomal metabolite export will have effects that cannot be contained to the 
organelles directly affected but will impact the whole cell.  In the case of cholesterol 
the onward destination from the lysosome has not been fully elucidated - there seem 
to be multiple cholesterol transport pathways operating simultaneously102–105 and 
other proteins seem to have roles that have yet to be discovered.106,107  However it 
is generally agreed that NPCD results in a cholesterol deficit at both the ER108,109 and 
the Golgi110 with consequences for protein regulation (Figure 2 where the suffix * 
denotes a protein in its activated state). 
 
Reduced levels of cholesterol at the Golgi110 (Figure 2, ❶) affect the sterol 
homeostatic protein SREBP and its regulator SCAP.  Under normal conditions 
cholesterol binds to SCAP inducing conformational change and keeping it associated 
with SREBP (Figure 2, ❷).  Under conditions of low Golgi cholesterol, such as 
found in NPCD, SCAP dissociates from SREBP which is therefore broken down by 
Golgi proteases.  A SREBP fragment then migrates to the nucleus (Figure  
 
Autophagy is also 
dysfunctional in NPCD; 
though not certainly for 
the same reasons as 
endocytosis 
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Figure 2  From cholesterol storage to protein misregulation  Cholesterol 
storage in NPCD sets off chains of events that lead ultimately to the over-
expression of certain proteins and the under-expression of others.  For details 
see text 
 
2, ❸)111 where it acts as a transcription factor and upregulates the enzymes involved 
in cholesterol synthesis and uptake111 (Figure 2, ❹).  Thus NPCD produces a cellular 
excess of cholesterol but the defect in its lysosomal export fools the cell into 
believing that it is experiencing a cholesterol deficit.  The cell responds accordingly 
M
A
P
K
* 
TF
E
B
 
S
R
E
B
P
 
L
X
R
 
C
L
E
A
R
 
A
u
to
p
h
a
g
y
 
L
y
s
o
s
o
m
a
l 
e
x
o
c
y
to
s
is
 
C
h
o
le
s
te
ro
l 
s
y
n
th
e
s
is
 
a
n
d
 u
p
ta
k
e
 
A
B
C
A
1
 
TF
E
B
 
TF
E
B
 
L
X
R
 
ca
lc
in
e
u
ri
n
* 
P
L
A
2
* 
C
a
2
+
 
S
R
E
B
P
 
S
C
A
P
 
HO 
N
P
C
1 
C
el
l 
m
em
b
ra
n
e
 
L
ys
o
so
m
e
 
G
o
lg
i 
N
u
cl
eu
s 
❶
 
❷
 
❸
 
❹
 
❺
 
❻
 
❼
 
❽
 
❾
 
❿
 
⓫
 
⓬
 
HO 
Decreased in NPCD Increased in NPCD 
Cholesterol 
TP
C
1,
 
TR
P
M
L
1 
22 
 
by making more cholesterol and attempting to gather more from the extracellular 
medium.112,113 
 
For reasons that have yet to be fully explained (but were alluded to briefly above24,56) 
NPCD lysosomes have lower Ca2+ content than normal53–55 and thus calcium efflux 
is impaired114,115 (Figure 2, ❺).  This in turn leads to a reduced activity of the 
cytosolic phosphatase calcineurin116 (Figure 2, ❻) which hydrolyses transcription 
factor EB (TFEB)117 rendering it active (Figure 2, ❼).  Thus there is less active TFEB 
to translocate to the nucleus.114  TFEB upregulates the CLEAR network118,119 of genes 
necessary for lysosomal function and also enhances autophagy120 and lysosomal 
exocytosis121 (Figure 2, ❽) which lead to cellular off-load of toxic substances and 
their metabolites.  Thus the consequences of reduced lysosomal calcium in NPCD is 
a reduction in all these processes at the transcriptional level as well as through the 
vesicle fusion defect discussed above.  This is reinforced by the over-activation of 
mitogen activated protein kinase (MAPK) in NPCD,122,123 which occurs for reasons 
to be discussed later, as one report makes this enzyme responsible for 
phosphorylating TFEB keeping it inactive124 (Figure 2, ❾).  (A variant account125 
makes the nutrient sensing complex mTORC1 the kinase for TFEB though the impact 
of cholesterol storage on mTOR status is still debated.98,125,126)  MAPK is also known 
to phosphorylate and thereby activate PLA2 (Figure 2, ❿)127,128 which in turn reduces 
the action of the transcription factor liver X receptor (LXR, Figure 2, ⓫) and reduces 
expression of one of its target genes the cell surface cholesterol exporter ABCA1 
(Figure 2, ⓬).129,130  Thus cholesterol is retained in the cell and, again, the net result 
of storage of excess cholesterol is to make the cell behave as though it was suffering 
a cholesterol deficit. 
 
From cholesterol storage to cell death 
As significant as these processes are, we may question whether the errors are serious 
enough in NPCD to account for the progressive cell death seen in patient neurones.  
This can be explained by a complex series of events shown in Figure 3 (the * suffix 
represents a protein in its activated state). 
 
Along with cholesterol NPCD endolysosomes accumulate other lipids including 
sphingomyelin (SM).43,61  These can permeabilise the lysosomal limiting membrane 
(Figure 3, ❶);131–133 the glycocalyx which lines the membrane and protects it from 
the harsh degradative environment of the lysosomal interior is also altered in 
NPCD.134  Such perforations allow molecules usually localised to the lysosomal 
interior to escape into the cytosol; among these are the cathepsin proteases (Figure  
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Figure 3  From cholesterol storage to cell death  Dysfunction in NPCD cells 
activates events that ultimately result in cell death.  For details see text. 
 
3, ❷) which have been shown to damage mitochondria (Figure 3, ❸).133,135  
Mitochondrial damage can also result indirectly from a cellular state known as 
oxidative stress.  Oxidative stress is a harmful increase in reactive oxygen species 
(ROS, hydrogen peroxide, and the superoxide and hydroxide radicals) caused in turn 
by their increased generation (often resulting from mitochondrial leak, Figure 3, ❹) 
or decreased detoxification pathways (such as catalase in peroxisomes).  Increased 
ROS have been observed in NPCD cells136–138 (with patient biochemistry also being 
affected139,140) which leads by an unknown mechanism to the activation of the kinase 
c-Abl (Figure 3, ❺)137,141,142 and thereby to mitochondrial damage.143  Whether 
initiated either by cytosolic cathepsins or by activated c-Abl, mitochondrial damage 
leads to release of respiratory chain protein cytochrome c (cyt c) from mitochondria 
(Figure 3, ❻).133,135,143  This triggers the intrinsic apoptotic pathway144 resulting in 
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the activation of the caspase proteolytic cascade (Figure 3, ❼)145 which ultimately 
dismantles key cellular components including the nuclear envelope and leads to cell 
death.  The extrinsic apoptotic pathway, triggered by binding of TNFα at its receptor 
(Figure 3, ❽), is also up-regulated in NPCD.146  Accordingly both a c-Abl inhibitor147 
and an anti-TNFα antibody148 have demonstrated symptomatic improvement in 
NPCD mice.   
 
A second pathway leads to cell death: in NPCD MAPK is found activated122,123 
(Figure 3, ❾).  The reasons for this are unclear, though MAPK can be activated by 
binding of TNF to its receptor149 and this pathway is up-regulated in NPCD 146 
MAPK activation by this means has not yet been explicitly demonstrated for this 
disease.  More commonly MAPK is regarded as being on the EGFR pathway where 
protein kinase C (PKC) normally serves as a brake150,151 (Figure 3, ❿).  Sphingosine 
(Sph), another lipid that accumulates in NPCD,54 may152,153 or may not154,155 inhibit 
PKC (IC50 at least 1M) so if enough Sph escapes the lysosome to effect inhibition, 
itself an open question, then the brake on the EGFR pathway may be removed 
leading to activated MAPK.  Alternatively localisation may play a role.  In rat brain 
synapse PKC has been found associated with cholesterol and AnxA6.156  If the 
AnxA6 is diverted to lysosomes, as it is in NPCD,61 then the PKC may also be 
removed from proximity to the cell membrane and so to EGFR.  One of the targets 
of aberrantly activated MAPK is the cytoskeletal protein tau () and so in NPCD this 
activation leads to hyperphosphorylated tau (Figure 3, ⓫)122,123 possibly consistent 
with the finding of increased tau in the CSF of NPCD patients.157  This forms 
fibrillary tangles similar to those found in Alzheimer's disease;158 neuronal cell death 
results.  In NPCD cells hyperphosphorylation was reduced in vitro on treatment with 
a MAPK inhibitor.123  An alternative pathway to hyperphosphorylated tau starts with 
the observation that the protein p25, also known as Cdk5R1 and a proteolytic 
fragment of p35, is increased in NPCD.  p25 serves as an activator of cyclin 
dependent kinase 5 (cdk5, Figure 3, ⓬) which then hyperphosphorylates tau;159 
cdk5 inhibition led to reduced phosphorylation and symptomatic improvements in a 
mouse model of NPCD.160 
 
None of the preceding paragraph can be regarded as uncontroversial.  When MAPK 
inhibition was translated from in vitro to a mouse model enzyme activity was indeed 
reduced, but tau phosphorylation was increased and no clinical improvement could 
be observed.161  However, selectivity in kinase inhibition is notoriously hard to 
achieve and the MAPK inhibitor used in both studies123,161 hits a range of enzymes;162 
it is therefore difficult to be clear on the origins of the observed effects.  Similarly 
neither of the cdk inhibitors used160 is selective for cdk5 (data from the ChEMBl 
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database163). The genetic knockout of p35, the cdk5 activating protein, would be 
expected to give more targeted effects but did not result in the expected clinical 
improvements in NPC mice.164 
 
Nonetheless PKC activation has been reported by two groups to result in 
improvements in NPCD cell culture models165,166 which was attributed to a pathway 
involving rab9 and the cytoskeletal protein vimentin (see also167,168);  the possible 
involvement of tau was not examined.  None of the studies cited in this section 
investigates the idea that PKC has a potential role in the regulation of vATPase169 
and the lysosomal potassium channel BK (Figure 3, ⓭),170 proteins we will meet 
again in subsequent chapters. 
 
Mitochondria 
Mitochondrial damage (Figure 3, ❻) raises the expectation of metabolic dysfunction 
in NPCD and indeed reduced mitochondrial potential,55,171 reduced oxygen 
consumption,138,172 reduced ATP production171 and increased levels of lactate138 have 
all been reported alongside increased ROS.136–138  Most workers attribute this 
respiratory impairment not to loss of cyt c, or structurally aberrant mitochondria 
more generally, but to excess mitochondrial cholesterol poisoning the organelle.  
This hypothesis is superficially appealing and also consistent with mitochondrial 
dysfunction induced by cholesterol over-feeding in hepatic173 and pancreatic174 cells.  
However it is also problematic as mechanisms for cholesterol-induced mitochondrial 
toxicity have been postulated but not yet proved.172,175  Additionally mitochondria 
play a role in cellular cholesterol homeostasis for they house Cyp27A1 an enzyme 
responsible for converting cholesterol to 27-hydroxycholesterol, a ligand of the liver 
X receptor (LXR).176  Agonism of this receptor in turn signals increased expression 
of the cell surface cholesterol exporter ABCA1.  Thus high levels of cholesterol at 
the mitochondrion, postulated to account of respiratory dysfunction in NPCD, 
function as a signal that the cell has excess cholesterol and will lead to export of 
this lipid via increased expression of ABCA1.  In fact ABCA1 expression is reduced 
in NPCD129,130 (though other studies disagree113,177) and, as we shall see later, LXR 
agonists have enjoyed some success as therapies.  (The role, if any, of SREBP in 
regulating ABCA1 is unclear with contradictory results having been reported.178,179) 
Different pieces of evidence therefore lead to the construction of different arguments 
for different conclusions regarding the question of cholesterol over-load at the NPCD 
mitochondrion.  The issue could perhaps be settled if cholesterol in control and 
disease mitochondria could be quantitated, but this requires isolation of clean and 
complete mitochondrial samples, a problem noted for its difficulty.180  The NPCD 
studies that work with isolated mitochondria and assess the purity of this cellular 
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fraction do uniformly report increased mitochondrial cholesterol.138,171,181,182  
However in all cases they also find mitochondrial marker proteins in other fractions 
so while these results are highly suggestive they cannot be regarded as conclusive.  
Intriguingly, work with isolated mitochondria from healthy cells171,183 reported a 
decrease in respiration on cholesterol lowering which, taken together with the NPCD 
work, may suggest that mitochondria have a narrow range of tolerable cholesterol 
levels. 
 
The idea that excess cholesterol poisons mitochondria in NPCD also asks how excess 
cholesterol in the LELs might find its way to mitochondria when it never arrives at 
its more expected destinations in the ER or Golgi.108,184  It has been hypothesised 
that lysosomal luminal protein NPC2 transports cholesterol to the LEL outer 
membrane in a manner independent of NPC1185 and from there it is collected by 
steroidogenic acute regulatory protein D3 (StARD3, also known as MLN64)181,186 
and/or StARD1187 and inserted into the mitochondrial membrane.  This pathway, 
and how it might be manipulated for benefit in NPCD, will be investigated in much 
greater detail in chapter 4. 
 
Thus starting from a simple failure of metabolite export, NPCD progresses via 
multiple pathways to affect numerous important cellular functions and results 
ultimately in cell death.  This multi-faceted pathology poses an obvious question to 
those who would treat the disease: which aspect do you target?  Perhaps 
surprisingly, many of the treatment options that have been explored depend upon 
the sphingolipids which co-accumulate with cholesterol in the NPCD lysosome.  
Thus it is important to understand their metabolism - for a recent review see.188 
 
Sphingolipid metabolism 
Sphingolipid synthesis in vivo begins with the condensation of serine with a long-
chain acyl-CoA, usually palmitoyl, mediated by serine palmitoyl transferase (Figure 
4A, ❶).  The reduction of the ketone group thereby generated gives 
dihydrosphingosine (dhSph, also known as sphinganine), acylation of the nitrogen 
with a second long-chain acyl-CoA mediated by ceramide synthase (Figure 4A, ❷) 
gives dihydroceramide before oxidation to give a carbon-carbon double bond yields 
ceramide.  These steps happen in the ER (Figure 4B, ❶, ❷).189  Ceramide  
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Figure 4A  Simplified biochemistry of sphingolipid metabolism  The 
numbered steps are the same as those in Figure 4B which shows subcellular 
localisation 
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Figure 4B  Simplified schematic of sphingolipid metabolism  The 
numbered steps are the same as those in Figure 4A which shows chemical 
structures 
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is then transported to the Golgi in a vesicular manner and also by ceramide transfer 
protein (CERT, also known as StARD11, Figure 4B, ❸).190  Translocation to the 
luminal face of the Golgi membrane allows addition of a zwitterionic head group to 
give sphingomyelin (SM, Figure 4A,B, ❹).  Ceramide remaining on the cytoplasmic 
face can be glycosylated to give glucosylceramide (GlcCer) by the requisite synthase 
GCS (Figure 4A,B, ❺).191,192  GlcCer is thus the simplest glycosphingolipid (GSL).  
GlcCer can then be transferred to the opposite face of the Golgi membrane, likely 
by an indirect mechanism,193 where elaboration to higher GSLs such as gangliosides 
occurs (Figure 4B, ❻).  GlcCer is also transported to the cell membrane (Figure 4B, 
❼) by a non-vesicular route194 mediated by glycolipid transfer protein (GLTP) and 
phosphatidylinositol-four-phosphate adapter protein 2 (FAPP2, also known as 
PLEKHA8) where it eventually emerges on the cell surface (Figure 4B, ❽).194  This 
renders it susceptible to endocytosis and metabolism.  Thus on an internal lysosomal 
membrane GlcCer is hydrolysed to ceramide by glucocerbrosidase (GBA1)195 with 
saposin C as an essential co-factor (Figure 4B, ❾).196  Ceramide is further 
catabolised by acid ceramidase (Figure 4A,B, ❿) to sphingosine (Sph) which is 
returned to the ER by an unknown mechanism (Figure 4B, ⓫) and processed to 
regenerate ceramide (Figure 4B, ⓬).  Sphingosine in the cytosol is generally 
phosphorylated by sphingosine kinase (SphK, Figure 4A, ⓭) to give sphingosine-
1-phosphate (S1P) before irreversible carbon-carbon bond cleavage by S1P lyase 
(Figure 4A, ⓮, zig-zag line marks the bond broken) removes the molecule from the 
sphingolipid pathway completely.  A minor sub-population of GlcCer on the 
cytosolic face of membranes can be hydrolysed by specific enzyme GBA2 (Figure 
4B, ⓯).  These metabolic pathways have several consequences for the life of the 
cell. 
 
Most obviously the localisation of sphingolipid metabolic enzymes means the two 
sides of the lipid bilayers which form cell and organelle membranes are 
inequivalent.197  Ceramide is glycosylated only on the cytosolic face of the Golgi 
membrane, and subsequent processes preserve the asymmetry this induces.  For 
example GLTP and FAPP2 transport GlcCer to the cell membrane (Figure 4B, ❼)194 
where they are believed to interact with existing lipids198 to insert GlcCer.  This 
insertion necessarily occurs only on the cytosolic (inner) leaflet.  Equally endocytosis 
does not disturb membrane asymmetry: note that the receptor on the cell surface 
(Figure 1, ❶) progresses exclusively to the luminal face of the endosome (Figure 1, 
❹).  This spatial property can, however, be removed by proteins that translocate 
('flip') lipids from one membrane leaflet to the other.  All these features will become 
important later in this chapter and again in chapter 3. 
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Treatment 
Expression 
Histone deacetylases (HDACs) are a family of enzymes involved in regulating gene 
transcription and are over-expressed in NPCD199 possibly as a result of c-Abl 
activation (Figure 3, ❺).200  Consequently inhibition of HDACs leads to increased 
expression of NPC1,201,202 enough of which can then be transported to the lysosome 
where sufficient function is preserved to export stored cholesterol and normalise 
levels of this lipid.199,203  From testing various small molecule inhibitors with different 
selectivity profiles HDAC1 and -2 were tentatively identified as the key enzymes to 
target.201  Experiments in mice have thus far failed to confirm the in vitro promise 
of such compounds.204 
After translation to protein newly synthesised NPC1 is transported from the ER to 
the lysosome chaperoned by Hsp70;205 mutant protein misfolds and is targeted for 
degradation.206  Supplying a small molecule scaffold of the correct shape can cause 
mutant protein to fold correctly and thereby escape proteolysis.  While the structural 
requirements of such an agent have been defined,207 and correct protein localisation 
demonstrated,208 studies have not progressed to disease modification.   
A recent approach seeks to correct protein misfolding by manipulating ER 
calcium.209  While this has been successful in a mouse model of another LSD210 its 
potential in NPCD is currently unclear given that pathology depends on calcium in 
various ways.  
 
Cholesterol 
Trapping excess cholesterol in the lysosome fools the NPCD cell that it is 
experiencing a cholesterol deficit.  We may expect therefore that therapies aimed at 
cholesterol reduction at the whole-body level will be ineffective.  Indeed when 
various combinations of lipid-lowering agents were tried in patients, levels of plasma 
and hepatic cholesterol fell, but no impact on disease was reported.211  In NPCD 
mice nifedipine (a Ca2+-channel blocker, postulated also to induce cholesterol efflux) 
and probucol (an inhibitor of cell surface cholesterol exporter ABCA1) led to 
reductions in hepatic cholesterol but no effect on disabling neurological 
symptoms.212  (Given the later finding that ABCA1 is downregulated in NPCD 
(Figure 2)129,130 this is not surprising.)  Lipid lowering agent clofibrate failed to reduce 
cholesterol levels in disease fibroblasts,213 though given the pleiotropic effects of 
this class of drugs this finding might have been expected.  Statins have recently been 
revisited and found ineffective in iPSC-derived neurones,214 though showing some 
promise in oligodendrocyte culture.215 
31 
 
A subtler approach to cholesterol reduction is an agonist of the liver X receptor 
(LXR) which leads to an increase in ABCA1 levels in turn causing cholesterol offload 
in NPC1-deficient cells.216,217  This increased the lifespan of NPCD mice though 
offered only a very slight improvement in neurological symptoms.218 
Cyclodextrins (CDs) are large hydrophilic molecules containing a hydrophobic cleft  
and are thus suitable for solubilising lipophilic molecules including cholesterol.  A 
range of studies has demonstrated the effectiveness of CDs in treating NPCD, 
though not, as might first be expected, by extracting cholesterol from membranes.219  
Rather CDs are endocytosed219,220 where they sequester excess cholesterol in the LEL 
and return it to circulation – cholesterol is thus exocytosed,219,221 reduced at the 
lysosome220 and increased at the ER;222 cholesterol synthesis is reduced.223  (An 
alternative narrative makes cholesterol normalisation dependent on corrected 
autophagy.224  While an explanation of the reasons behind this is not offered it is 
noteworthy that the sphingolipid field has produced similar findings on the 
interdependence of the two processes.225,226)  Mitochondrial dysfunction is also 
normalised by cyclodextrin treatment,171 though these experiments were conducted 
on isolated mitochondria which questions whether this approach would be 
successful in whole cells.  CDs have been successfully used in mouse models of 
NPCD223,227,228 though a major drawback is their inability to cross the blood-brain 
barrier.229  Use in patients thus requires intrathecal administration; this technique 
underpinned the initial success230,231 of a small clinical trial (NCT01747135), though 
a phase IIb/III clinical trial (NCT02534844) failed to demonstrate statistically 
significant improvement in patients.a 
 
LEL calcium 
As we have already seen NPCD cells have a deficit in endolysosomal Ca2+, as 
demonstrated by multiple studies53–55 (though there has been some disagreement115).  
This might explain the defects in endocytosis and autophagy, both of which depend 
on Ca2+-efflux from the lysosome.  Thus inhibiting Ca2+-uptake by the ER might 
increase cytosolic Ca2+, allow lysosomal stores to refill and so restore LEL function.  
Accordingly curcumin, an inhibitor of the SERCA calcium pump, restored aberrant 
endocytosis in vitro and improved lifespan in NPCD mice.54  While neurological 
defects in the murine model were unaffected by curcumin monothereapy,232,233 the 
benefits of other treatments were amplified.232   
Calcium is also a key intermediary in the pathway of adenosine2A receptor (A2AR) 
agonists the only extra-cellular target successfully investigated to date.  The success 
                                                          
a See https://mallinckrodt.gcs-web.com/static-files/e0712994-a013-4658-b8be-
0a3bc4da0c5b, accessed 21st August 2019. 
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of this approach in correcting both lysosomal and mitochondrial defects in a whole 
cell model55,234 marks it as unique.  Pharmacological experiments suggest a 
downstream effect of A2AR agonism is PKA activation234 consistent with the classical 
pathway of this GPCR (though earlier work in fibroblasts invoked the ERK class of 
MAP kinases instead55).  The pathway between PKA activation and Ca2+-
mobilization is not explored, nor is the idea that PKA can activate CFTR and induce 
lysosomal re-acidification.235,236  The finding that A2AR agonism can lead to 
cholesterol efflux via increased ABCA1 expression237 is likewise neglected.  A2AR 
agonists in NPCD mice give small improvements in neurological symptoms and 
lifespan.238 
Vitamin E component -tocopherol has also been reported to repair the lysosomal 
calcium deficit in NPCD, though the endocytic defect was unaffected.53  Two reports 
claim the almost identical compound -tocopherol is stored alongside cholesterol in 
NPCD,239,240 while another suggests the same molecule as a therapy.241 
 
Sphingolipids 
Some lysosomal storage disorders result from an inability to metabolise gangliosides 
correctly (formed at stage ❻, Figure 4B); these lipids thus accumulate.  The 
observations that NPCD patients have a secondary accumulation of gangliosides and 
present clinically similar symptoms to patients with a deficiency in ganglioside 
metabolism prompted the notion that gangliosides could be pathological in NPCD.242  
Given the absence of small molecule inhibitors of ganglioside synthases a logical 
treatment choice would therefore be to inhibit GlcCer synthesis (stage ❺, Figure 
4A,B) and indeed GCS inhibitor N-butyldeoxynojirimycin (NB-DNJ) proved 
successful at alleviating symptoms in both cat and mouse models of the disease.242  
The first report of the effective treatment of a human patient emerged in 2004243 
and was followed by clinical trials which demonstrated stabilisation of disease 
progression and even some improvements.244,245  These developments led to the 
approval of NB-DNJ (miglustat, Zavesca®, reviewed246) in Europe in 2009.  
Subsequent studies have questioned miglustat's mode of action.  While the 
improvement in a murine model was confirmed, brain lipid analysis showed an 
increase in GlcCer (and no effects on gangliosides GM2 or GM3) - inconsistent with 
its postulated action as a GCS inhibitor.247  Off-target effects at GlcCer hydrolase 
GBA2 were suggested (stage ⓯, figure 4B) and in vitro work later confirmed that 
miglustat was in fact a more potent inhibitor of this enzyme than of the synthase.248  
Use of a rationally designed GBA2 inhibitor249 has recently been effective in treating 
NPCD mice250 while genetic deletion of GM2 or -3 synthases in murine models failed 
to yield improvements.251,252  This is consistent with miglustat being clinically 
effective but not altering GM2 or -3 levels and suggests that these gangliosides are 
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not the toxic lipids in NPCD.  Thus the sub-population of GlcCer on the cytosolic 
face of membranes ('cytosolic GlcCer') emerges as an important factor in NPC 
disease.  This topic will be examined in more detail in chapter 3. 
 
There are some possible commonalities here with Gaucher disease which results 
from loss of function mutations of the lysosomal GlcCer hydrolase GBA1 (Figure 
4B, stage ❾).  Both Gaucher and NPCD feature lysosomal storage of GlcCer, both 
have upregulated GBA2250,253 and both are clinically treated with GBA2 inhibitor 
miglustat.  Thus it may be that, through upregulation of GBA2, GlcCer is the toxic 
lipid in both diseases.  Whether this is genuinely the pathway, and if so whether it 
can be generalisable to other LSDs, remains to be seen. 
 
Another important sphingolipid pool is that of sphingomyelin (SM) in the intra-
lysosomal membranes mentioned above (Figure 1, ❻).  These membranes are rich 
in specialised lipid lysobisphosphatidic acid (LBPA), also known as 
bis(monoacylglycero)phosphate (BMP).254,255  SM is degraded at these membranes 
(analogous to stage ❾, Figure 4B) by acid sphingomyelinase (aSMase), a process 
which depends on the interaction of the enzyme with LBPA.256,257  The activity of 
aSMase is reduced in NPCD256,257 despite normal expression256 and localisation.257  
This contributes to high levels of SM in NPCD endolysosomes which, as noted 
above, can permeabilise the limiting membrane131–133 leading ultimately to apoptosis.  
Hsp70 stabilises the aSMase-LBPA interaction258 and thus dosing recombinant 
Hsp70 corrects errors in a murine model of NPCD.259  (These mice entirely lack 
NPC1 so it was not possible to assess whether Hsp70 also chaperoned transport of 
mutant NPC1 to endolysosomes205 thus giving sufficient NPC1 activity.)  The effect 
could be recapitulated by synthetic Hsp70 inducer arimoclomol.259  A human clinical 
trial (NCT02612129) with this agent has recently concluded with positive results.b  
This research raises other questions.  Both SM260 and LBPA254,255 are reported to 
associate strongly with cholesterol at the intra-luminal membranes; computational 
and model membrane studies also suggest SM has an inhibitory effect on cholesterol 
transfer261,262 and increasing aSMase activity results in increased cholesterol export 
in normal cells.263  More surprisingly, but consistently, increasing aSMase activity 
decreased lysosomal cholesterol in NPCD cells.264  Comparable findings have 
recently been reported with LBPA.265  Thus it would appear to be possible to reduce 
lysosomal cholesterol in NPCD by doing nothing more than altering the population 
                                                          
b See https://www.orphazyme.com/news-feed/2019/1/30/orphazyme-reports-
positive-results-from-full-data-set-of-phase-iiiii-arimoclomol-trial-in-niemann-pick-
disease-type-c-npc, accessed 21st August 2019 
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of another lipid inside the lysosome.  Other work finds that the same result can be 
achieved by over-expression of rab7,41 use of a viral rab7 equivalent,266,267 by 
increasing expression of ABCA1216,217 or by inhibiting O-glycosylation of lysosomal 
membrane proteins.268  At the very least this suggests that NPC1 is not required for 
endolysosomal cholesterol export (though NPC2 may be217,267).  By this account, and 
as previously argued on kinetic grounds,54 cholesterol storage in NPCD is not 
primary but secondary and therefore the main or only function of NPC1 is not 
cholesterol export but some other form of endolysosomal regulation.  We will return 
to these ideas in chapters 2 and 3.   
 
 
This chapter has provided the tools necessary to understand the interplay of lipids 
and proteins, organelles and processes which characterises NPCD cells.  Subsequent 
chapters will investigate how these interactions impact both the pathology and 
treatment of this disease in lysosomal function (chapters 2 and 3), endocytosis 
(chapter 3) and energy production (chapter 4). 
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Aims 
- to investigate computationally the mode of action of NPC1 and -2 and 
particularly the idea that these proteins can process sphingosine in the same 
manner as cholesterol 
- to use in silico tools to ask if the documented endolysosomal errors in NPCD 
cells can be understood in terms of lipid-protein interactions 
- to measure the pH of the endolysosomal compartment in NPCD cells and to find 
if it is altered by GBA2 inhibition 
- to ask if GBA2 inhibition can be a pharmacological treatment for other 
neurodegenerative diseases 
- to measure the impact, if any, of GBA2 inhibition (and sphingolipid 
manipulations more generally) on the mitochondrial defect in NPCD cells 
- to examine pharmacological manipulations of mitochondrial cholesterol overload 
in NPCD cells, postulated to be responsible for the respiratory defect  
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In chapter 1 we briefly and sporadically encountered the idea that cholesterol is not 
the only lipid that accumulates in the lysosomes of Niemann-Pick type C disease 
(NPCD) cells.  The idea to be explicated in this chapter is that these lipids interact 
with lysosomal proteins and that these interactions are ultimately responsible for the 
endocytic and autophagic defects present in NPCD.  These interactions can be 
simulated by computer.  Thus the methods used in this chapter see biological events 
as being essentially chemical, chemical change as driven by physics and physics 
expressed and quantitated by mathematics.  The results derived from such a 
reductionist approach will be better understood with a brief sketch of the reverse 
process: how the basic idealisations of physics can be slowly elaborated to the real 
complexities of biology. 
 
Introduction 
Energy 
It is important to realise that in physics today we have no knowledge of what energy 
is.  
Richard Feynman 
Six Easy Pieces 
 
Our ignorance of energy’s essential nature does not condemn us to a total absence 
of understanding of its role in the world.  We do know that energy comes in different 
forms, such as those relating to electrical charge or to movement.  We can also 
know, and indeed measure, if a given change in a given system either requires work 
to be done to that system, or conversely releases energy that is able to do work.  
Thus closing an electrical circuit releases electrical energy to perform work, for 
example causing a bulb to emit light, whilst pushing a stationary object into motion 
requires work to be done.  Energy able to do work is termed ‘free energy.’  Changes 
that release free energy are favourable and are given a negative sign; changes that 
require free energy to be supplied are unfavourable and are given a positive sign.  
The size of the change is proportional to the degree of favourability or 
unfavourability.  One change that can be quantitated in this way is that of the shape 
of a molecule. 
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Molecular shape and interactions – basic considerations 
Chemical compounds have a molecular structure defined by the constituent atoms 
and the bonds between them, but this does not necessarily define the shape the 
chemical will adopt, and indeed this shape will vary depending on the environment.  
That environment may include other molecules of the same or different types and 
this raises the question of how the molecules will interact with each other.  
(Interactions open the possibility of chemical reactions to give new molecules; the 
treatment here does not consider this possibility as such events are not relevant for 
work discussed in this chapter.)  Both changes in the shape of one molecule and 
changes in interactions between molecules are determined by the free energy 
changes that accompany them – those which are more energetically favoured will 
be more likely.  In turn the free energy changes can be usefully attributed to one of 
three sources: charge-charge interaction, hydrogen bonds and van der Waals 
bonding, all of which are weaker than covalent chemical bonds and vary in strength 
as now discussed. 
 
Some biologically relevant entities such as the potassium ion (Figure 1A) carry 
electrical charges which generate repulsive force between them (Figure 1B) as 
defined by the equation: 
 
𝐹 =  
𝑘𝑞1𝑞2
𝑟2
 
 
where q1 and q2 are the electrical charges, r is the distance between them and k is 
Coulomb’s constant.  Thus forcing two such ions close together (making the inter-
molecular distance small) results in a large, positive free energy change and so is 
unfavourable but at larger distances the energy penalty is much smaller, even 
negligible.  Therefore the interaction energy is not fixed but may take a variety of 
values.  Plots such as Figure 1B, and the equations that underlie them, show what 
the interaction energy may be and so are referred to as potential energy plots, or 
simply potentials.  Of course in more complex systems containing multiple charges, 
both positive and negative, interaction could lead to a negative free energy change 
and so be favourable. 
 
Even systems with simple biological molecules fit this description.  This is partly 
because it is also possible for atoms to carry partial charges which result from 
differences in electronegativity between the two atoms at either end of a chemical 
bond.  (This itself is actually a simplification, but the reasons for that need not detain 
us.)  More electronegative atoms attract the electrons in the bond and thus  
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Figure 1  Interactions and shapes of molecules  (A) Two potassium ions 
separated by inter-atomic distance r.  (B) Electrostatic force between two 
entities of like charge.  (C) Some of the partial charges on a serine molecule.  
(D) Hydrogen bonds illustrated for water.  (E) Decane.  (F) van der Waals 
interactions vary with intermolecular distance.  (G) Rotation of decane about 
bond a produces a clash between the two hydrogens shown.  (H) A second 
rotation about bond b produces a more serious clash. 
 
have a partial negative charge (notated -) leaving the other atom with a partial 
positive charge (notated +).  This is illustrated for the O-H and O-C bonds of serine 
in Figure 1C.  These partial charges vary in size depending on the exact environment 
producing them.  They induce inter-molecular attraction and repulsion just as the 
whole charge on a potassium ion does, but they also lead to the phenomenon of 
hydrogen bonding.  This is where the size of the partial charges can be reduced by 
a hydrogen atom ‘borrowing’ some of the excess negative charge from another 
atom.  (Describing this with a potential as for charged interactions in Figure 1B is 
not a simple task269 and so is omitted here.)  It is perfectly possible for molecules to 
form more than one hydrogen bond at a time, as illustrated for water in Figure 1D. 
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For reasons that are beyond the scope of this thesis atoms and molecules also 
experience van der Waals interactions – indeed in molecules which contain no 
charges (either full or partial) these are the dominating interactions.  Van der Waals 
energies can either be attractive or repulsive and are approximated by the formula 
 
𝑉 =  𝜀 [(
𝑎
𝑟
)
12
−  (
𝑎
𝑟
)
6
] 
 
where V is the potential energy, r is the distance between the relevant entities and 
a and  are constants whose values are determined by the system.  Thus if molecules 
of the simple hydrocarbon decane (Figure 1E) are brought very close together the 
energy change will be large and positive and so unfavourable (Figure 1F).  At long 
distances the energy change will be close to zero but at intermediate distance the 
energy change is negative (Figure 1F) and so the interaction is favourable – 
uncharged, fatty molecules will tend to associate with each other.  But such organic 
molecules often have flexible chains of atoms and this gives rise to a particular form 
of van der Waals interaction.  Thus Figure 1G shows decane (Figure 1E) but with 
the bond labelled a rotated.  Different shapes of a molecule that has undergone no 
chemical change are named conformations or conformers.  This rotation brings the 
two hydrogen atoms shown so close together that they experience a van der Waals 
repulsion.  This degree of rotation is thus unfavourable.  A second rotation around 
bond b (Figure 1H) will lead to more severe clashes.  The amount of rotation is 
measured by the torsion angle (also referred to as the dihedral angle) about the bond 
in question; the torsion potential follows a cosine function (not shown). 
 
These ideas enable us to say what will happen if a quantity of uncharged, fatty 
decane is added to an equal quantity of water and the vessel shaken.  That process 
would disrupt the favourable van der Waals interactions (Figure 1F) between the 
decane molecules and the favourable hydrogen bonds (Figure 1D) between the water 
molecules.  As no comparable compensatory process is available the change would 
be unfavourable.  Oil and water don’t mix. 
 
Amphiphilic molecules 
But what of molecules that contain both sorts of moieties?  For example 
phosphatidylserine (PS, Figure 2A) has a headgroup with features permitting 
extensive hydrogen bonding and charged interactions both with other molecules of 
itself as well as any surrounding water molecules.  As well as this polar or 
hydrophilic region it also has two fatty, and so hydrophobic, tails capable of 
extensive favourable van der Waals interactions both within and between PS 
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Figure 2 Structures and self-assembly properties of lipids  (A) 
Phosphatidylserine (PS) has both a polar headgroup and non-polar (or 
lipophilic) tails  (B) In water (represented by red dots) PS will arrange itself into 
bilayers where only the polar parts are in contact with the aqueous phase (C ) 
Phosphatidylinositol (PI) has a structure which is both similar and different to 
PS  (D) Sphingomyelin (SM), an exemplar sphingolipid has similar  lipophilic 
tails but a headgroup with different H-bonding capacity  (E) Cholesterol has a 
small headgroup and a rigid lipophilic region  
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molecules but whose interactions with water would not be favourable.  The fatty 
tails have a slight preference to be straight to avoid the unfavourable interactions 
shown in Figure 1G,H.  Placing such molecules in water, therefore, is likely to trigger 
a self-assembly process with the headgroups interacting with each other and the 
water and the tails interacting with each other but away from the water.  Thus 
physics predicts the generation of a structure known to biology as a lipid bilayer 
(Figure 2B). 
 
The real biological situation is more complicated because bilayers are not composed 
of one lipid type but of several.  Thus phosphoinositide (PI, Figure 2C) differs from 
PS in being capped with not with serine but with a sugar which confers very different 
ionic and H-bonding properties.  The sugar can also be phosphorylated in one or 
more places yielding the phosphoinositide phosphates which are important 
signalling lipids.  The sphingolipids (eg sphingomyelin (SM), Figure 2D) have been 
introduced in chapter 1.  The lipids shown in Figure 2 all have tails based on stearic 
acid.  In reality tail lengths can vary and such differences can be important.270,271  
Not all lipids have such tails: cholesterol (Figure 2E) has a rigid tetracyclic core which 
imparts particular properties when cholesterol is mixed with other amphiphilic 
lipids.272  Cholesterol also has a very small headgroup (just an OH) which gives rise 
to other phenomena in bilayers.273  Thus real biological systems are considerably 
more complicated than the idealised cartoon of Figure 2B and such complication is 
only increased by the realisation that individual lipid molecules can move around in 
the bilayer.  This raises the question of whether lipids show any preferences in their 
associations. For reasons that physics does not yet fully understand274,275 cholesterol 
preferentially associates with certain other lipids, particularly sphingolipids such as 
GlcCer and SM276 (Figure 2D).  The resulting regions of membrane are termed lipid 
rafts (reviewed277–280) and have been implicated in diverse biological functions.  
These structures are shown in cartoon form in Figure 3.  They are transient,281 but 
show short-range order and are resistant to extraction with detergent, hence the 
alternative names of liquid-ordered phase (Lo) and detergent resistant membrane 
(DRM).  Whilst phosphoinositides may or may not occupy lipid rafts282,283 they are 
also clustered by cholesterol.284,285  Fairly obviously such self-organisation will lead 
to areas of high local concentration of certain lipid species even if those species are 
a minor overall component of the cellular lipidome.  Thus we would expect 
sphingolipids and PIs to accumulate in Niemann-Pick lysosomes and lipid rafts to be 
found there.  All those expectations are fulfilled.43,61 
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Figure 3 Lipid rafts  Sphingolipids and cholesterol preferentially associate with 
each other to form semi-ordered domains called lipid rafts; phosphoinositides 
may be included  
 
Proteins in membranes 
Membranes contain not just a lipid bilayer but also proteins which interact with the 
lipids by one (or sometimes more) of four modes (Figure 4A-D).  Peripheral 
membrane proteins (Figure 4A) such as AnxA2286 typically bind by electrostatic 
interaction with the lipid head groups.  Membrane-associated proteins have a small 
portion of their structure inserted into the membrane, either an -helix (Figure 4B) 
or a lipid tail (Figure 4C).  Examples of these are Syntaxin763 and rab7287 respectively.  
Integral membrane proteins (figure 4D) span the bilayer completely often to allow 
hydrophilic substances to pass through.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Four modes of protein-membrane association  (A)  Peripheral 
membrane proteins interact with lipids through polar residues on their surface  
(B) Membrane associated proteins possess an α-helix which is able to insert 
into the membrane  (C) Other proteins become membrane associated by 
acquiring a lipid tail  (D) Transmembrane proteins completely span the bilayer 
 
As well as the trans-membrane segment they may contain very large domains on 
one or both sides of the membrane (eg NPC1, Figure 7).  Each of these interaction 
modes places demands on the local lipid population, thus domains within 
membranes where local concentration of certain lipids is high, can influence the 
localisation and even function of proteins which interact with those membranes.  
Lipid-protein interactions form an important refinement of the classical fluid-mosaic 
model of membrane organisation288 and have therefore become an important area 
of study289–292 with much of the effort focussed on explaining how lipids can affect 
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the functions of proteins.  (For further details of membrane organisation including 
protein inclusion see.293) 
 
Lipid-protein interactions 
While implicating diverse cellular processes the review of NPCD in chapter 1 showed 
that lysosomal dysfunction is central to the pathology of this condition and identified 
the involvement of certain key proteins, most of them embedded in the lysosomal 
membrane.  To that picture this chapter has added a disturbed distribution of 
lysosomal lipids.  The question of the role of lipid-protein interactions in NPCD thus 
naturally arises.  (The remainder of this chapter is an expanded version of294.) 
 
To examine lipid–protein interactions, it is necessary to identify the region of the 
protein where the lipid associates or binds.  If a lipid-binding motif has been 
identified then a protein’s sequence can be searched using computer algorithms 
(e.g., FuzzPro, bioinformatics.nl/cgi-bin/emboss/fuzzpro).  The predictive power of 
this technique is variable.  The most common cholesterol-binding motif, termed 
CRAC (Cholesterol Recognition Amino acid Consensus),295 was first described on 
the protein TSPO296 which we shall meet again in chapter 4.  Using single letter 
amino acid code it is defined as L/V-X1-5-Y-X1-5-R/K (X can be any residue) and so 
is of variable length and strictly defined at only one position.  Thus algorithmic 
searching for this motif typically generates numerous false positives for any given 
protein sequence.  For example it is found over 5700 times in the proteome of a 
cholesterol-free bacterium.297  The reverse motif CARC298 also binds cholesterol but 
has a similarly lax definition and so identical concerns will apply.  More recently, 
the protein p24 was found to bind to sphingomyelin via a defined region.271  
Analysing statistical over-representation enabled this finding to be generalised to a 
set of sphingolipid-binding motifs, e.g., VX2V2X2LF, some of which were confirmed 
experimentally.299  However, as far as can be ascertained, no interactions between 
sphingolipids and specific residues within these motifs were identified, nor is it clear 
whether the required terminal aromatic residue of the motif should be positioned 
closer to the edge of the membrane in which the protein is embedded or closer to 
the centre.  Thus algorithmic searching of sequences for binding motifs offers only 
an approximate guide to where lipid–protein interactions may occur, and gives only 
limited information of three-dimensional features of such interactions.  The work 
reported in this chapter set out instead to use molecular docking, which not only 
allows the exploration and rationalization of lipid binding in structural detail, but 
also allows ruling out some sites if binding proves impossible or implausible and so 
is much more reliable than merely identifying motifs. 
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Determining protein structure 
Molecular docking can be performed only if the 3D structure of the protein is known.  
The determinants of molecular structure were set out above, though proteins are an 
exceptionally complex case – for example they are subject to particular constraints 
on dihedral angles300 (Figure 2E, G-H).  For this reason their structures cannot in 
general be predicted ab initio with any useful levels of accuracy and must therefore 
be experimentally determined.  This has usually been achieved with x-ray 
crystallography301 though recent advances in cryoEM have vastly increased the 
number of proteins whose structures are known.  Protein structure can also be 
determined by NMR, though historically this has been limited to smaller molecules.  
Protein structures are deposited in the Protein Data Bank (PDB, rcsb.org) and can 
be freely downloaded. 
 
The core of such pdb files is a list of all heavy atoms (atoms that are not hydrogen) 
together with their co-ordinates on an x,y,z grid.  PDB entries are accompanied by 
numerous quality measures of which the most accessible is the resolution.  This is 
quoted in ångstroms (Å) and is a measure of the average uncertainty in the position 
of the atoms – a useful comparison is the carbon-carbon single bond length of 1.4Å.  
Other ways to assess the quality of a PDB structure are discussed elsewhere.302 
 
For proteins without a PDB entry a structure can sometimes be derived from the 
experimentally determined structure of a related protein by a technique known as 
homology modelling.  The protein with known structure (called ‘the template’) is 
considered ‘related’ if about 30% or more of its amino acids are identical to those 
in the protein being modelled (‘the target’).  Modelling may still be possible if the 
two proteins share 25% sequence identity but below that threshold any models 
produced are generally unreliable.303  The procedure next assigns the same x,y,z co-
ordinates to all atoms of identical residues in the target protein as the corresponding 
residues in the template protein.  Co-ordinates for the atoms in the remaining 
residues can then be inferred yielding what we might call a first-draft structure.  This 
can then be adjusted to reduce or eliminate the kinds of unfavourable interactions 
discussed above and increase the favourable ones – this process is known as energy 
minimisation and various procedures are used.  For individual proteins homology 
modelling has progressed to being an almost fully automated process run on 
webservers (eg304,305). 
 
As the resulting models are not derived from experiments with measurable errors 
the question arises of how we measure their quality.  The approach taken in this 
work is to use the QMEAN service.306  Essentially this selects four mathematical 
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descriptors of protein structure and uses these to compare a model with a set of 
experimentally determined structures of proteins of a similar size.  The closeness of 
similarity between the model and set of reference structures is taken as a measure 
of model quality.  This approach yields not only a global score for the model as a 
whole but also a local score for each individual residue.  Scores for the protein 
structures used in this work are shown in Table S2. 
 
In this work we are mostly concerned with proteins that are integral to the lysosomal 
membrane or associated with it (Figure 4B-D) and so we need to know 
approximately where on the protein structure the boundaries of the membrane lie.  
The QMEAN service has been expanded (and named QMEANBrane307) to deal with 
membrane-bound proteins and the output provides an estimation of the protein’s 
position in the membrane.  For experimentally determined structures a similar service 
is provided by the OPM database (opm.phar.umich.edu).308 
 
Docking lipids to proteins 
With a structure of the protein in hand it is possible to progress to attempted docking 
of lipids.  This was mostly done with AutoDock309,310 software which holds the 
protein mostly rigid, but gives flexibility to some designated side chains.  The lipid 
is allowed to vary its bond angles (Figure 2E, G-H) and both orientation and position 
within a defined search space.  (Table S3 gives parameters for the docking runs used 
in this work.)  The calculations were started with the bond angles of the ligand in 
an energy-minimised state; the docking software randomly selects a starting position 
and orientation.  All these parameters are then systematically altered until an 
energetically favourable binding 'pose' – assessed by an energy scoring function – 
is discovered, if that is possible.  This procedure is repeated multiple times and the 
results ranked to show more or less energetically favourable binding poses.  These 
poses are grouped into clusters defined by root mean square difference (RMSD) of 
atomic positions with the cut-off for membership of a cluster set at > 2Å. 
 
For some proteins the ROSIE-Rosetta ligand docking protocol311–313 was also used 
(for an example of the critical comparison of somedocking programs  see314) .  Rather 
than specifying a search space as with AutoDock, ROSIE requires the user to provide 
co-ordinates for the starting position of the ligand.  The small molecule is then 
randomly moved until its centre is in a position not occupied by the protein.  (For 
this reason the academic group behind the software recommend ROSIE not be used 
for binding sites on the edge of proteins – the ligand tends to end up in empty 
space.)  After positioning of the ligand ROSIE allows both amino acid side chains 
and the protein backbone to flex slightly in order to reduce unfavourable ligand-
How to assess the 
quality and membrane 
positioning of protein 
structures 
51 
 
protein interactions and increase favourable ones.  The success of this process is 
measured by an energy scoring function which gives values both for the interface 
score (protein-ligand interaction) and the total score (measuring if the protein has 
adopted an unfavourable conformation).  Thus ROSIE is much better than AutoDock 
at allowing for flexibility in the protein but its built-in conformer generator315 does 
not generally produce molecular shapes significantly different from the starting 
conformer.  Minor bond rotations (less drastic than those shown in Figure 2G-H) 
attract only a very small energy penalty meaning that some of the molecules 
considered in this chapter are very flexible.   
 
However the calculations are run, they are limited by the accuracy of the scoring 
function and examine only a sample of all possible combinations of parameters.  
This second limitation can be circumvented by the use of a molecular dynamics 
(MD) simulation of the protein with bound lipid. 
 
The x,y,z co-ordinates of all the atoms in such a system are known and, as discussed 
above, these atoms feel forces from interactions with other atoms.  MD assumes the 
net force on any individual atom is the sum of all the different forces and then 
employs Newton's observation that force leads to acceleration.  Thus each atom is 
constantly in motion.  The basic premise of MD is that if we know the initial position 
of each atom in a lipid-protein complex and if we know the forces acting on each 
atom then we should be able to calculate the new position of each atom a short time 
later.  This 'short time' is known as the time step and in this work is set to 2fs to 
accommodate bond vibrations which are the fastest events in protein molecules and 
occur approximately every 10fs.  (Vibrations of bonds to hydrogen occur faster than 
this and are usually neglected in MD simulations.) 
 
For the simulations to be realistic the protein should be embedded in an environment 
that at least approximates to its native one.  The proteins simulated here are all 
soluble and so are placed in a 'box' which is filled with water molecules and salt 
molecules at a physiologically relevant concentration  (Figure 5).  This requires us 
to know something about how water behaves or, in MD terms, water should be 
parameterised.  This is a solved problem.  Various models are available – in this 
work the TIP3P model was used.316  It is also a solved problem for protein structure317 
and for cholesterol;318 for other small molecules of interest, eg sphingosine, 
acceptable parameterisation can be accomplished using CGenFF  
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Figure 5 Illustration of a solvent box used in MD simulations  (A) Sph 
(purple) bound to SphK (PDB: 3vzb319).  (B) The same structure embedded in 
a 2Å water box. 
 
(cgenff.paramchem.org/).320  For proteins embedded in membranes it is not so easy.  
Single component lipid membranes have been well studied experimentally so their 
physical properties are known and they can be parameterised with relative ease.  As 
we have seen lysosomal membranes are multi-component mixtures containing some 
non-standard lipids so parameterisation is non-trivial.  For this reason, and the fact 
that we are only beginning to know the composition of the lysosomal 
membrane,43,321 MD simulations of membrane-bound proteins are not conducted 
here.  
 
The first phase of an MD simulation is equilibration, the aim of which is to find 
approximately the state of the lipid-protein complex under normal conditions.  To 
accomplish this atoms are assigned initial velocities according to the Maxwell-
Boltzmann distribution and the ensemble is slowly heated from 60 to 300K over the 
course of 1.2ns.  The thermal energy thereby supplied to the system can be 
converted to other forms but the ensemble should reach a state of limited change.  
After this the production phase begins where the system is allowed to behave as it 
would in its native state.  For this to be reliable correction terms are applied to the 
mathematics to ensure the ensemble experiences invariant temperature and pressure.  
This is done automatically by the software used.322–324  The solvent box is also 
considered as a periodic boundary so that if a water molecule exits the box on one 
side then another enters from the opposite side  In this work the production phase 
was set to 10ns; on completion the system can be analysed for changes, particularly 
H-bonds and RMSD of atomic positions.  As the entire protein-lipid assembly is 
subject to random Brownian motion the RMSD analysis includes a step where this 
is factored out of the calculation leaving only the movements of interest.  Should 
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the lipid remain in essentially the same orientation relative to the protein then this 
is good evidence that the binding pose is stable, at least on the timescale of the 
simulation.  Stable binding poses imply control and control in turn implies design.  
Hence if a binding pose is stable under MD then this is good evidence that that pose 
really occurs. 
 
No matter how closely computer simulations approach biological reality the results 
are hypotheses that need to be inspected and tested.  Such testing will ultimately 
come from ‘wet’ lab experiments, but a useful first step is to ask if a binding pose 
is biologically plausible – a favourable energy score is no guarantee of that. 
 
Biological plausibility of docking results 
With membrane-bound and –associated proteins, such as most of those considered 
here, the orientation of the protein in the membrane offers a significant clue as to 
the biological plausibility of binding poses.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6  Four idealised possibilities for cholesterol binding to a trans-
membrane protein  Trans-membrane proteins (light grey) are embedded in 
the lipid bilayer (dark grey).  (A) Cholesterol (orange) may bind parallel to the 
membrane (energetically favoured)  (B) parallel to the membrane but vertically 
displaced from it (energetically less favoured)  (C) perpendicular to the 
membrane (energetically disfavoured) or  (D) antiparallel (energetically 
disfavoured). 
 
Thus a lipid, illustrated by cholesterol (orange) in Figure 6, may bind to a trans-
membrane protein (light grey) in various orientations which can be idealised as 
shown.  Cholesterol can be parallel to the lipophilic section of the membrane and 
with the hydroxy group aligned with other lipid head groups (Figure 6A).  This is 
the most energetically favourable situation.  However the lipid may also be parallel 
to the membrane but vertically displaced from it (Figure 6B).  Whilst possible, this 
A  Parallel, favoured B  Displaced parallel, less 
favoured 
C  Perpendicular, disfavoured D  Antiparallel, disfavoured 
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requires a deformation in the membrane and the consequential loss of some 
favourable van der Waals contacts between lipids (Figure 1F).  Therefore this attracts 
an energy penalty and such a pose would be energetically less favoured.  Burying 
the hydroxy group inside the lipophilic portion of the membrane by orienting it 
perpendicular (Figure 6C) or antiparallel (Figure 6D) is still possible,325 but 
energetically disfavoured.  In this work binding poses similar to those in Figure 6B-
D were considered only when calculations did not generate poses corresponding to 
the more favourable situation shown in Figure 6A.   
 
Calculations were made more computationally tractable by neglecting the membrane 
and thus we assess only lipid-protein interactions.  Lipid-protein interactions 
considered in isolation may be energetically favourable with the lipid in 
perpendicular or antiparallel situations.  As the lipid starting position and orientation 
are randomised, some of the iterations of the docking calculations will start with the 
lipid in a position perpendicular or antiparallel to the lipophilic section of the 
membrane.  Thus some docking runs will start with the lipid in an orientation that 
is energetically favourable when considered in isolation but energetically 
disfavourable when considered in the context of the membrane as a whole.  Such 
an orientation is biologically implausible.  Energetic refinement of this orientation 
will not necessarily result in the lipid adopting a parallel orientation.  Therefore some 
docking runs may result in binding poses that appear energetically favourable 
because they only consider lipid-protein interactions but would be energetically 
disfavourable overall and thus biologically implausible.  This is a consequence of the 
randomisation of the initial position of the lipid, not a flaw in the docking 
experiments.  If the docking algorithm is run a sufficient number of times then an 
energetically favourable, biological plausible binding mode should emerge, if one 
exists 
 
Whilst this discussion applies mostly to cholesterol, similar considerations pertain to 
other lipids.  Aliphatic lipid tails generally make non-specific interactions with trans-
membrane proteins so docking calculations are routinely performed here with only 
the lipid head group to focus attention on the distinctive part of the molecule.  These 
head groups include the first carbon atoms of the aliphatic chains and it is quite 
possible that the randomised initial positioning for the docking calculation will orient 
these atoms, and thus either or both alkyl chains, away from the membrane and into 
the cytosol.  As discussed above this is highly energetically unfavourable.  It is 
equally possible that the energy minimisation, because done in isolation from the 
membrane and solvent, will retain such an orientation if adopted by the initial 
random positioning.  Thus once again docking calculations may output binding 
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poses that are energetically favourable in isolation but disfavourable overall and so 
biologically implausible.  This does not indicate a flawed method.   
 
For these reasons it is necessary that the output of such docking first be inspected 
for biological plausibility.  The figures show representative binding poses that result 
from the docking runs – these are both energetically favourable and biologically 
plausible.  (Table S4 presents extended data including number of clusters, cluster 
size, assessment of favourability and interacting residues.)  Once filtered for 
energetic favourability and biological plausibility, the results of docking experiments 
should next be tested by 'wet' experiments.  Whilst no new lab data is presented in 
this chapter, the results are fully consistent with existing findings from other labs. 
 
Biological plausibility can also be assessed, for all proteins, using a surface 
conservation analysis, conducted here using the ConSurf server 
(http://consurf.tau.ac.il/).326,327  The assumption here is an evolutionary one: that if a 
residue is conserved across numerous different organisms then it must be important 
to the function of the protein.  ConSurf gives high scores to highly conserved 
residues, the presence of highly scored residues at putative lipid binding sites is 
taken as evidence that these sites are functionally important, which in turn suggests 
lipid binding may genuinely occur as calculated. 
 
Results and discussion 
What does the NPC system do? 
All mammalian cells require cholesterol.  LDL-derived cholesterol is delivered to the 
cell in the form of cholesteryl esters; transporting cholesterol imposes certain 
structural requirements on proteins (reviewed328,329).  These esters are carried by the 
endocytic pathway to the lysosomes where they are hydrolysed by lysosomal acid 
lipase (LAL) at intraluminal membranes (Chapter 1, Figure 1, ❻).  Unesterified 
cholesterol (sometimes termed ‘free cholesterol’) must then be exported to be used 
by the cell which is accomplished by the co-operative action of NPC2 and NPC1, as 
reviewed briefly in Chapter 1   
 
NPC1 is a 13-TMH protein also containing 3 luminal loops (Figure 7A-C); loop 1 is 
usually referred to as the N-terminal domain (NTD), loop 2 as the middle luminal 
domain (MLD) and loop 3 as the C-terminal domain (CTD).  The TM region was 
recognised as posessing a sterol sensing domain (SSD, Figure 7A,C) as well as other 
helices whose function is unknown.  At the start of this work cholesterol binding 
had been experimentally verified only at the NTD (Figure 7B).330  Binding at a second  
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7  Structure and regions on NPC1  (A) Cartoon of NPC1.  (B) Crystal 
structure of the NTD (PDB : 3gki).  (C) Crystal structure of residues 334-1255 
(PDB: 5u74) showing putative cholesterol binding site in the SSD (orange box).  
(D) Colours used in panels (A)-(C).  (E) Structures of NTD (left) and 334-1255 
(right) showing disease-associated mutations (red) and binding regions 
identified in (green). 
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site in the SSD (orange box in Figure 7C) had been suggested by ligand docking331 
and was also implied, not least because mutation of Pro691 reduced labelling by a 
fluorescent cholesterol analogue;11 mutation of Pro691 is also disease-causing 
(Figure 7E).10  The path from the NTD to the SSD was unknown but disease-
associated mutations occur all through NPC1 (red residues in Figure 7E) suggesting 
that the whole protein may be involved.  This idea is also supported by a proteomic 
study332 with a tritiated cholesterol anaolgue which identified diverse binding sites 
in NPC1 (green in Figure 7E), though it should be noted that that study found no 
binding sites in the SSD and did not identify NPC2 as binding cholesterol at all.  
How cholesterol export is completed from the putative SSD binding site is not 
known. 
 
The understanding of the export of unesterified cholesterol at the start of this work 
is shown in Figure 8.  Cholesterol is first collected from the intraluminal membranes 
by NPC2 (Figure 8A, ❶).  This carrier protein then binds to loop 2 of NPC1333,334 in 
the correct position for the next step which is transfer of cholesterol to the NTD of 
NPC1335 (Figure 8A, ❷).  This transfer has not been observed in live cells but has 
been studied in model systems336 and computationally.337  At some point NPC2 
presumably dissociates and the NTD, with the assistance of loop 3, then relays the 
cholesterol to the NPC1 sterol sensing domain (Figure 8A, ❸).18,330,338,339  The 
geometry of these steps is likely to be important.  It has been shown 
crystallographically that NPC2 binds cholesterol with the polar hydroxy group 
oriented toward the cytosol15,334 (Figure 8C); transfer of cholesterol to NPC1’s NTD 
therefore positions the hydroxy group inwards (Figure 8B) as confirmed by another 
x-ray study.330  The orientation of the cholesterol molecule after its transfer to the 
SSD has not been unambiguously determined but an alignment parallel to the 
luminal side of the lysosomal limiting membrane would be expected (Figure 8A, 
❸). 
 
Despite the numerous studies that have contributed to our developed understanding 
of the NPC system, this account is not without its difficulties.  NPC2 can 
transfercholesterol to model membranes lacking a glycocalyx with equal speed in 
the presence or absence of NPC118,340,341 so it would appear that the reason for this 
rather complicated relay mechanism of cholesterol export is to allow the lipid to pass 
through this thick, highly polar carbohydrate layer342 which protects the luminal face 
of the lysosomal limiting membrane.  Consistent with this idea is the finding that 
inhibiting O-glycosylation in NPC1-deficient cells leads to decreased lysosomal 
cholesterol.268  Why, then, the need for the SSD?  Given that cholesterol translocates 
(or ‘flips’) rapidly343 from one face of the membrane to the other, isn’t it sufficient  
Deficiencies in the 
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Figure 8 Cartoon of cholesterol export by the NPC system 
(A) ❶ NPC2 collects cholesterol from intraluminal membranes and transports 
it to NPC1 in the limiting membrane.  After binding at loop 2 cholesterol is 
transferred to the NTD of NPC1 ❷ and then to the SSD ❸.  This work 
postulates that cholesterol can flip to a cytosolic facing binding site ❹.  Export 
of cholesterol returns the system to its resting state ❶.  (B) X-ray structure of 
cholesterol bound to NPC1 NTD (PDB: 3gki330).  (C) X-ray structure of 
cholesterol-O-sulfate bound to NPC2 (PDB: 5kwy334). 
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just to get cholesterol to the membrane?  If so, what is the purpose of NPC1’s 13 
transmembrane helices?  Would not 1 or 2 TMHs suffice to anchor the N-terminal 
domain next to the membrane?  And even if an SSD is necessary, what is the purpose 
of the remaining 8 helices (Figure 7)?  The work described here attempts to begin 
an answer to these questions. 
 
Ligand docking had previously identified a cholesterol binding site on the luminal 
side of the SSD of NPC1.331  This experiment was repeated setting the search space 
as the entire SSD of NPC1 (Table S3) using a more recently published x-ray structure 
(PDB 5u74, see Table S1).338  Lipid binding poses were found in not one but two 
energetically favourable clusters aligned to both the luminal and cytosolic faces of 
the membrane.  Representative examples are shown in Figure 9A; extended results 
are given in Table S4.  In both cases binding is anchored by an H-bond between the 
cholesterol hydroxy group and the side chain of an Asp residue whilst the remainder 
of the sterol is encased in a cavity formed from lipophilic side chains (Figure 9A, 
Table S4).  These side chains make van der Waals contact with the cholesterol 
molecule.  Crucially, Pro691 is among the residues predicted to interact with 
cholesterol (pink in Figure 9).  Mutation of this residue has been shown to reduce 
cholesterol export10 and to reduce labelling of NPC1 by a photoactivatable 
cholesterol analogue11 implying that Pro691 plays an important role in cholesterol 
binding.  The emergence of this residue from docking calculations forms an 
important agreement between in vitro and in silico approaches.  The suggestion of 
two binding pockets means that NPC1 can potentially be added to the list of proteins 
featuring cholesterol binding in both leaflets of a lipid bilayer,125,344 a phenomenon 
termed the 'mirror code.'345  It also means that the cholesterol export narrative can 
possibly be extended to include stage ❹ (Figure 8) where the cholesterol is aligned 
with the cytosolic face of the lysosomal limiting membrane. This offers, for the first 
time, an idea of how cholesterol export can be completed.  Both putative binding 
sites were supported by a surface conservation analysis (Figure 9B) showing that 
residues in these site are highly conserved, especially for the luminal site; similar 
considerations apply to the locations of disease-associated mutations which can be 
found in both binding sites (Figure 7E). 
 
Shortly after this work was completed and published294 a combined docking-MD 
study on cholesterol binding to NPC1 emerged.346  While that study also found 
cholesterol binding aligned to both faces of the membrane the binding positions of 
the lipid in the protein are at variance with those suggested here.  The root cause of 
the difference is likely to be the protein structure used in the other study (PDB: 
3jd8335) which is more complete but significantly less accurate than the one used in  
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Figure 9  Docking identifies two potential binding pockets on NPC1 
aligned to each side of the lysosomal membrane  (A) Sample poses for both 
cholesterol (orange) show binding in these pockets consistent with evidence of 
NPC1’s role as a cholesterol exporter.  Selected interacting residues are 
labelled, H-bonds are shown in green.  Pro691 is shown in pink; mutation of 
this residue results in reduced cholesterol binding.10,11  (B) ConSurf analysis 
shows residues in the luminal pocket are highly conserved; residues in the 
putative cytosolic pocket slighly less so.  
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this work (resolution 4.4Å versus 3.3Å; for a full list of available NPC structures see 
Table S1).  In particular the two structures locate key residue Pro691 differently 
(Figure S1).  The other modelling study346 did implicate this residue in binding 
cholesterol but, unlike the work reported here, the lipid contacted the proline only 
by forming an H-bond to the backbone carbonyl, an interaction that might be 
expected to persist on mutation and so explaining the loss of function induced by 
mutating that residue10,11 is perhaps harder.  Additionally the other study conducts 
docking experiments on the whole protein.  Whilst this conveys the advantage of 
being completely unbiased, the necessary compromise is that the electrostatic grids 
are calculated at a lower resolution than those used here which unavoidably imparts 
computational errors of potentially greater magnigtude.  This disadvantage is 
possibly mitigated by the MD simulations performed in the other study. 
 
Cholesterol export may not be the only function of the NPC system.  Indeed export 
of sphingosine (Sph) from NPC1-deficienct cells was found to be impaired using a 
photo-activatable analogue that localises to lysosomes and whose export can then 
be followed by pulse-chase experiments.347  This implies either that storage of Sph 
is induced by storage of cholesterol or that sphingosine uses the NPC export 
machinery.  The second explanation is favoured by experiments using 
pharmocological inhibition of NPC1 which induced lysosomal accumulation of 
sphingosine at an earlier time point than accumulation of cholesterol.54  NPC1 has 
also been identified as a sphingosine-binding protein in a proteomic screen.c   
 
To investigate this further the docking experiments described above were repeated 
with Sph in place of cholesterol.  Consistent with the studies just cited plausible 
binding poses were found for sphingosine aligned to both sides of the LEL 
membrane (Figure 10).  Reminiscent of cholesterol the polar head group of Sph 
forms H-bonds or ionic interactions with the side chains of Asp residues while the 
lipophilic tail makes van der Waals contact with the same set of lipophilic side chains 
as cholesterol (Figure 10, Table S4).  Thus it seems plausible that sphingosine can 
use the cholesterol export machinery as suggested by previous experiments.347  
Indeed the presence of anionic Asp residues on both sides of the membrane may 
suggest that this protein is better suited to exporting cationic Sph than neutral 
cholesterol.  (The pKa of sphingosine has been reported as 6.6 in solution348 and 9.1 
in a model membrane.349  Thus Sph will likely be protonated both in the acidic 
endolysosomal lumen and when incorporated in the cytosolic face of the membrane  
 
                                                          
c Dr Per Haberkant (EMBL), personal communication 
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Figure 10 Putative binding of sphingosine to the SSD of NPC1.  Docking 
experiments suggest that sphingosine can bind to the SSD of NPC1 in the same 
two sites as cholesterol. 
 
so these and subsequent docking experiments were performed with protonated 
sphingosine.) 
 
This raises the expectation, given also that Sph is generated in the lysosome at the 
same intraluminal membranes as cholesterol (Chapter 1, Figure 4, ❿), that both 
NPC2 and the NTD of NPC1 would be able to bind sphingosine.  Investigations of 
this began with the published x-ray structure330 of cholesterol bound to the NTD 
(PDB: 3gki, Figure 11A).  Cholesterol was removed from the structure and redocking 
of the lipid to the apo protein attempted using AutoDock.  This successfully 
replicated the binding pose in the crystal (Figure 11B) with the hydroxy group of 
cholesterol pointed inwards (the ‘in’ orientation, Table S4) and forming H-bonds 
with Asn41 and Gln79.  H-bonds like these between a bound ligand and ‘buried’ 
residues confer particular strength to the ligand-protein bond.346  Repeating the 
docking procedure with sphingosine yielded analogous results (Figure 11C, Table 
S4).  Sph was found predominantly in the ‘in’ orientation with the positively charged 
lipid headgroup making additional making ionic interactions with Glu30; lipophilic 
side-chains making van der Waals contact with Sph were the same as those doing 
so with cholesterol (Table S4). 
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Figure 11 Comparison of cholesterol and sphingosine docking with 
crystallographic conformations  (A)  Cholesterol in the NTD of NPC1 (PDB: 
3gki330) forms H-bonds (green) to Asn41 and Gln79 (B)  Docking of cholesterol 
reproduces the binding found in the crystal  (C) Docking of sphingosine 
preferentially orients the molecule the same way as cholesterol; as well as H-
bonds to Glu30 and Gln79, an ionic interaction (magenta) with Glu30 is present  
(D) Cholesterol-O-sulfate in NPC2 (PDB: 5kwy334) forms a CH-π interaction 
with Phe85  (E) Docking of cholesterol reproduces the binding found in the 
crystal  (F)  Docking of sphingosine preferentially orients the molecule the same 
way as cholesterol. 
 
An exactly similar procedure with was followed with NPC2.  PDB entry 5kwy was 
selected as, although it also includes the MLD of NPC1, it is  the only structure of 
human NPC2 with a bound sterol, cholesterol-O-sulfate (Table S1, Figure 11D).15  
This has the polar end of the lipid facing outwards (the ‘out’ orientation), has no 
hydrogen bonds between lipid and protein but doesfeature a CH- interaction 
between the sterol’s smooth  face and the aromatic ring of Phe85,This particular 
form of van der Waals interaction as well as the lipid's orientation were replicated 
in docking experiments between the free protein and cholesterol (Figure 11E).  
Docking of sphingosine yielded binding poses much less energetically favourable 
than cholesterol, but the vast majority had the ligand adopting the biologically 
correct ‘out’ orientation (Figure 11F, Table S4) and interacting with the same 
lipophilic residues lining the pocket as had been found for cholesterol. 
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Given that binding of Sph to NPC proteins has not yet been experimentally 
demonstrated it was decided to employ MD simulations to investigate putative 
binding further – similar previous work on NPC2350 has examined only cholesterol 
and structural analogues thereof.  These simulations were set up as described briefly 
above using the QwikMD plug-in323 to the VMD interface351 of NAMD software.322  
By default QwikMD sets the solvent box as the width of the protein in each 
dimension plus an extra 15Å.  Whilst rather large this size is a useful feature as it 
provides enough space for a lipid to escape into if that is more energetically 
favourable than remaining bound to the protein.  Simulations were performed for 
the binding poses of cholesterol and Sph shown in Figure 11B, C, E and F.  As an 
additional control a simulation of the same length was performed on Sph bound to 
sphingosine kinase (SphK, PDB: 3vzb319) – see video SphK_3vzb_SphH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  12  Output of MD simulations  (A) Ligand RMSDs for Sph in NPC2 
(purple), cholesterol in NPC2 (orange) and Sph in SphK (grey).  (B) RMSF of 
cholesterol in NPC2.  (C) RMSF of Sph in NPC2.  (D) RMSF of Sph in SphK. 
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In NPC2 cholesterol moves slightly from its starting position (Video 
NPC2_5kwy_chol) and thereafter is relataively stable as shown by its low ligand 
RMSD values (Figure 12A).  Movement can also be quantitated by a root mean 
square fluctuation (RMSF) analysis which asks how much each atom moves on 
average over each time-step.  Thus Figure 12B shows cholesterol’s movement is 
limited, larger fluctuations being found only in the atoms at the end of the flexible 
tail.   Sphingosine in NPC2 behaves rather differently.  The head group moves away 
from the protein almost immediately (Video NPC2_5kwy_SphH) to form H-bonds 
with solvent (data not shown) – the starting binding pose does not H-bond with the 
protein.  Thereafter the highly polar headgroup acts almost as a free molecule within 
the solvent and moves around considerably while the carbon atoms at the other end 
of the chain move no more than the corresponding atoms in cholesterol (see RMSF 
analysis in Figure 12C, note the scale difference to Figure 12B).  The high RMSD 
values for Sph in NPC2 (Figure 12A) mostly reflect the extreme mobility of the 
headgroup.  RMSD of NPC2 α-carbon atoms were comparable regardless of bound 
ligand and approximately the same as those for SphK with sphingosine bound 
(Figure S2).   Under MD simulation, therefore, the cholesterol-NPC2 complex 
behaves similarly to the sphingosine-SphK complex while sphingosine in NPC2 is 
rather less tightly bound.  Crucially sphingosine remained stably within the NPC2 
cavity. 
 
When considering the lipids in the N-terminal domain (NTD) of NPC1 a slightly 
different picture emerges.  Figure 11A,B showed that docking replicated the 
experimentally found binding pose of cholesterol in the NTD with the lipid forming 
H-bonds with Asn41 and Gln79 at the back of the cavity.  This arrangement 
remained stable under MD simulation. Asn41 formed an H-bond with cholesterol 
for 71% of the production phase while Gln79 did so for 79% of this time period. 
(Figure 13A).  This is reflected in the small RMSD for cholesterol in this protein 
(Figure 13B).  See video NPC1_3gki_chol.  The simulation of Sph in the NTD of 
NPC1 began with the binding pose shown in Figure 11C.  The lipid headgroup is 
located at the back of the pocket where it makes an ionic interaction with Glu30 
and an H-bond with Asn41; these interactions persist for the duration of the 
simulation (residues coloured grey in Video NPC1_3gki_SphH).  After about 0.3ns 
of equilibration the Sph forms an additional hydrogen bond with Asn86 (dull bronze 
in video) located midway along the pocket.  This persists until 1.4ns of the 
production phase, at which point the lipid undergoes a sudden movement and 
establishes an H-bond with Gln79 (video).  This arrangement remains stable till the 
end of the simulation and thus replicates the binding arrangement of cholesterol but 
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Figure 13 MD simulations of lipids bound in NPC1 NTD  (A) Residence 
times of cholesterol at key binding residues.  (B) RMSDs of sphingosine 
(purple) and cholesterol (orange) bound in NPC1 NTD.  (C,D) RMSF of 
sphingosine and cholesterol during MD simulation.  (E) Final binding pose of 
sphingosine; H-bonds shown in green, ionic interaction in magenta. 
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with the addition of the ionic interaction with Glu30.  An H-bond with the backbone 
of Arg39 also forms.  Video NPC1_3gki_SphH shows all these changes; Figure 13E 
shows the final binding arrangement.  Thus MD refines the binding pose suggested 
by docking - the final arrangement of the lipid having a greater number of bonded 
interactions with the protein.  The RMSD for Sph in this protein is slightly larger 
than that for cholesterol but comparable with that for Sph in SphK (Figure 13B, 
compare Figure 12A).  RMSF analyses for both lipids are comparable (Figure 13C,D) 
as was RMSD of protein α-carbon atoms (Figure S3). 
 
Docking calculations suggest that Sph can bind to both NPC2 and the N-terminal 
domain of NPC1 in same orientation as cholesterol in the vast majority of cases 
(Table S4); this geometry is biologically significant (Figure 8).  MD simulations 
suggest that Sph is not tightly held in NPC2 but that the binding pose is stable; 
however this technique yields a very stable binding of Sph to the NPC1 NTD.  We 
may question whether or not NPC2 was designed to bind sphingosine (although it 
is able to do so) but the calculated binding of Sph to the NPC1 NTD features bonded 
interactions with three residues, including a charged interaction, and so is unlikely 
to be an experimental artefact. 
 
Hence the idea, suggested but not proved by various experiments,54,114,347 that the 
NPC system can act to export sphingosine as well as cholesterol is endorsed by this 
computational work. This idea would explain the accumulation of sphingosine in 
NPCD,61 although favourable interactions with cholesterol may also be a factor.352,353  
Sphingosine’s protonated, highly polar headgroup would make energetically 
unfavourable contacts with membrane lipids meaning that it likely requires a flippase 
for export from the lysosome.  This work tentatively identifies that flippase as NPC1.  
The flipping pathway will nonetheless require the Sph headgroup to be shielded 
from the lipophilic section of the membrane, a requirement that is probably not met 
by the binding sites identified here (Figure 10) as these are open to surrounding 
membrane.  NPC1 helix 1 (Figure 7) could probably not serve this purpose as a low-
resolution cryoEM structure (PDB: 3jd8)335 places it on the opposite side of the 
protein.  Shielding could, however, plausibly be accomplished by one of the proteins 
with transmembrane domains noted to interact with NPC1.354,355  The question was 
raised above of why NPC1 has 13 trans-membrane helices when far fewer than that 
would probably suffice to facilitate cholesterol export.  This question receives a 
tentative and partial answer from this work: some of the helices are needed to export 
Sph which, unlike cholesterol probably does not flip rapidly and so requires binding 
sites on both faces of a membrane.  Thus dysfunctional NPC1 would precipitate a 
MD simulations of 
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failure of sphingosine export; the functional consequences of this failure will be 
considered again in chapter 3. 
 
NPC1 protein-protein interactions 
Earlier in this chapter various questions were raised about NPC1 function and in 
particular why cholesterol, which flips rapidly,343 requires an export protein at all, 
let alone one with a cytosol-facing binding site.  The presupposition underlying this 
interrogation of NPC1 is that cholesterol needs merely to reach the cytosolic face of 
the LEL membrane to become available to the rest of the cell, initially the ER at 
LEL-ER membrane contact sites.  This in turn requires either that cholesterol diffuse 
freely away from the LEL membrane, or be collected by another protein which will 
convey it to another organelle.  Whilst free diffusion happens surprisingly rapidly (t½ 
~ 30 minutes)356 this mechanism would lack control and so the idea of a relay protein 
is more attractive.  The picture of cholesterol trafficking within the cell is still 
emerging102–105 and it appears that multiple pathways operate.  In an attempt to 
integrate the cytosol-facing binding site of NPC1 with this developing account, its 
interactions with a StAR protein were investigated to ask if cholesterol might be 
transferred from NPC1 to a member of this family. 
 
The StAR protein family contain a cytosolic START domain which binds lipids and 
transfers them between membranes at contact sites.357,358  Connected to the common 
START domain by a flexible linker are varying domains which localise the proteins 
to the correct organelles; for example StARD3 (also known as MLN64) contains a 
MENTAL domain which targets it to endolysosomes.  The common START domain 
is comprised of an -helix grip structure (Figure 14A).  We will meet these proteins 
more fully in chapter 4 but for now we note that it is believed that the 1 loop 
(Ala335-Arg345, Figure 14A) flexes to allow cholesterol to enter or leave the 
binding domain, and that cholesterol’s polar OH group is oriented toward the back 
of the pocket (the part of the domain coloured orange in Figure 14A).359,360   
 
To investigate the putative transfer of cholesterol directly from NPC1 to a StAR 
protein the best available structure of a member of this family (StARD3, PDB 5i9j360) 
was used.  To simulate 1 opening this loop was removed from the structure and 
the resulting truncated protein assigned a ‘best guess’ position close to the cytosolic 
part of NPC1 (PDB 5u74).338  The resulting complex was then submitted to ROSIE 
which is able to simulate protein-protein interactions361 by essentially the same 
procedure as outlined above for lipid-protein interactions.  A relatively large 
perturbation from the initial guessed position resulted in an orientation of the two  
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Figure 14 Putative cholesterol transfer between NPC1 and StARD3        
(A) StARD3 showing the Ω1 loop; the cholesterol binding pocket composed of 
a-helix and b-sheet elements  (B) Initial protein-protein interaction result 
showing alignment of the cholesterol binding regioins  (C) Protein complex with 
(re)built loops; a plausible cholesterol transfer pathway is indicated with an 
arrow  (D) Plausible bonding interactions between the two proteins in refined 
orientation; NPC1 residue labels are edged in grey; H-bonds are shown in 
green, ionic interactions in magenta; some protein structure is omitted for clarity  
(E) Analysis of the StARD3 structure predicts key interacting residues are 
conserved (some of Lys377 missing in the crystal). 
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proteins that aligned the known cholesterol binding pocket of StARD3 with the 
putative cytosolic cholesterol binding pocket of NPC1 (Figure 14B).  This binding 
pose was also energetically favourable (Figure S4). 
 
Cholesterol egress from NPC1 may be blocked by the Cys800-Ser813 and/or Ile642-
Leu649 loops of this protein both of which are missing from the PDB structure,338 
usually a sign of a region being highly flexible.302  Thus the possible structures of 
these loops, together with 1, were predicted using the program Modeller362 
implemented in UCSF Chimera.363  As expected a diverse set of results was obtained 
(consistent with high flexibility) all with favourable energy scores (data not shown).  
Among these were loop models with 1 open and neither Cys800-Ser813 nor 
Ile642-Leu649 obstructing the putative cytosolic binding pocket.  Thus cholesterol’s 
path from NPC1 to StARD3 is potentially open (Figure 14C). 
 
To check the (re)built loops did not interfere with protein-protein interaction the 
ensemble was resubmitted to ROSIE.  This resulted in a smaller RMSD of atomic 
positions and improved energy scores for the most favourable poses (Figure S4)  
suggesting that the initial binding arrangement had been refined rather than 
contradicted.  Manual inspection of a sample of results also showed a relatively 
small positional deviation.  Closer examination of one arrangement showed the 
likelihood of a set of ionic and H-bond interactions holding the two proteins together 
(Figure 14D).  As analysed by ConSurf Lys377 is quite variable, but this residue 
forms a backbone H-bond so the variability is not significant, while the residue 
forming ionic interactions (Lys 411 and Arg413) are both conserved (Figure 14E).  
Thus it is plausible that StARD3 binds to NPC1 to collect cholesterol and that this 
interaction explains the presence of a lipid binding site on the cytosolic face of the 
endolysosomal membrane.  StARD3 can then dissociate from NPC1 and insert 
cholesterol to the ER membrane. 
 
Another family of sterol transporting proteins with a soluble domain is the oxysterol 
binding protein related proteins (ORPs).  ORP5 localises to the ER by a single trans-
membrane helix and has been implicated in the transfer of cholesterol from 
endolysosomes to the ER102,109 using its large cytosolic domain.  Thus an exactly 
similar approach was taken to simulate NPC1-ORP5 interaction using a model of 
ORP5 derived from a structure of a yeast homologue from the osh family (36% 
sequence identical, PDB 4ph7,364 see Table S2 for details).  Repeated attempts failed 
to yield an arrangement of the two proteins that was energetically favourable and 
allowed unimpeded transfer from the NPC1 cytosolic pocket to the lipid carrying 
domain of ORP5.  Whilst this may be due to shortcomings in the model or the 
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docking procedure it is consistent with in vitro studies of osh4 which suggest a 
sterol-phosphoinositide exchange mechanism365 (ORP5 can also transport PIs366) and 
MD work suggesting that osh4 interacts with membranes367 rather than another 
protein. 
 
Hence we may hypothesise models for post-NPC1 cholesterol transfer (Figure 15).  
In one route cholesterol is collected from the cytosolic pocket of NPC1 by the START 
domain of StARD3 before rearrangement of the flexible linker positions this domain 
at the ER membrane allowing the completion of cholesterol transfer.  The second 
route depends on cholesterol leaving NPC1 – the open binding sites suggested here 
(Figure 9) and elsewhere331 would permit this.  Once on the cytosolic face of the 
membrane cholesterol could be collected by ORP5, possibly in exchange for a 
phosphoinositide; ORP5 would then rearrange itself just like StARD3 before 
inserting cholesterol into the ER membrane.  Both these mechanisms depend on a 
stable tethering of LELs to the ER – varying accounts attribute this to the interaction 
of VAP-A with ORP1L24 (as shown in Figure 15) or with StARD3 itself.368   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Models of post-NPC1 cholesterol transport  Cholesterol (orange) 
may be collected from the cytosolic pocket of NPC1 by the StARD3 START 
domain which then transfers it to the ER membrane (route 1) or may diffuse 
from NPC1 and be collected by ORP5, possibly in exchange for a 
phosphoinositide (turquoise), and thereby conveyed to the ER. 
 
Revising the BK-cholesterol interaction site 
Whatever the function of NPC1, cholesterol accumulation resulting from its failure 
will likely affect the big potassium channel (BK, also known as MaxiK and KCa1.1) 
which has recently been found on lysosomes.369,370  It has long been recognised as 
being sensitive to its lipid environment with cholesterol suggested as the key  
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Figure 16  The BK channel  (A) functional domains in a cartoon representation 
of one of the 4 proteins that comprise the homotetramer.  (B) functional 
domains shown in one of the proteins from the model based on 5tj6.371  (C) 
Putative lipid binding domains of interest.  In (B) and (C) three of the proteins 
are shown in white for clarity; approximate position of the membrane shown by 
translucent discs. 
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species372–375 and there is evidence, not least structure-activity studies, to suggest a 
specific interaction rather than an influence on bilayer thickness.376,377  Thus we 
would expect cholesterol to bind to the BK protein.  BK is composed of 4 identical 
subunits each of which contain a voltage sensor and two regulatory of conductance 
for potassium (RCK) domains.  Each subunit also contributes two helices to the 
channel pore (Figure 16).  A 2012 paper378 traced cholesterol sensitivity to a motif 
(Val509-Lys518) positioned in RCK1; this sensitivity was lost when the protein was 
cleaved before Val509.  This cleavage was quite drastic removing all of RCK1 and 
-2, thus significantly weakening the link between Ca2+ binding and channel opening 
and questioning the physiological relevance of these findings.  Additionally MD 
simulation of lipid binding did not identify a stable binding pose.  More importantly 
still, recent structural work on the protein,371,379 locates the region identified as 
binding cholesterol in the cytosol where levels of cholesterol will be lower than in 
the membrane.  Given that the membrane region has 4 cholesterol binding motifs 
(Figure 16C) this seems unlikely.  Thus the question of where cholesterol binds to 
BK was deemed worthy of re-examination.  
 
To do this a model of the membrane section of the human BK channel was built 
based on a recent cryoEM structure (PDB 5tji)371,379 of an orthologue from a sea 
hare.  Docking of cholesterol was attempted at each of the intra-membrane 
cholesterol binding motifs.  For the CARC or for CRAC1 or CRAC3  (all defined as 
in378) no poses could be found that were both energetically favourable and 
biologically plausible, as discussed above, even when flexibility was allowed in 
residue side chains.  Docking cholesterol was then attempted in the space near 
CRAC2 (Val258-Arg266, located on the voltage sensor) allowing various 
combinations of side chains to be flexible.  Using this procedure a number of 
plausible binding poses were found (Figure 17).  These poses feature the classical 
elements of binding at a CRAC motif - H-bond to polar residue, CH- interaction 
with an aromatic residue and favourable van der Waals bonding with a lipophilic 
residue - but not derived from a contiguous section of protein sequence.  This has 
previously been found for the 2 adrenoceptor380 and illustrates the perils of trying 
to identify lipid-binding by searching sequences.  Neither illustrative pose shown in 
Figure 17 is likely to represent a static binding situation, rather cholesterol will flit 
between these and other poses with residue sidechains adopting a set of 
conformations.  Surface conservation analysis of these residues (Figure 17C) was 
less than fully convincing, although it is not clear that cholesterol modulation of BK 
activity is a natural mode of regulation (this role is usually accorded to the β subunit 
that has no role in pore forming381–383) so we would not necessarily expect to find 
these residues conserved.  Whilst these docking results cannot disprove cholesterol  
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Figure 17 Putative cholesterol binding at the voltage sensor of BK   
Cholesterol (orange) is able to form H-bonds (green) with Lys211 (A, B) and 
Asn265 (A), CH- interaction with Tyr263 (B) and hydrophobic interaction with 
Leu226 (A, B).  (C) Surface Conservation analysis of putative binding residues 
 
binding in the cytosolic domains, they are fully consistent with all relevant data on 
BK being a cholesterol sensitive channel and offers a plausible explanation for this 
observation.   
 
So when the NPCD lysosome accumulates cholesterol its BK channel activity will 
be reduced; conversely channel agonism384 or over-expression370 repairs the 
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endocytic defect in this disease.  As BK has been reported as a regulator of LEL-ER 
membrane contact sites (MCSs)385 these are likely to be impaired in formation and/or 
function.  A key function of MCSs is refilling endolysosomal Ca2+ stores which 
become depleted as the organelles acidify along the endocytic pathway.52  Thus we 
would expect that BK impairment in NPCD would lead, indirectly, to reduced 
endolysosomal calcium which has indeed been found by multiple groups53–55 (though 
not without some dissent115).   
 
. 
LEL calcium and TRPML1 
Reduced LEL Ca2+ will result in impaired calcium release via the TRPML1 channel 
which has been observed in NPCD.115  (Dysfunction of TRPML1 causes the storage 
disorder mucolipidosis type IV, which we will meet again in chapter 3.)  But as with 
so much else, TRPML1 impairment in NPCD actually results from multiple factors.  
This channel exists as a homotetramer whose assembly is driven by interactions 
between the loop 1 regions on adjacent subunits (Figure 18A).386  An aspartate-rich 
region on each loop forms a pore which confers pH-sensitivity on the channel.  At 
low pH the aspartate residues are all protonated so Ca2+ ions can pass freely through.  
As pH rises the aspartates become deprotonated and the resulting anionic 
carboxylate moieties bind Ca2+ which thereby inhibits its own conductance as 
demonstrated by the structural study.386  We saw in chapter 1 that the pH of the LEL 
compartment in NPCD is increased - something to which chapter 3 will return - and 
this is another reason for expecting reduced TRPML1 function in NPCD.  The 
increased levels of cholesterol in the LELs of NPCD cells is associated with the 
accumulation of sphingomyelin (SM) which has also been reported to inhibit Ca2+ 
efflux through TRPML1.115,387  The question thus arises of where SM binds to 
TRPML1.   
 
 
There are at least 3 possibilities for the site of this interaction: (1) SM binds at the 
same site as synthetic ligand ML-SA1, (2) SM uses its anionic portion to compete 
with the natural ligand PI(3,5)P2, (3) SM inhibits assembly of the four proteins into 
the channel (Figure 18A).  The first of these is precluded as the ML-SA1 binding 
site lies in the intra-membrane region (Figure 18A)388,389 and will thus be inaccessible 
to the SM headgroup.  (The headgroup is the distinctive part of lipid molecules with 
two tails (Figure 2A,C,D) and so likely to be the part of the molecule that determines 
lipid-protein interactions.)  The second possibility was investigated by docking the 
relevant lipid head groups to a region of the human protein (PDB: 5wj9)388 
equivalent to that recently identified in a marmoset TRPML3 channel390 as being the 
ligand binding site (sequence alignment in Figure 16B).  Both PI(3,5)P2 and natural 
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Figure 18  Possible SM binding sites on the TRPML1 channel  (A) SM may 
bind at one of 4 locations – two ligand binding sites and two sites of interaction 
between neighbouring protein chains.  Chains are shown in different colours 
and the approximate location of the membrane is indicated with discs.  (B) 
Alignment of human TRPML1 (PDB: 5WJ9388) and marmoset TRPML3 (PDB: 
5W3S390) locates conserved residues (red boxes) of the phosphoinositide 
binding site.   
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inhibitor PI(4,5)P2 were found to bind to this polybasic region (Table S4) thus 
supporting mutagenesis experiments390 locating binding here (After this work was 
completed crystallography confirmed this as the ligand binding site.389)  SM was also 
successfully docked to this region (Table S4) but the energy of interaction was much 
weaker than with the phosphoinositides suggesting that SM will not effectively 
compete with endogenous ligands for this binding site.   
 
The third possibility for SM inhibiting TRPML1 function is inhibition of channel 
assembly which has previously been shown to lead to reduced TRPML1 function.386 
Two sites of inter-chain binding have been identified in structural studies: Arg146-
Val175 (H-bonded) in the linker region386 and Arg486-Glu276 (zwitterionic) in the 
juxta-membrane region388 (Figure 18A).  The Arg146-Val175 site is too far from the 
membrane to be relevant.  Docking of the SM headgroup to the Arg486-Glu276 
region suggested that, whilst the residue side chains are very flexible, they preserve 
interactions between them rather than become separated by SM.  Channel assembly 
is thus maintained in the presence of this polar lipid (Figure 19).  Considering this, 
direct effects of SM on the TRPML1 channel appear unlikely and thus the inhibitory 
properties of this lipid may well derive from indirect effects, perhaps mediated 
through membrane organisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 Putative binding sites of lipids at TRPML1  (A) Glu276 from one 
chain (blue) forms a charged interaction with Arg486 from another (grey); 
interatomic distance 3.77Å.  (B) Modelling suggests plausible binding poses for 
SM (example shown) but these do not disturb the inter-residue interactions 
present in the apo state; interatomic distance 2.97Å.  Protein oriented as in 
Figure 18. 
 
TRPML1 plays roles in endocytosis391,392 and autophagy393 so the failure of these 
process in NPCD41,42,394,395 is unsurprising, though there may be some redundancy 
with the TPCs,396,397 P2X4 398 and P/Q-type VGCC.113,399  
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Annexins and phosphoinositides 
Endocytosis27 and autophagy400 also involve the peripheral membrane protein 
annexin A2 (AnxA2, previously annexin II).  This is reported to mislocalise in NPCD, 
associating with late rather than early endosomes27,61 thereby raising the expectation 
that its membrane binding will involve cholesterol, something later confirmed by 
experiment.27,57  Closer examination reveals phosphoinositides, and especially 
PI(4,5)P2, to have a key role.286,401,402  These observations can be harmonised by the 
result that cholesterol acts to aggregate PIs284,285 in a similar manner to its function 
in raft organisation so that NPCD triggers an accumulation not just of cholesterol 
but also other lipids including PIs.43  Significantly, the only study to report that 
AnxA2 membrane association is cholesterol-independent was conducted in model 
membranes that did not contain phosphoinositides.403  Thus it seemed reasonable to 
ask if phosphoinositides could bind to AnxA2.  If binding is favourable then the 
protein will go where the lipid is and AnxA2 mislocalisation would be thereby 
explained.  Other work reverses this direction of causality and suggests that AnxA2 
induces lipid raft formation401,404 – it is quite possible that both process occur 
simultaneously. 
 
A published x-ray structure of AnxA2 (PDB: 2hyw405) was used in preference to a 
previous structure (PDB: 1xjl406) as the earlier work had slightly worse resolution 
(2.59 vs 2.1Å) and quite a high number of water molecules per protein (212 for 319 
residues) which can be an indication of lower quality.302  The search was 
concentrated in a region including Lys279, Lys281 (as site-directed mutagenesis had 
identified these residues as important for PI(4,5)P2 binding401); a nearby residue 
Arg284 was also included in the search space.  All these residues are basic and are 
thus likely to protonated and positively charged in vivo.  The presence of a nearby 
bound Ca2+ ion was a difficulty as by default AutoDock sets charges on metals to 
zero.  This is not only unrealistic in itself but also leads to errors in the partial charges 
computed for atoms co-ordinated to the metal and others in the vicinity.  Thus 
Atomic Charge Calculator407 (webchem.ncbr.muni.cz/Platform/ChargeCalculator) 
was used to calculate the charges on all the atoms in the system and the AutoDock 
files manually edited to change the charge on the calcium and on all atoms nearby.  
Docking experiments could then be performed as normal. 
 
Consistent with the previously reported results286,401,402 the cationic residues interact 
with the two anionic phosphates while the two lipid side chains point away from 
the protein and remain in the membrane (example binding pose shown in Figure 
20A).  Docking of SM was also performed and the results were much less 
energetically favourable than for PI(4,5)P2 (Table S4) suggesting that the 
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phosphoinositide is genuinely responsible for AnxA2 binding.  Thus in NPCD AnxA2 
will be expected to mislocalise away from early endosomes and to cholesterol-rich 
late endosomes as observed27,61 and contribute to the documented endocytic 
defect.41,42  (Surface conservation analysis suggested this region of the protein is 
rather variable (data not shown); however given the in vitro demonstration that 
phosphoinositide binding depends on Lys279 and Lys281401 the value of this output 
is unclear.) 
 
Previous studies have reported conflicting results on the Ca2+-dependence of 
membrane binding by AnxA2.57,286,408  Consistent with in vitro work401 the results 
here support a direct interaction of the protein with PI lipids and thus do not require 
a specific role for calcium.  This is consistent with an MD study409 which found 
Lys281 interacting with membranes without requiring Ca2+ even as the interaction 
overall remained dependent on calcium and phosphatidylserine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20  Site of PI(4,5)P2 binding to AnxA2  (A)  PI(4,5)P2 (turquoise) binds 
to the convex face of AnxA2 (grey) driven (B) by zwitterionic interactions 
(magenta) with Lys279, Lys281, Arg284. 
 
Another member of the annexin family, AnxA8,d has also been reported to have 
roles in regulating endocytosis where it localises to late endosomal membranes.410  
However, this association increases on pharmacological inhibition of NPC1411 and 
AnxA8 is found to bind phosphoinositides including PI(4,5)P2.412  Given also the 
accumulation of PIs in NPCD the question arises of whether AnxA8 binds these 
lipids in a similar manner to AnxA2.  Sequence alignment of AnxA8 with –A2 
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revealed a similar polybasic region, though with one lysine mutated to an alanine 
(Figure 21A, red box).  The AnxA8 crystal structure (PDB: 1w3w413) shows that 
these residues are on the convex face of the protein where annexins tend to interact 
with membranes409,414 and so docking was attempted in this region.  When the 
equivalent basic residues (Lys267 and Arg272) were allowed to be flexible no 
binding pose could be found where PI(4,5)P2  interacted with both sidechains (data 
not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 Phosphoinositide binding to AnxA8  (A) Sequence alignment of 
AnxA8 with –A2 reveals two dissimilar basic regions.  (B) PI(4,5)P2 binds on 
the convex face of AnxA8.  (C) Detailed view of the binding site showing 
zwitterionic interactions. 
 
Inspection of the structure revealed that Arg272 was proximately located to Lys107 
and Lys112, a region where AnxA2 contained an aspartate residue (Figure 21A, blue 
box).  When docking was attempted in this region, allowing the basic sidechains to 
be flexible, numerous plausible binding poses featuring interactions with all 3 
positively charged centres were found (representative example shown in Figure 
21B,C, extended data in Table S4).  This binding, which requires validation from in 
vitro experiments may have functional consequences for NPCD which will be 
discussed later. 
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SNARE proteins and phosphoinositides 
Whilst it is clear that AnxA2 is important in endocytosis, its precise role has not yet 
been discovered (though recent work suggests it may assemble into dimers or 
heterotetramers to bridge membranes29). The same could not be said of SNARE 
proteins such as syntaxins and VAMPs (also known as synaptobrevins).  These are 
membrane-associated proteins, generally with one trans-membrane helix (Figure 
4B), which form complexes with SNAP-29 thereby mediating membrane fusion 
events (Chapter 1, Figure 1, ).  These complexes are subsequently disassembled 
so that the individual components can be re-used.  This disassembly is retarded in 
cholesterol rich membranes65 such as those present in the endolysosomal 
compartment of NPCD cells.  The molecular reasons for cholesterol-mediated 
slowing of this process are not known.   
 
Significant work has been done on the juxta-membrane region of syntaxin 1 (Stx1) 
which is polybasic and thus polycationic in vivo.415–418  Many other syntaxins have a 
similar region, as do their VAMP partners (see multi-sequence alignments, Figure 
22C) where less extensive work has been reported.419  This raises the questions of 
how two protein regions with like charges can get close enough together to form a 
complex, and how the complex stays assembled despite the electrical repulsion 
present.  These questions could be plausibly answered by invoking a bridging role 
for a negatively charged phosphoinositide lipid similar to that repeatedly found for 
Stx1.415–418 
 
To investigate this a model of a SNARE complex featuring Stx7 and VAMP8 – a 
combination reported necessary for endocytosis32–34 – was built based on an x-ray 
structure (PDB: 3hd7420) of a related bundle.  Docking was then attempted with 
PI(3,5)P2 allowing various combinations (Table S4) of juxta-membrane basic residues 
(VAMP8: Arg67, Lys68, Lys72; Syntaxin 7: Arg232, Lys233, Arg235) to be flexible. 
Numerous plausible poses were found where the anionic ligand bound to cationic 
residues of both SNARE partners (Figure 20A,B).  This would be expected to 
promote SNARE interaction and thus inhibit complex disassembly.  The previously 
reported cholesterol-mediated clustering of PI(3,5)P2284,285 means not only that this 
lipid will accumulate in NPCD but that it will accumulate in defined areas which 
thus have a high local concentration of phosphoinositide.  Thus should an assembled 
SNARE cluster escape one phosphoinositide molecule and begin diffusing through 
the bilayer it will likely encounter another phosphoinositide and so remain trapped.  
Thus the recycling defect observed in cholesterol rich membranes65 can be explained 
by appealing to the effect of cholesterol on another lipid rather than on the protein 
directly.  (The apparent paradox of Stx7, a cholesterol binding protein that lacks a  
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Figure 22  PI(3,5)P2 can bind to two members of a SNARE bundle  
simultaneously.  Sample poses from juxta-membrane region 1 (A) and 2 (B) 
of PI(3,5)P2 (turquoise) bridging VAMP8 (blue) and syntaxin 7 (grey) in the 
assembled SNARE bundle with zwitterionic interactions (magenta).  (C) Multi-
sequence alignment of human Stx (top) and VAMP (bottom) proteins showing 
the common polybasic region (red boxes) next the the TMH (blue boxes). 
 
recognised cholesterol binding motif,63 can plausibly be resolved along similar lines.)  
Repeated attempts to dock PI(4,5)P2 to the model consistently failed to give plausible 
binding poses (data not shown) suggesting that clustering is dependent on only the 
3,5-isomer.   
 
The situation with autophagy is more complicated as this has been reported to rely 
on Stx17 in both mammals and Drosophila;94,421 Stx7 does not appear to be 
involved.95  Stx17 is unusual in its possession of two trans-membrane helices, neither 
of which has a polybasic juxta-membrane region (Figure 22).   
 
Proteins where modelling is not currently helpful 
Annexin A6 
Chapter 1 advanced various ways in which Annexin A6 (AnxA6) might be implicated 
in NPCD pathology.  A typical annexin protein consists of a bundle of 4 ankyrin 
repeats;422 AnxA6 is atypical in that it has two such bundles connected by a flexible 
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linker423 (Figure 23) which means it can undergo internal re-organisation on 
membrane binding.424  Consistently, two groups report it binding membranes in 
more than one conformation but remaining peripheral425,426 (Figure 4A)  Other 
workers disagree finding it binds membranes in an integral mode427 (Figure 4D) 
possibly even trimerising and forming an ion channel.428  The Trp343 residue has 
been reported as key to binding58,428 though other reports do not examine this 
possibility.  In similarity with AnxA2 this protein has been reported to associate with 
phosphoinositides.429 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 Key areas of AnxA6  The polybasic regions aligning with those in 
AnxA2 and Trp343 all localise away from the periphery of the protein (structure 
taken from 1m91). 
 
To investigate if membrane association could occur by the same mechanism the 
AnxA6 sequence was split into its two halves and each multi-aligned with AnxA2 
(data not shown).  The polybasic region of AnxA2 implicated in membrane binding 
has approximate counterparts in each half of human AnxA6 and these can be located 
in a published crystal structure of the protein423 (PDB 1m9i, Figure 23).  However 
both these regions are at least partly buried in the interior of the protein (Figure 23) 
so for them to bind phosphoinositides in a membrane would require either forcing 
other parts of the protein to contact the membrane (so making modelling 
computationally very expensive409) or exposing the basic residues by large-scale 
conformational change (which is in the category of speculation).   Trp343 is also 
located in the interior of the protein in the crystal structure (Figure 23) but it is also 
part of the flexible linker and may be more or less exposed dependent on 
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Bundle 1 Bundle 2 
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conditions423 so using computation to examine its role in binding lacks the necessary 
well-defined starting point. 
 
rab7 and -9 
As we saw in chapter 1 rab7 apparently associates with cholesterol-rich membranes 
on NPCD endolysosomes from which it is recycled slowly thus contributing to the 
endocytic defect.26,50  Rab proteins become membrane-associated through the 
acquisition of  geranylgeranyl tails287 which insert into lipid bilayers (Figure 4C); 
however such a tail is  generally considered excluded from lipid rafts.430  Raft-
inclusion and hence impaired recycling of rab7 thus appear paradoxical and require 
further investigation as part of ongoing work to understand the complexities of 
membrane dynamics.  It may be postulated that lipid head groups interact with the 
residues close to the lipidation sites at the protein’s C-terminus in a manner similar 
to that advanced above for the SNAREs.  Indeed this region contains residues likely 
to carry charges at cytosolic pH (data not shown) so ionic interactions with 
accumulating charged lipids such as PIs and SM are possible; modelling could be a 
good way to investigate this.  Unfortunately in all of the published structures of 
human431,432 or rat433 rab7 the relevant C-terminal region is missing rendering such 
an approach impossible.  Exactly similar considerations apply to rab9.434–436 
 
ClC channels 
There are excellent reasons for studying the ClC chloride transporters, not least that 
in mice knockout81,83 or mutation82 of members of this family led to 
neurodegeneration.  ClC3, -6 and -7 are localised to the endolysosomal 
compartment437–439 where they associate with lipid rafts437,440 which are reported to 
disrupt their activity.440  They are likely to be implicated in maintaining the acidity 
of the lysosomal lumen75,439,441 (though there is some dissent about this442) and 
therefore storage of unmetabolised material in the lysosome.83  A proteomic study 
reports two members of this family upregulated in NPCD113 while a sub-population 
of NPCD lysosomes appears deficient in both H+ and chloride.441  The best available 
structures443,444 of eukaryotic ClC proteins have only low sequence identity with 
endolysosomal transporters (ca 25%, data not shown) and low resolution (ca 4Å) 
meaning models derived from them are likely to be of very low quality and therefore 
unsuitable for modelling lipid-protein interactions.  Provocatively, one of the 
published structures (PDB: 5tr1)443 has a cholesterol associated with it. 
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Two-pore channels 
Confusion characterises our current understanding of two-pore channels (TPCs)445 
extending as far as the ions they conduct where calcium,396 sodium446 and even 
hydrogen447 have all been reported. While localised to the endolysosomal 
compartment448 and implicated widely in its functions,396,397,449 no disease is yet 
associated with knockout or mutation of these proteins, unlike the better known 
calcium release channel TRPML1.80  (The possible involvement of the TPCs in 
Parkinson’s disease450 is an interesting hypothesis that has yet to be established.)  
The only definite link with NPCD is the report that sphingosine targeted to the 
lysosome results in Ca2+ release via TPC1.114  Whilst the pathogenic relevance of this 
finding has yet to be established the accumulation of Sph in NPCD endolysosomes61 
is suggestive.  Sphingosine has a chemical structure markedly dissimilar to the 
reported endogenous396,451 and synthetic452 ligands of the TPCs meaning its binding 
site requirements will be very different.  In turn this suggests that the Ca2+ release is 
unlikely to arise from direct binding to the ligand binding-sites determined by 
structural work (PDB: 5dqq and 6c9a)451,452 and so modelling work is unlikely to 
yield new insights. 
 
TMEM192 
TMEM192 is a lysosomal transmembrane protein453 implicated in autophagy;454 it 
also binds sphingolipidse and so may well have a role in NPCD, though no study 
has yet investigated that and knockout of the protein in mice did not lead to 
lysosomal dysfunction.455  Algorithmic searching of its primary sequence reveals a 
p24-like sphingolipid binding motif (discussed above) on one of its predicted456 
transmembrane helices (data not shown).  As previously noted this motif contains a 
compulsory aromatic residue at one end, however whether that residue should be 
near the membrane edge or near the membrane centre is not defined.  In fact this 
residue in TMEM192 (Trp55) is positioned near the membrane centre whereas the 
corresponding residue in p24 (Tyr189) is positioned near the membrane edge.271  
This questions whether or not sphingolipid binding occurs at this site and until the 
roles of the individual residues in the p24-like motif are understood more clearly 
modelling of lipid-TMEM192 interactions will likely provide nothing more than 
curiosities.  
 
TMEM175 
TMEM175 is a lysosomal potassium channel76 implicated in numerous aspects of 
degradative function including acidification.76,85  Intriguingly knockout of this 
                                                          
e Dr Per Haberkant (EMBL), personal communication 
86 
 
protein also results in reduced mitochondrial oxygen consumption.85  Given such 
widespread effects on metabolic function it is perhaps unsurprising that mutation of 
this protein has been associated with decreased age of onset of Parkinson’s 
disease84,457 and raises the question of whether it has roles in other 
neurodegenerative diseases.  The recent disclosure of the structure of a similar 
bacterial channel458 with ca. 30% sequence identity opens the possibility of 
constructing a homology model of this protein.  However no studies have yet 
examined lipid modulation of TMEM175 function so even if lipid binding could be 
successfully modelled its functional consequences would be unclear. 
 
Open questions and future work 
Extensive modelling work has generated evidence for NPC1 and -2 as binding 
cholesterol (which is widely accepted) and sphingosine (which is more 
controversial).  These ideas could be tested by mutating residues predicted to be key 
for binding; in particular Glu30 of the NPC1 NTD is an attractive target as this plays 
no role in cholesterol binding but is predicted to be important for sphingosine.  If 
mutating this residue provoked an NPCD-like phenotype then that would be good 
evidence of the involvement of Sph in the pathogenesis of this condition.  Equally 
the reality of sphingosine binding to NPC2 and the NPC1 NTD could be tested by 
co-crystallising the lipid and the protein in the same way as has been done for 
cholesterol.15,330   Recent MD studies of the transfer of cholesterol from NPC2 to the 
NTD of NPC1337,459 could be repeated with Sph.  The question of whether or not 
NPC1 acts to transfer cholesterol from one binding pocket in the SSD to the other 
(Figure 9) could be addressed using the methods of a separate MD study of NPC1 
in a model membrane.346  Whilst caveats should be attached to this work – the 
possibility that NPC1 occurs in complex with other proteins,354,355 the question of 
whether the composition of the model membrane adequately approximates reality – 
it would be significant if a similar result could be obtained with sphingosine. 
 
The question of NPC1 transferring lipids directly to soluble domains of carrier 
proteins, as predicted in Figure 14, could be addressed by mutating those residues 
identified as key to the association, especially those involved in charged interactions.  
If the proposed NPC1-StARD3 complex is real then such mutation would be 
expected to reduce the interaction and thus the transfer of lipid to other organelles.  
The opposite experiment, relief of disease burden by activating post-NPC1 
cholesterol transport by over-expression of StARD3 or ORP5, is unlikely to be 
successful.  Cholesterol transfer to the ER depends on formation of LEL-ER contact 
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sites (Figure 15) and multiple lines of evidence suggests the disruption of these in 
lysosomal storage disorders like NPCD.24,48,56   
 
Whilst this protein-protein interaction might explain the need for the 5 TMHs of 
NPC1’s SSD (Figure 7) it does not, as noted above, explain why NPC1 has an 
additional 8 helices spanning the bilayer.  It has recently been proposed that NPC1 
exports cholesterol via a pathway featuring wholesale conformational change in the 
protein460 so that the lipid passes not round the edge of the protein, as suggested 
here and elsewhere,331 but through the middle.  This would potentially be consistent 
with the finding that NPC1 regulates the activity of cathepsin D via binding to 
luminal loop 3461 – if cholesterol passing through the protein causes it to rearrange 
then cathD binding may be altered.  In the absence of any structural information 
supporting this pathway the modelling approaches used here are inappropriate.  
However, should such information emerge the modelling the putative NPC1-cathD 
interaction becomes feasible and interesting. 
 
The evidence that the BK channel is cholesterol sensitive is extensive372–375 but the 
binding site predicted here is novel.  This hypothesis could be tested by mutagenesis 
experiments involving key hydrogen-bonding residues Lys211 and Asn265 which 
would be likely to reduce binding and therefore cholesterol sensitivity.  If either of 
these mutations produced a fully functional but  cholesterol-insensitive channel then 
it would be interesting to produce the same mutant protein in NPCD cells as this 
might correct the endocytic defect as has been demonstrated by channel agonism384 
or over-expression.370  If such a mutation also corrected with lysosomal Ca2+ refilling 
defect (proposed to be dependent on BK369) then this would give great insight into 
the molecular pathology of NPCD. 
 
The failure of docking approaches to identify a binding site for SM on TRPML1 is 
disappointing in view of the reported channel inhibition by this lipid and hence 
reduced calcium efflux through it.115  That report did not demonstrate direct SM-
channel binding and found lysosomal calcium normal in NPCD, a result at odds with 
multiple other studies which report a reduction.53–55  Given that calcium efflux 
through TPC1 is also reduced in NPCD cells114 perhaps the simplest explanation is 
that lysosomal calcium is genuinely reduced in this pathology.  Such a reduction 
could account for the reduced TRPML1 calcium current without the need to invoke 
lipid-induced malfunction. 
 
The work on Annexin A2 reported here is in excellent agreement with existing in 
vitro studies (especially401).  Next it would be interesting to extend a recent high-
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level MD study of the interaction of AnxA2 with membranes409 to consider the 
interaction of the basic residues identified in Figure 20 with anionic membrane 
lipids.  To investigate further the reported accumulation of phosphoinositides in 
NPCD disease43 cells could be transfected with a YFP-tagged plekstrin homology 
(PH) domain177 (which recognises phosphoinositides).  Co-localisation of this protein 
with fluorescently-tagged antibodies to an LEL maker protein, eg LAMP2, would be 
expected.  If AnxA2 also held a fluorescent tag which co-localised with YFP-PH 
then the pathological relevance of the PIP-AnxA2 interaction would be confirmed.  
A similar approach with AnxA8 is also likely to be profitable as the mislocalisation 
of this protein in disease cells has not yet been demonstrated, only in cells treated 
with a pharmacological inhibitor of NPC1.411  The functional consequences of 
AnxA6 and –A8 (if confirmed) mislocalisation and likely to form a profitable area 
for investigation.  Both proteins have been reported to interact with actin412,462 and 
so may contribute to the defect in lysosomal localisation,24,26,51 although the current 
absence of small molecule modulators of the function of these proteins may restrict 
their usefulness in NPCD treatment. 
 
The association of the juxta-membrane region of syntaxin 1 with phosphoinositides 
has been demonstrated using a fluorescently tagged protein415,416 – the same 
approach could be taken with Stx7 and VAMP8.  It might also be possible to tag 
these two proteins with different fluorescent labels and use FRET to measure their 
association.  The modelling work in this chapter would predict that the degree of 
association would be greater in membranes with reasonable phosphoinositide 
content than in membranes devoid of those lipids.  Such an experiment would not 
demonstrate that the recycling defect from cholesterol-rich membranes65 is actually 
a direct result of PI-protein interaction, as this work proposes, but would point in 
that direction.  It would also be possible to extend the docking work described here 
to an MD simulation of the assembled SNARE bundle (as has been done with 
Stx1417) which would increase confidence in the reality of PI-protein binding.  A 
further extension to simulation of complex disassembly is more challenging as the 
mechanism of this process is only just emerging463 and simulation has not yet been 
attempted using an explicit lipid component.464 
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Summary 
Docking and MD simulations have supported the idea of NPC1 as a cholesterol 
export protein and postulated a direct interaction with StARD3 as part of the onward 
pathway.  Dysfunctional NPC1 will lead to the accumulation of cholesterol in the 
lysosome which will inhibit BK channel function.  This accumulation will also trigger 
the secondary storage of sphingomyelin (which may inhibit TRPML1) and 
phosphoinositides (which will mislocalise AnxA2 and impair SNARE recycling).  As 
consequences of all this endocytosis and autophagy will be impaired.  This chapter 
has also supported the idea of NPC proteins as a sphingosine export system; the 
next chapter will examine what might be the functional consequences of the 
impairment of this function. 
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Materials and methods 
Multi-sequence alignments were performed in Clustal Omega 
(ebi.ac.uk/Tools/msa/clustalo/)465 and visualised in JalView.466  Lipid binding motifs 
were located using Fuzzpro (bioinformatics.nl/cgi-bin/emboss/fuzzpro). 
Protein structures were either downloaded from the PDB or models built using 
SwissModel304 (swissmodel.expasy.org/).  Quality was assessed using 
QMEANBrane;306,307 see Table S2.  Approximate positions in the membrane were 
found using the OPM database (http://opm.phar.umich.edu/).308  The AnxA2 
structure features calcium ions which by default are set to zero charge by AutoDock.  
Thus atomic charges for these and spatially proximate atoms were calculated using 
the Atomic Charge Calculator (webchem.ncbr.muni.cz/Platform/ChargeCalculator)407 
and the relevant AutoDock files manually edited.  Ligand structures were prepared 
in Avogadro (avogadro.cc/) and minimized using the MMF94 force field with at 
least 5000 steps; other settings were defaults.   
Docking of lipids to proteins was performed using AutoDock 4.2.6309,310 using 
default settings.  AutoDock requires a search space (in which the docked ligand 
must fit) to be defined; this is accomplished by specifying the region’s centre, its 
offset from this centre in each of the x,y,z directions measured in points (1 point = 
0.375Å) and its dimensions also measured in points.  For each protein this 
information is given in Table S3 along with the residue sidechains allowed to be 
flexible.  The various descriptors of the ligand’s relation to the protein (position, 
orientation, bond angles) are then altered and a certain amount of mixing between 
different states allowed; hence the procedure is termed a genetic algorithm (GA).  
This is run a set number of times.  AutoDock clusters binding poses by RMS distance 
(cut-off > 2Å); extended data are given in Table S4.   Docking scores were used as 
a preliminary assessment followed by manual inspection for biological plausibility 
as discussed.   
For MD simulations sphingosine was parameterised using CGenFF 
(cgenff.paramchem.org/);320 the lipid structure file was the same as used in docking 
calculations but converted to sdf format (https://cactus.nci.nih.gov/translate/).  
CGenFF calculates approximate values for partial charges, bond angles and dihedral 
angles; the degree of approximation is given by a penalty score which should be less 
than 10 and must be less than 50.  The partial charge penalty scores of concern are 
given in Figure 24.  All these charges were considered reasonable given the 
electronegativity of the atoms in question.  Penalty scores above 20 were returned 
for some bond angles and dihedrals in the grey oval but the angles were also 
considered acceptable given that sphingosine was used in its energy minimized 
conformation.  In any case the sphingosine sdf file from the ZINC database,467 
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recommended by the authors of CGenFF, gave identical results.  Cholesterol has 
already been parameterised.318 
Pdb files containing both bound ligand and protein were made in UCSF Chimera363 
and then manually edited so that the atom numbers matched those in the lipid 
parameter files. 
MD simulations were run using the VMD interface351 of NAMD software;322 for ease 
the QwikMD plug-in323 was used to set up calculations.  Simulations were run in a 
15Å water box with 0.1M NaCl as an approximation for the complex ionic 
environment of the lysosome lumen.101  The equilibration phase was set at 1.24ns 
and the production phase at 10ns; CHARMM36 force field was used.317  Post-
simulation analysis was conducted in QwikMD;323 images for videos were recorded 
using the MovieMaker plug-in of VMD,351 made into videos using Adobe Photoshop. 
Protein structures, including docking results, were visualised in UCSF Chimera.363   
 
 
 
 
 
 
 
 
 
 
Figure 24 CGenFF penalty scores for protonated sphingosine  For details 
see text  
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Figure S1 Differences between published structures of NPC1  Structure of 
NPC1 (PDBs 3jd8 shown in white and 5u74 shown in grey) adopt approximately 
the same overall shape (left panel).  In the SSD (right panel) they locate Leu637 
essentially identically near the cytosolic end of helix 3 (right panel).  Because 
5u74 resolves all side chains the authors realised that the loop between helices 
3 and 4 was missing (dashed line) from their x-ray data whereas the authors of 
3jd8, where the side chains are not resolved, assumed the structure was 
continuous at that point.  Thus the two structures position different residues at 
the cytosolic end of helix 4 (Lys653 for 5u74 (and as predicted by InterPro) but 
Gly640 for 3jd8).  The significance of this for the current study is that key 
residue Pro691 is in a dramatically different location in the two structures (pink 
for 5u74, blue for 3jd8). 
 
Figure S2  Output of NPC2 MD simulations  RMSD of protein Cα atoms of 
NPC2 with bound cholesterol (orange), NPC2 with bound sphingosine 
(purple) and SphK with bound sphingosine (grey). 
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Figure S3  Output of NPC1 NTD MD simulations  RMSD of protein Cα atoms 
of NPC1 NTD with bound cholesterol (orange) and bound sphingosine (purple). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4 Extended data for modelled interaction between NPC1 and 
StARD3  (A) Initial simulation of NPC1 and StARD3 interaction results in 
energetically favourable binding poses; some of these align the cholesterol 
binding regions (see main text).  (B) Refinement of a selected initial result with 
(re)built loops generates smaller changes in position and a more favourable 
energy score. 
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Table S1  Available stuctures of NPC proteins 
Protein, 
Residues 
PDB Method Resolution 
(Å) 
Comments Ref 
NPC2 
1-130 
1nep X-ray 1.7 Bovine 14 
NPC2 
1-130 
2hka X-ray 1.8 Bovine 
In complex with 
cholesterol-O-
sulfate 
15 
NPC1 
23-247 
(NTD) 
3gkh X-ray 1.8 - 330 
NPC1 
23-247 
(NTD) 
3gki X-ray 1.8 In complex with 
cholesterol 
330 
NPC1 
23-247 
(NTD) 
3gkj X-ray 1.6 In complex with 25-
hydroxycholesterol 
330 
NPC1 
23-1251 
3jd8 cryoEM 4.4 - 335 
NPC1 
390-604 
(MLD) 
5f1b X-ray 2.3 In complex with 
Ebola virus 
glycoprotein 
468 
NPC1 
390-604 
(MLD) 
5f18 X-ray 2.0 - 468 
NPC1 
392-606 
(MLD) 
5hns X-ray 2.5 - 469 
NPC1 
23-1251 
5jnx cryoEM 6.6 In complex with 
Ebola virus 
glycoprotein 
335 
NPC1 
400-607 
(MLD) 
NPC2 
20-152 
5kwy X-ray 2.4 In complex with 
cholesterol-O-
sulfate (in NPC2) 
334 
NPC1 
334-
1255 
5u73  3.4 New designation for 
5i31 
331 
NPC1 
334-
1255 
5u74  3.3 New version of 5u73 
with sidechains 
resolved 
338 
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Table S2 Protein models used in this work  Experimentally determined and model 
structures are shown; QMEANBrane scores give a measure of quality from good (higher 
score) to bad (lower score).  QMEANBrane output also offers an idea of the position of the 
protein in the membrane which shows local quality scores from good (blue) to bad (orange). 
 
Protein Struc
-ture 
Model 
based on 
Resolu-
tion (Å) 
QMEAN 
Brane 
score 
Position in membrane Ref 
NPC1 
membrane 
region 
5u74  3.34 -4.23  
 
 
 
 
 
 
338 
NPC1 NTD 3gki  1.8 0.64a 
 
330 
NPC2 5kwy  2.41 -0.2 a 
 
334 
StARD3 5i9j  1.74 0.93 a 
 
360 
ORP5  4ph7 
36% 
identical 
2.55 -1.66 a 
 
364 
BK  5tji 
55.7% 
identical 
3.8 -5.85  
 
 
 
 
 
 
371 
TRPML1 
 
 
 
 
 
 
 
 
5wj9  3.49 -5.08  
 
 
 
 
 
 
388 
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Protein Struc
-ture 
Model 
based on 
Resolu-
tion (Å) 
QMEAN 
Brane 
score 
Position in membrane Ref 
AnxA2 2hyw  2.1 0.48 a  
 
405 
AnxA8 1w3w  2.1 0.69 a 
 
413 
Stx7 
VAMP8  
bundle 
 3hd7 
(Stx7 
36.2% 
identical, 
VAMP8 
35.6% 
identical) 
3.4 -2.87  
 
 
 
 
 
 
420 
Notes: a soluble protein, score generated by QMEAN. 
 
  
97 
 
Table S3  Particulars of docking procedures  In AutoDock the search space is centred on 
an atom and has a length in points (1 point = 0.375Å) in each of the three spatial dimensions.  
This space can be moved by the specified offset amounts.  While AutoDock holds the protein 
backbone rigid, it does allow the sidechains of certain residues to be made flexible.  The 
various descriptors of the ligand’s relation to the protein (position, orientation, bond angles) 
and then altered and a certain amount of mixing between different states allowed; hence the 
procedure is termed a genetic algorithm (GA).  For more details on the procedures used to 
perform docking and calculate the grids used, see.309,310 
 
Protein, 
region 
Grid centre Grid 
dimensions 
(points) 
Grid 
offsets 
(points) 
Residues with 
flexible 
sidechains 
Lipid (number of 
GA runs) 
NPC1, 
SSD 
Phe779,  
C 
x=80 
y=76 
z=126 
x=-7.583 
y=5.5 
z=7 
none Cholesterol (100) 
Sphingosine (300) 
NPC1, 
NTD 
Asn86, 
C 
x=40 
y=40 
z=60 
x=3 
y=0 
z=0 
none Cholesterol (20) 
Sphingosine (200) 
NPC2 Protein centre x=80 
y=80 
z=80 
x=0 
y=0 
z=0 
none Cholesterol (50) 
Sphingosine (200) 
BK, 
CRAC2 
Tyr263, 
C 
x=46  
y=40 
z=60 
x=0 
y=-2.5 
z=3.75 
Lys211 
Asn265 
Tyr263 
Cholesterol 
(300) 
TRPML1, 
Juxta-
membrane 
Asp114  
(chain A),  
CZ 
x=40 
y=50 
z=60 
x=10 
y=-3.75 
z=0 
Glu276 (chain A) 
Arg486 (chain D) 
Sphingomyelin 
(300) 
TRPML1, 
agonist 
Pro52, 
C 
x=40 
y=40 
z=40 
x=8.5 
y=-6.5 
z=0 
Lys55 
Arg61 
Lys65 
Arg318 
PI(3,5)P2, 
PI(4,5)P2, 
Sphingomyelin  
(all 500) 
AnxA2 Gly279, 
C 
x=60 
y=40 
z=60 
x=0 
y=-2.75 
z=-2 
Lys279 
Lys281 
Arg284 
PI(4,5)P2 
(400) 
AnxA8 Gly274 
C 
x=50 
y=40 
z=70 
x=0 
y=0 
z=6 
Lys107 
Lys112 
Arg272 
PI(4,5)P2 
(400) 
Stx7/VAMP8, 
juxta-
membrane 1 
Lys62 
(VAMP8), 
C 
x=60 
y=60 
z=60 
x=4 
y=0 
z=0 
Lys66 (VAMP8) 
Lys72 (VAMP8) 
Arg235 (Stx7) 
PI(3,5)P2 
(600) 
Stx7/VAMP8, 
juxta-
membrane 2 
Lys161 (Stx7), 
NZ 
x=54 
y=58 
z=50 
x=-1.5 
y=0 
z=-1.75 
Arg67 (VAMP8) 
Lys233 (Stx7) 
PI(3,5)P2 
(400) 
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Table S4  Details of AutoDock output  AutoDock clusters binding poses by RMSD (cut-off > 2.0Å) and 
orders clusters by binding energy of most favourable member.  For each binding experiment the clusters 
are given with the number of members of each in parentheses.  The mean binding energy is given; 
AutoDock’s margin for error is ± 1.5 kcal/mol so clusters with mean energies within this margin are 
energetically indistinguishable.  The status of each cluster (assessed as described in main text) is given.  
The interacting residues for each cluster are listed along with the position in the LEL membrane.  H-bonds 
were detected by AutoDock, ionic interactions were assumed when oppositely charged groups were within 
4Å of each other, the cut-off previously identified. The binding pose from each cluster chosen as 
representative and shown in the main text is indicated; the difference from the mean binding energy of the 
cluster (kcal/mol) is given in parenthesis – a negative value indicates more favourable and a positive value 
less favourable. 
 
Protein, 
region 
Lipid Cluster 
(members)a 
Mean 
binding 
energy 
(kcal/mol) 
Status Position 
Interactions (side-chain van der 
Waals unless stated) 
Member 
shown  
in text 
NPC1, 
SSD 
Cholesterol 1 (74) -9.50 Parallel, 
favoured 
Luminal 
Asp620 (side-chain, H-bond), Val 
621, Val624, Val625, Tyr628, 
Leu665, Val668, Ile687, Glu688, 
Pro691  
1  
(-0.38) 
2 (4) -9.42 Parallel, 
favoured 
Luminal 
Ser627 (side-chain, H-bond), Val 
621, Val624, Val625, Ala629, 
Tyr628 Phe632, Ile687, Glu688, 
Pro691 
 
4 (3) -8.93 Anti-parallel, 
disfavoured 
-  
5 (7) -8.51 Parallel, 
favoured 
Cytosolic 
Ile654, Ile361Ala695, Leu663, 
Ser655, Cys778, Leu782, Leu785, 
Asp786 (side-chain, H-bond), 
Arg789 
1  
(-0.25) 
6 (10) -8.25 Anti-parallel, 
disfavoured 
-  
Sphingosine 1 (115) -5.67 Parallel, 
favoured 
Luminal 
Ser627 (backbone, H-bond), 
Asp620 (side-chain, ionic), Val 
621, Val625, Tyr628, Ile687, 
Glu688, Pro691, Phe1221 
1  
(-1.36) 
2 (47) -5.53 Parallel, 
favoured 
Luminal 
Ser617 (backbone, H-bond), 
Asp620 (side-chain, ionic), Val 
624, Val668, Leu672, Val686, 
Ile687, Leu682, Glu688, Ile690, 
Pro691, Phe1221 
 
3 (24) -5.59 Parallel, 
favoured 
Luminal 
Ser617, Asp620 (side-chain, 
ionic), Val621, Val 624, Tyr628, 
Leu665, Val668, Ala669, Glu688 
(side-chain, H-bond), Pro691, 
Phe1221 
 
4 (22) -5.30 Parallel, 
favoured 
Luminal 
Asp620 (side-chain, ionic), 
Val621, Val 624, Val625, Tyr628, 
Phe632, Leu665, Glu688, Pro691, 
Phe1221 
 
5 (5) -5.26 Parallel, 
favoured 
Luminal 
Asp620 (side-chain, ionic), 
Val621, Val 624, Val625, Tyr628, 
Phe632, Ile687, Glu688, Pro691, 
Phe1221 
 
6 (8) -4.43 Parallel, 
favoured 
Luminal 
Asp620, Val 624, Tyr628, Leu665, 
Ile687, Glu688 (side-chain, H-
bond), Pro691, Leu695, Phe1221 
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Protein, 
region 
Lipid Cluster 
(members)a 
Mean 
binding 
energy 
(kcal/mol) 
Status Position 
Interactions (side-chain van der 
Waals unless stated) 
Member 
shown  
in text 
7 (5) -3.99 Anti-parallel, 
disfavoured 
-  
8 (13) -4.54 Parallel, 
favoured 
Cytosolic 
Ile354, Ile361, Ser655, Ile662, 
Ile663, Leu665, Cys778, Leu785, 
Asp786, Arg789, Asp796 (side-
chain and backbone, H-bonds) 
3  
(-0.76) 
9 (5) -4.76 Perpendicular, 
Disfavoured 
-  
10 (10) -4.34 Parallel, 
favoured 
Luminal 
Ser617 (side-chain and backbone, 
H-bonds), Asp620 (side-chain, H-
bond), Val621, Val 624, Val625, 
Tyr628, Ile687 
 
11 (8) -4.11 Anti-parallel, 
disfavoured 
-  
12 (9) -4.39 Parallel, 
favoured 
Luminal 
Ser617 (side-chain and backbone, 
H-bonds), Asp618, Val621, Val 
624, Tyr628, Phe632, Leu684, 
Pro691 
 
13 (8) -4.38 Perpendicular, 
Disfavoured 
-  
NPC1, NTD Cholesterol 1 (18) -13.11  Asn41 (side-chain H-bond), Gln79 
(side-chain, H-bond), Thr82, 
Leu83, Pro90. Phe108, Thr112, 
Leu176, Tyr192, Met193, Ala201, 
Phe203 
1  
(-0.19) 
2 (2) -12.18  Out  
Sphingosine 1 (107) -7.12  In 
Glu30 (ionic), Asn41 (side-chain 
H-bond), Gln79 (side-chain, H-
bond), Thr82, Leu111, Thr112, 
Tyr192, Met193, Ala201, Pro202, 
Phe203, Ile205 
1  
(-1.25) 
2 (31) -6.33  In 
Asn41 (side-chain H-bond), 
Thr82, Leu83, Asn86 (side-chain, 
H-bond), Leu111, Leu176, 
Met193,Ile205, Phe108, Phe203, 
Ile205 
 
3 (16) -5.51  Out  
4 (15) -5.79  In 
Leu83, Asn86 (side-chain, H-
bond), Leu87, Pro90, Phe106, 
Thr112, Met193, Tyr192 
 
5 (14) -5.59  Out  
6 (7) -5.53  In 
Leu83, Pro90, Phe108, Thr112 
(side-chain, H-bond), Leu176, 
Met193, Ala201, Pro202, Phe203, 
Ile205 
 
7 (8) -5.12  Out  
NPC2 Cholesterol 1 (19) -11.51  Out 
Leu49, Tyr55, Ser56, Val57, 
Gly76, Val83, Phe85, Leu113, 
Pro114, Tyr119, Leu124 
1  
(-0.11) 
2 (1) -11.16  In  
Sphingosine 1 (3) -4.71  Out 
Val39, Tyr55, Val57, Val74, 
Phe85, Leu113, Pro114 
(backbone, H-bond), Tyr119 (side-
chain, H-bond), Val126, Trp128 
 
2 (30) -3.92  Out 1  
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Protein, 
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Lipid Cluster 
(members)a 
Mean 
binding 
energy 
(kcal/mol) 
Status Position 
Interactions (side-chain van der 
Waals unless stated) 
Member 
shown  
in text 
Val39, Tyr55, Leu113, Pro114, 
Val115, Tyr119, Pro120 (side-
chain, H-bond), Ile122, Val126, 
Trp128, Trp141 
(-1.36) 
3 (40) -4.46  Out 
Tyr55, Gly76, Val83, Pro84, 
Phe85, Leu113, Pro114, Val115, 
Tyr119, Ile124, Val126, Trp128, 
Trp141 
 
4 (23) -4.00  In  
5 (31) -4.40  Out 
Tyr55, Val57, Gly76, Val83 
(backbone, H-bond), Leu113, 
Pro114, Val115, Leu124, Val126 
 
7 (23) -4.04  Out 
Val39, Leu47, Tyr55, Val57, 
Val74, His75 (backbone, H-bond), 
Gly76, Phe85, Leu124, Trp128, 
Val145 
 
8 (14) -3.97  Out 
Val39, Tyr55, Ser56, Val57, 
Val74, Gly76, Val83, Pro84 
(backbone, H-bond), Phe85, 
Leu124, Trp141 
 
BK, 
CRAC2 
Cholesterol 1 (109) -6.26 Displaced 
parallel, 
disfavoured 
-  
2 (72) -6.05 Parallel, 
favoured 
Lys211 (side-chain, H-bond), 
Leu215, Val223, Leu226, Val255, 
Val262, Tyr263, Asn265 (side-
chain, H-bond) 
22  
(-0.27) 
3 (56) -6.05 Parallel, 
favoured 
Leu215, Val223, Leu226, Val255, 
Val262 (side-chain, H-bond and 
van der Waals), Tyr263, Asn265 
(side-chain, H-bond) 
 
4 (6) -5.49 Parallel, 
favoured 
Lys211 (side-chain, H-bond), 
Leu215, Val223, Leu226, Val255, 
Val262, Tyr263 (side-chain, CH-) 
4 (+0.34) 
5 (3) -5.57 Perpendicular, 
disfavoured 
-  
8 (7) -5.63 Displaced 
parallel, 
disfavoured 
-  
9 (5) -4.68 Anti-parallel, 
disfavoured 
-  
10 (3) -4.93 Displaced 
parallel, 
disfavoured 
-  
11 (17) -5.14 Anti-parallel, 
disfavoured 
-  
TRPML1, 
Juxta- 
membrane 
SM 
head group 
1 (2) -3.40 Splayed 
Disfavoured 
-  
2 (2) -3.04 Anti-parallel, 
disfavoured 
-  
3 (3) -2.60 Splayed 
Disfavoured 
-  
4 (3) -2.35 Anti-parallel, 
disfavoured 
-  
6 (2) -2.53 Anti-parallel, 
disfavoured 
-  
7 (2) -3.12 Splayed 
Disfavoured 
-  
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Protein, 
region 
Lipid Cluster 
(members)a 
Mean 
binding 
energy 
(kcal/mol) 
Status Position 
Interactions (side-chain van der 
Waals unless stated) 
Member 
shown  
in text 
8 (2) -3.05 Perpendicular, 
disfavoured 
-  
9 (8) -1.41 Anti-parallel, 
disfavoured 
-  
11 (5) -2.76 Anti-parallel, 
disfavoured 
-  
12 (6) -1.71 Parallel,  
favoured 
Asp114 (side-chain, H-bond), 
Glu276 (side-chain, ionic), Arg486 
(side chain, ionic) 
1  
(-1.63) 
14 (4) -2.21 Anti-parallel, 
disfavoured 
-  
15 (3) -3.02 Splayed 
Disfavoured 
-  
16 (2) -2.71 Perpendicular, 
disfavoured 
-  
17 (3) -1.45 Perpendicular, 
disfavoured 
-  
20 (3) -1.41 Splayed 
Disfavoured 
-  
21 (7) -1.73 Anti-parallel, 
disfavoured 
-  
22 (2) -2.50 Splayed 
Disfavoured 
-  
23 (2) -1.92 Anti-parallel, 
disfavoured 
-  
25 (2) -2.37 Perpendicular, 
disfavoured 
-  
28 (4) -1.84 Anti-parallel, 
disfavoured 
-  
29 (3) -1.44 Perpendicular, 
disfavoured 
-  
31 (2) -2.37 Perpendicular, 
disfavoured 
-  
TRPML1, 
agonist 
PI(3,5)P2 
headgroup c 
1 (27) -17.40 Parallel,  
favoured 
Lys55 (side-chain, ionic), Arg67 
(side-chain, ionic), Lys65 (side-
chain, ionic), Arg318 (side-chain, 
ionic) 
 
PI(4,5)P2 
headgroup 
c 
2 (22) -19.11 Parallel,  
favoured 
Lys55 (side-chain, ionic), Arg67 
(side-chain, ionic), Lys65 (side-
chain, ionic), Arg318 (side-chain, 
ionic) 
 
SM 
headgroup c 
8 (9) -6.05 Parallel,  
favoured 
Lys55 (side-chain, ionic), Arg67 
(side-chain, H-bond), Lys65 (side-
chain, ionic), Arg318 (side-chain, 
H-bond), Arg322 (side-chain, H-
bond) 
 
AnxA2 PI(4,5)P2 
headgroup d 
1 (1) -7.82 Parallel,  
favoured 
Lys279 (side-chain, ionic), Lys281 
(side chain, ionic and H-bond), 
Arg284 (side-chain, ionic) 
 
2 (4) -7.07 Parallel,  
favoured 
Lys279 (side-chain, ionic and H-
bond), Lys281 (side chain, ionic 
and H-bond), Arg284 (side-chain, 
ionic) 
 
3 (4) -4.07 Parallel,  
favoured 
Lys279 (side-chain, ionic and H-
bond), Lys281 (side chain, ionic 
and H-bond; backbone, H-bond), 
Arg284 (side-chain, ionic) 
 
7 (3) -2.76 Parallel,  
favoured 
Lys279 (side-chain, ionic), Lys281 
(side chain, H-bond), Arg284 
(side-chain, ionic) 
2 (+0.18) 
9 (3) -3.32 Parallel,  
favoured 
Lys281 (side chain, H-bond;), 
Arg284 (side-chain, ionic) 
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Interactions (side-chain van der 
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shown  
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10 (2) -4.36 Splayed, 
disfavoured 
-  
13 (2) -4.73 Perpendicular, 
disfavoured 
-  
15 (4) -3.48 Splayed, 
disfavoured 
-  
20 (3) -3.62 Parallel,  
favoured 
Lys279 (side chain, H-bond) 
Lys281 (side chain, H-bond), 
Arg284 (side-chain, ionic) 
 
21 (4) -4.00 Parallel,  
favoured 
Lys279 (side-chain, H-bond), 
Lys281 (side chain, ionic and H-
bond), Arg284 (side-chain, ionic) 
 
25 (2) -3.40 
 
Splayed, 
disfavoured 
-  
27 (4) -3.58 Anti-parallel, 
disfavoured 
-  
38 (2) -3.37 Perpendicular, 
disfavoured 
-  
40 (2) -3.88 Perpendicular, 
disfavoured 
-  
43 (3) -3.73 Perpendicular, 
disfavoured 
-  
44 (3) -3.31 Perpendicular, 
disfavoured 
-  
46 (2) -4.02 Anti-parallel, 
disfavoured 
-  
50 (3) -3.55 Perpendicular, 
disfavoured 
-  
AnxA2 SM 
headgroup 
1 (7) -3.09 Anti-parallel, 
disfavoured 
-  
2 (3) -3.34 Anti-parallel, 
disfavoured 
-  
3 (3) -3.63 Anti-parallel, 
disfavoured 
-  
5 (3) -2.36 Anti-parallel, 
Disfavoured 
 
-  
6 (4) -3.17 Anti-parallel, 
disfavoured 
-  
8 (2) -3.39 Perpendicular, 
disfavoured 
-  
9 (3) -2.55 Splayed, 
disfavoured 
-  
1 (7) -3.09 Anti-parallel, 
disfavoured 
-  
2 (3) -3.34 Anti-parallel, 
disfavoured 
-  
3 (3) -3.63 Anti-parallel, 
disfavoured 
-  
5 (3) -2.36 Splayed, 
disfavoured 
-  
6 (4) -3.17 Anti-parallel, 
disfavoured 
-  
8 (2) -3.39 Splayed, 
disfavoured 
-  
9 (3) -2.55 Anti-parallel, 
disfavoured 
-  
10 (3) -2.83 Anti-parallel, 
disfavoured 
-  
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AnxA8 PI(4,5)P2 
headgroup 
1 (4) -10.96 Parallel,  
favoured 
Lys107, Lys112, Arg272 (all 
electrostatic), Thr275 (sidechain 
H-bond) 
 
2 (5) -9.38 Parallel,  
favoured 
Lys107, Lys112, Arg272 (all 
electrostatic), Leu109 (backbone 
H-bond) 
 
3 (9) -8.51 Parallel,  
favoured 
Arg85, Lys112, Arg272 (all 
electrostatic), Lys107 (side chain 
H-bond) 
 
4 (6) -9.29 Parallel,  
favoured 
Arg85, Lys107, Lys112, Arg272 
(all electrostatic) 
 
5 (3) -7.60 Anti-parallel, 
disfavoured 
-  
6 (15) -8.83 Parallel,  
favoured 
Arg85, Lys107, Lys112, Arg272 
(all electrostatic) 
2  
(-1.58) 
8 (4) -9.65 Parallel,  
favoured 
Arg85, Lys107, Lys112 (all 
electrostatic), Arg272 
(electrostatic and sidechain H-
bond) 
 
10 (7) -8.89 Anti-parallel, 
disfavoured 
-  
11 (6) -9.22  Lys107, Lys112, Arg272 (all 
electrostatic), Leu109 (backbone 
H-bond) 
 
Stx7/VAMP8, 
juxta-
membrane 1 
 
PI(3,5)P2 
headgroup 
 
1 (10) -10.56 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic and H-bond), Lys72 
(VAMP8, side-chain, 
electrostatic), Arg235 (Stx7, side-
chain, electrostatic and H-bond) 
2 
(-2.15) 
2 (3) -11.58 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic), Lys72 (VAMP8, 
side-chain, electrostatic and H-
bond), Arg235 (Stx7, side-chain, 
electrostatic and H-bond) 
 
3 (5) -9.99 Parallel,  
favoured 
-  
4 (5) -10.70 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic), Lys72 (VAMP8, 
side-chain, electrostatic and H-
bond), Arg235 (Stx7, side-chain, 
electrostatic) 
 
5 (2) -12.97 Anti-parallel, 
disfavoured 
-  
6 (2) -13.46 Anti-parallel, 
disfavoured 
-  
7 (6) -9.83 Anti-parallel, 
disfavoured 
-  
8 (6) -10.60 Anti-parallel, 
disfavoured 
-  
9 (10) -9.94 Anti-parallel, 
disfavoured 
-  
10 (7) -10.50 Anti-parallel, 
disfavoured 
-  
11 (8) -9.91 Anti-parallel, 
disfavoured 
-  
12 (4) -10.10 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic), Lys72 (VAMP8, 
side-chain, electrostatic and H-
bond), Arg235 (Stx7, side-chain, 
electrostatic and H-bond) 
 
14 (8) -10.00 Perpendicular, 
disfavoured 
-  
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15 (2) -11.20 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic), Lys72 (VAMP8, 
side-chain, electrostatic), Arg235 
(Stx7, side-chain, electrostatic and 
H-bond) 
 
17 (6) -9.97 Perpendicular, 
Disfavoured 
 
-  
18 (6) -8.82 Anti-parallel, 
disfavoured 
-  
19 (6) -11.93 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic), Lys72 (VAMP8, 
side-chain, electrostatic), Arg235 
(Stx7, side-chain, electrostatic) 
 
20 (3) -10.36 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic), Lys72 (VAMP8, 
side-chain, electrostatic), Arg235 
(Stx7, side-chain, electrostatic) 
 
22 (4) -9.91 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic and H-bond), Lys72 
(VAMP8, side-chain, 
electrostatic), Arg235 (Stx7, side-
chain, electrostatic and H-bond) 
 
23 (3) -10.91 Perpendicular, 
disfavoured 
-  
24 (6) -9.48 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic), Lys72 (VAMP8, 
side-chain, electrostatic), Arg235 
(Stx7, side-chain, electrostatic and 
H-bond) 
 
25 (7) -8.68 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic), Lys72 (VAMP8, 
side-chain, electrostatic and H-
bond), Arg235 (Stx7, side-chain, 
electrostatic and H-bond) 
 
26 (5) -9.97 Parallel,  
favoured 
Lys72 (VAMP8, side-chain, 
electrostatic), Arg235 (Stx7, side-
chain, electrostatic) 
 
28 (2) -11.04 Perpendicular, 
disfavoured 
-  
30 (9) -9.21 Perpendicular, 
disfavoured 
-  
31 (4) -9.16 Perpendicular, 
disfavoured 
-  
32 (5) -9.20 Parallel,  
favoured 
Lys68 (VAMP8, side-chain, 
electrostatic), Lys72 (VAMP8, 
side-chain, electrostatic), Arg235 
(Stx7, side-chain, electrostatic) 
 
Stx7/VAMP8, 
juxta-
membrane 2f 
PI(3,5)P2 
headgroup 
1 (8) -3.37 Perpendicular, 
disfavoured 
-  
2 (2) -4.75 Parallel, 
favoured 
Arg67 (VAMP8, side-chain, 
electrostatic), Lys233 (Stx7, side-
chain, H-bond) 
 
3 (4) -2.75 Parallel, 
favoured 
Arg67 (VAMP8, side-chain, 
electrostatic), Tyr230 (Stx7, side-
chain, H-bond), Lys233 (Stx7, 
side-chain, electrostatic and H-
bond) 
1  
(-2.50) 
4 (18) -2.20 Antiparallel, 
disfavoured 
-  
5 (12) -1.92 Parallel, 
favoured 
Lys233 (Stx7, side-chain, 
electrostatic) 
 
6 (4) -2.76 Antiparallel, 
disfavoured 
-  
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7 (8) -2.23 Antiparallel, 
disfavoured 
-  
8 (6) -2.45 Perpendicular, 
disfavoured 
-  
9 (8) -2.69 Perpendicular, 
disfavoured 
-  
10 (5) -3.41 Perpendicular, 
disfavoured 
-  
11 (4) -3.30 Perpendicular, 
disfavoured 
-  
12 (3) -2.99 Parallel, 
favoured 
Lys233 (Stx7, side-chain, 
electrostatic and H-bond) 
 
13 (12) -2.65 Perpendicular, 
disfavoured 
-  
14 (6) -2.87 Parallel, 
favoured 
Lys233 (Stx7, side-chain, 
electrostatic) 
 
17 (3) -3.68 Parallel, 
favoured 
Lys233 (Stx7, side-chain, 
electrostatic) 
 
19 (4) -3.41 Antiparallel, 
disfavoured 
-  
20 (10) -1.62 Antiparallel, 
disfavoured 
-  
21 (6) -1.97 Perpendicular, 
disfavoured 
-  
22 (6) -2.49 Parallel, 
favoured 
Arg73 (VAMP8, side-chain, 
electrostatic), Lys233 (Stx7, side-
chain, electrostatic) 
 
23 (2) -2.46 Perpendicular, 
disfavoured 
-  
24 (4) -2.28 Parallel, 
favoured 
Asn73 (VAMP8, side-chain, H-
bond), Lys233 (Stx7, side-chain, 
electrostatic and H-bond) 
 
25 (3) -1.95 Antiparallel, 
disfavoured 
-  
26 (16) -2.00 Parallel, 
favoured 
Asn73 (VAMP8, side-chain, H-
bond), Lys233 (Stx7, side-chain, 
electrostatic) 
 
27 (10) -2.16 Perpendicular, 
disfavoured 
-  
28 (2) -3.45 Perpendicular, 
Disfavoured 
-  
29 (12) -2.54 Perpendicular, 
Disfavoured 
-  
30 (4) -2.03 Perpendicular, 
disfavoured 
-  
 
Notes: aDocking experiments generally produce a long ‘tail’ of small clusters with less favourable binding 
energies.  These are omitted as are clusters with only 1 member. bThe smaller size of the clusters 
aligned to the cytosolic face relative to those aligned to the luminal face is likely a consequence of the 
larger size of the luminal binding pocket.  When cholesterol is positioned randomly at the start of the 
calculation run it is more likely to be close to the luminal pocket.  The energetic favourability of binding 
poses aligned to the cytosolic face was confirmed by independent docking experiments using ROSIE-
Rosetta software (rosie.rosettacommons.org/ligand_docking, data not shown).  cData given for the most 
energetically favourable and biologically plausible cluster only.  dIncreasing the RSMD cut-off to 4.0Å 
dramatically reduced the number of clusters but clustered some antiparallel binding poses together with 
parallel ones (data not shown).  eAn abbreviated list of results is shown due to the diffuse nature of the 
clustering and that many of the clusters have indistinguishable interactions.  fRSMD cut-off of 2.5Å was 
used. 
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Chapter 1 introduced Niemann-Pick type C disease (NPCD) as most frequently 
originating with dysfunction of NPC1, a protein of late endosomes and lysosomes, 
and consequently featuring widespread errors of the endocytic system.  Chapter 1 
also questioned whether the traditional role of NPC1 and its partner NPC2 as 
mediating cholesterol export from the lysosome is their main or only function.  
Chapter 2 provided evidence that these proteins may also export sphingosine.  This 
chapter attempts to connect those two strands of thought by examining endocytic 
dysfunction in NPCD cells and asking if this can be corrected in a way that mimics 
the correction of faulty sphingosine export. 
 
Introduction 
Measuring the functions of the endocytic system 
Perhaps the most widely known feature of the endocytic system is the acidic pH of 
the lumen of the lysosome, the key degradative organelle.  Quantifying this acidity, 
however, proves less easy, especially in the context of NPCD.  One approach is to 
use acridine orange73,470,471 which undergoes a pH-dependent colour change but the 
behaviour of this probe can also be affected by cholesterol levels472 making its use 
in NPCD problematic.  LysoTracker red (Figure S1) is a useful probe for labelling 
acidic organelles by virtue of its weakly basic nature (pKa = 7.5473).  The same 
property ensures, however, that it is almost fully protonated at all pH values below 
ca. 6.5 meaning it is likely insensitive to any lysosomal pH changes thus rendering 
results, including from NPCD cells,474 difficult to interpret.  Both acridine orange 
and LysoTracker red diffuse freely through membranes; their basicity means they 
become protonated in acidic organelles and so are trapped inside as the resulting 
positive charge stops their free diffusion.  An alternative approach is to use pH 
probes conjugated to dextrans,54,73,475 polysaccharides which are internalised through 
the endocytic pathway.  Such probes access cells in a given time period (the 'pulse' 
time) and are then 'chased' into cells for the time required to localise them correctly.  
The trouble is that lysosomal storage disorders (LSDs) like NPCD feature delayed 
endocytosis – colloquially referred to as a traffic jam45,476 – meaning that defining 
the chase time is not easy.  This difficulty means that it is perfectly possible for 
dextran probes to measure a subtly different compartment in control compared with 
disease cells.  This complication becomes yet more apparent in the light of recent 
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work which suggests that, rather than being homogeneous, the cell’s population of 
lysosomes contains differing sub-groups.441,477,478  Ideally then, we require a 
lysosomal pH probe which is lipid-insensitive, sub-population specific, and that 
works across the relevant pH range.  Such probes have only recently been 
reported441,479 and are not commercially available making compromise inevitable.  
The present work used LysoSensor yellow/blue (Figure S1),480 a freely diffusing 
probe which protonates in acidic compartments (and consequently remains trapped 
there) and fluoresces at two wavelengths – the ratio of the intensities correlates with 
pH in the range 3-7.5.  In comparison with these virtues its disadvantages are minor: 
various experimental parameters must be carefully controlled,481 and simultaneous 
measurement of all acidic organelles is unavoidable.  This second fact means that 
this chapter refers to endolysosomes (ELs) to signify the totality of the endocytic 
acidic compartment. 
 
Other assays of the functions of the endocytic system are subject to less ambiguity.  
Thus LysoTracker red (Figure S1) can be used to label all acidic organelles and 
thereby assess the size of the endolysosomal compartment.  BODIPY-LacCer (Figure 
S1) is a lipid labelled with a fluorescent tag which inserts into the outer leaflet of 
the cell’s plasma membrane.  Pulse-chase experiments transport the marker, and 
therefore the fluorescence, to the preferred destination of its carrier lipid, in this case 
the Golgi via a pathway dependent on NPC1, rab7 and -9 and TRPML1.41,391  
Examining cells for the location of the fluorescence thus gives a measure of any 
delay in the endocytic process. 
 
Whilst the obvious platform for studying NPCD at the cellular level is to use cells 
obtained from patients a pharmacological approach is also popular.  This involves 
the use of U18666a (Figure S2), a blocker of NPC1112,482 which is likely to be trapped 
in lysosomes by virtue of its weakly basic nature. 
 
Results and Discussion 
Defining the endocytic defects in NPCD 
U18666a has traditionally been used at concentrations in the low micromolar range.  
In mouse RAW macrophages this treatment gave an endolysosomal pH of 6.3±0.4, 
significantly higher than the control value of 5.3±0.2 (Figure 1A) and consistent with 
a previous report in baby hamster kidney cells.475  However a lysosome with a 
luminal pH of 5 will have an H+ concentration of ca. 10M so the alkalinising effect 
of 5M U18666a could be attributed to simple acid-base chemistry.  Indeed 9 basic  
 
 
LysoSensor yellow/blue 
as the best compromise 
pH probe 
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Figure 1  Effect of U18666a treatment on RAW cells  (A) U18666a at a dose of either 
5µM or 300nM induces increases in endolysosomal pH; results are the mean ± SEM of 
at least 4 independent experiments.  (B) Correlation curve for LysoSensor yellow/blue 
in RAW cells; points are mean ± SEM from independent experiments (n=24, r2=0.965).  
(C) Representative images of BODIP-LacCer endocytosis in RAW cells; scale bar 10µm. 
(D) Quantitation of Golgi targeting; results are mean ± SD from at least 2 independent 
experiments examining at least 150 cells per experiment. (E) Representative images for 
LysoTracker experiments in RAW cells  (F) Quantitation of acidic compartment volume; 
results are mean ± SEM of at least 3 independent experiments examining at least 100 
cells per experiment.  
p<0.01 
p<0.01 
3
4
5
6
7
8
0 1 2
p
H
Blue/yellow ratio
U18666a 
A B 
0%
20%
40%
60%
80%
100%
Control U18666a
P
e
rc
e
n
ta
g
e
 G
o
lg
i 
ta
rg
e
tt
in
g p<0.05 
C D 
U18666a 
Control 
0
500
1000
1500
2000
2500
3000
3500
Control U18666a
R
e
d
 p
ix
e
ls
 p
e
r 
c
e
ll
p<0.05 
E F 
3
4
5
6
7
8
Control 300nM 5uM
E
n
d
o
ly
s
o
s
o
m
a
l 
p
H
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Endolysosomal defects in NPCD  (A) Endolysosomal pH is increased in 
NPCD; results are the mean ± SEM of at least 4 independent experiments. (B) 
Correlation curve for LysoSensor yellow/blue in fibroblasts under various conditions with 
non-significant differences between datasets; points are mean ± SEM from independent 
experiments (for HF (white squares) n=6, r2=0.89, for NPC1F (black squares) n=8, 
r2=0.97). (C) Representative images of BODIPY-LacCer endocytosis in fibroblasts; 
scale bar 10µm. (D) Quantitation of Golgi targeting; results are mean ± SD from at least 
2 independent experiments examining at least 90 cells per experiment. (E) 
Representative images for LysoTracker experiments in fibroblasts  (F) Quantitation of 
acidic compartment volume; results are mean ± SEM of at least 3 independent 
experiments examining at least 30 cells per experiment.   
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drugs used at a dose of 10M all induced a lysosomal storage disorder (LSD)-like 
phenotype483 (possibly involving calcium and mTOR484).  This was despite the drugs 
having a diversity of chemical structures and none of them resembling U18666a 
making it highly unlikely that they would all bind to NPC1.  Thus potentially highly 
significant is the finding that U18666a inhibits lysosomal cholesterol export with a 
potency in the sub-micromolar range (while LDL degradation remains normal).482  
At such a dose the numerous off-target effects485–487 of U18666a are eliminated or 
reduced as confounding factors; perhaps more significantly a dose of around 300nM 
would be insufficient to neutralise an H+ concentration of 10µM   
 
Treatment of RAW cells with 300nM U18666a gave a pH increase indistinguishable 
from that seen with the higher concentration (Figure 1A).  Some previous work 
suggests that correct acidification is necessary for the successful completion of 
endocytosis.37,38  Thus pulse-chase experiments with BODIPY-LacCer, a Golgi-
targeted marker41 showing green fluorescence, were performed RAW cells and the 
proportion of cells where a fluorescently labelled Golgi could be seen was 
quantitated.  This proved considerably reduced on treatment with 300nM U18666a 
(Figure 1C for typical images (Golgi indicated by white arrow) and D for 
quantitation).  LSDs are often marked by a proliferation of the endocytic 
compartment which can be visualised by LysoTracker red488 and quantitated by 
counting red pixels – for full details see Materials and Methods.  Treatment of RAW 
cells with 300nM U18666a effectively simulated this disease phenotype (Figure 1E 
for typical images and F for quantitation).f   
 
When fibroblasts from patients deficient in NPC1 (denoted NPC1F, see Table S1) 
were examined all the features found in the drug induced phenotype were again 
observed.  Thus endolysosomal pH in control fibroblasts (denoted HF) was found to 
be 4.5±0.1 in line with previously reported values obtained with LysoSensor 
yellow/blue489,490 while in NPC patient fibroblasts this increased to 5.4±0.3 (Figure 
2A).  This is in contrast to previous reports that NPCD does not change 
endolysosomal pH54,73,470,474 though these accounts may suffer from the 
methodological flaws discussed earlier. (After this work was completed other reports 
emerged of increased endolysosomal pH in NPCD disease models.43,72,441)  The delay 
in appearance of BODIPY-LacCer fluorescence at the Golgi was also observed: the 
percentage of cells showing a clear Golgi after 90 minutes chase was reduced from 
78% in healthy cells to 13% in cells deficient in NPC1 (Figure 2C and D).  Consistent 
                                                          
f These experiments were performed by my colleague Meenakshi Bhardwaj; I am 
grateful for the use of her data. 
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with previous reports of NPCD491,492 and indeed other lysosomal storage disorders 
(LSDs)488 the LysoTracker red assay showed an increase in the size of the acidic 
compartment in NPC1-deficient fibroblasts (Figure 2E for typical images, 2F for 
quantitation).   
 
Does cholesterol accumulation increase endolysosomal pH?  
Given that NPCD lysosomes accumulate cholesterol an obvious hypothesis to 
explain the pH increases is that the lipid inhibits the vATPase proton pump 
responsible for acidifying the lysosomes.  This multi-subunit protein associates with 
lipid rafts,475,493,494 areas of high cholesterol concentration (see Chapter 2, Figure 3 
and accompanying discussion), while the lysosome has both the lowest amount of 
cholesterol and the most acidic pH of all the endocytic vesicles.495  Furthermore a 
photo-activatable tritiated cholesterol analogue labelled the c subunit of vATPase.332  
Each assembly has 10 of these subunits arranged in a rotating ring496 (grey in Figure 
3) and the Glu139 residue co-operates with Arg735 on the a subunit (blue in Figure 
3) to move the proton into the lysosomal lumen.36  The c subunit has been identified 
as the location of the binding site for almost all known inhibitors of vATPase whose 
interaction has been studied at the molecular level.  This includes three natural 
product families the conconamycins,497 bafilomycins498 and archazolides,499 a 
synthetic conconamycin analogue500 and an inhibitory protein.501  The inhibitors 
salicylihalamide502 and apicularen503 are exceptions to this pattern, though the 
apicularen binding site is partially on subunit c and partially on subunit a.  Thus a 
model was built (for details see Materials and Methods) of the decameric c ring of 
human vATPase based on the recently disclosed cryoEM structure of a yeast 
homologue (PDB:5tj5, 70% identical).496  This proved of acceptable quality (see 
Table S3) with a higher score than an alternate model based on the x-ray structure 
of a bacterial protein504 (data not shown).  Docking of the inhibitor archazolide gave 
results consistent with those previously reported505 increasing confidence in the 
model (data not shown). 
 
Attempted docking of cholesterol at a CARC motif (Arg126-Leu133) with the 
arginine sidechain allowed to be flexible indeed uncovered energetically favourable 
binding modes (Figure 3B) consistent with the localisation of this protein assembly 
to lipid rafts.  A similar tactic with Lys155 delivered similar results (Figure 3B).  
However neither set of binding poses covers Glu139 – as the inhibitor archazolide 
does499 – and so this residue remains free to collect the proton to be pumped into 
the lysosome.  Thus it is questionable whether such binding would be inhibitory.  
Some binding poses were found with the cholesterol covering Glu139 and lying 
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Figure 3  Cholesterol is unlikely to account for the acidification defect in NPC1 
cells  (A) Structure of the S. cerevisiae vATPase (PDB: 5tj5496); decameric c subunit 
ring in grey, a subunit in blue, other subunits in white; key residues for proton transport 
shown.  (B) Cholesterol docking poses are unlikely to impede proton pumping.  (C) 
Incubation of RAW cells with 300nM U18666a gives a pH increase in 2.25 hours, quicker 
than cholesterol accumulates under identical conditions (r2 = 0.979). 
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perpendicular to the bilayer (data not shown).  While such an orientation is possible 
its probability is low in thick membrane regions such as the rafts where vATPase 
resides.325  Thus direct inhibition of vATPase by cholesterol seems unlikely to be 
responsible for the pH defect in NPC1-deficient cells. 
 
In vitro studies led to the same conclusion.  Thus when RAW cells were treated with 
300nM U18666a an increase in endolysosomal pH was apparent almost immediately 
(Figure 3C); after 2.25hours the value had reached 6.6±0.4 (p<0.05 versus 
untreated), a value indistinguishable from the 16 hour incubation (Figure 1A).  
Previous studies in the same cell line had shown that U18666a begins to stimulate 
cholesterol accumulation only after 4 hours54 suggesting that this lipid is not 
responsible for the endolysosomal pH increase.  As it appeared difficult to follow 
the pathological steps of NPCD from protein dysfunction to increased 
endolysosomal pH a different approach was tried. 
 
Can endolysosomal defects be repaired? 
In chapter 1 we encountered NB-DNJ (miglustat, Zavesca®, Figure S2), approved in 
Europe for the treatment of NPCD and an inhibitor of GBA2 the enzyme that breaks 
down glucosylceramide on the cytosolic leaflet of membranes (‘cytosolic GlcCer,’ 
Chapter 1, Figure 4B, stage ⓯).248  Miglustat features a 4-carbon chain attached to 
the ring nitrogen atom (Figure S2).  Reasoning that GBA2 acts on a membrane 
bound lipid led to the idea that increasing the length of this chain would incorporate 
the inhibitor into membranes and so increase its effective concentration at the site 
of action.  This tactic led to AMP-DNJ (Figure S2),249 a compound with greater 
GBA2 potency than miglustat (1nM compared with 5-300nM248), though some loss 
of selectivity over GlcCer synthase (GCS, IC50 150nM versus 20-50µM248) and 
lysosomal hydrolase GBA1248 (Chapter1, Figure 4, stages ❺ and ❾, IC50 50-
200nM versus 400-500µM248).  (This is consistent with the success of the same tail-
lengthening tactic in preparing GBA1 inhibitors.506  Unfortunately neither study 
performs a lipophilic ligand efficiency analysis,507,508 which can sometimes unmask 
phantom inhibitory potency, eg.509  In any case assessing inhibitory potency against 
these enzymes is difficult.248,510,511)  AMP-DNJ rather than miglustat was selected for 
use in this studyg as its greater potency is likely to reduce off-target effects and its 
efficacy in a mouse model of NPCD has been demonstrated.250  It also has lower 
potency than miglustat at ERGluII (ca. 200µM249 compared with 5-13µM512,513); 
                                                          
g I am indebted to the laboratory of Prof Johannes Aerts (Universiteit Leiden) for a 
gift of a generous sample of this material prepared as previously described.249,682 
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Inhibitory activities at instestinal glucosidases have not been reported for either 
compound, though annecdotally GI side-effects are a common reason for 
discontinuing miglustat treatment. 
 
Wider considerations supported the investigation of sphingolipids, which 
accumulate in this disease,43,61 as having a role in pathology and indeed normal 
physiology.  (Sphingolipid (SL) metabolism was introduced in chapter 1 (Figure 4) 
including the elaboration to glycosphingolipids (GSLs).  Drugs which act on this 
pathway are shown in Figure S2 and detailed in Table S3.)  Endolysosomal 
acidification has been found to be controlled by glycolipids in neurons,514 
melanocytes,515 plant vacuoles,516  and C. elegans.517  It is increasingly apparent that 
aberrant lysosomal GlcCer in Gaucher disease, another LSD, is associated with 
elevated endolysosomal pH.518–521 
 
Following precedent522,523 20nM was selected as the dose of AMP-DNJ.  This 
treatment indeed reduced the aberrant endolysosomal pH of NPC1 cells from 
5.4±0.3 to 4.5±0.2 (Figure 4A).  When normal fibroblasts were subjected to the 
same treatment the endolysosomal pH also reduced to 4.1±0.1 (Figure 4A).  This 
dose also restored disrupted BODIPY-LacCer targeting in NPC1Fs (Figure 4B); Golgi 
targeting of this fluorescent lipid in healthy cells was not affected (data not shown).  
These findings are consistent with previous work linking endolysosomal pH with 
endocytic trafficking37,38 and with previous experiments in Gaucher disease where 
inhibiting GlcCer synthase gave aberrant trafficking which was repaired by 
specifically replenishing cytosolic GlcCer by adding GlcSph.524   In contrast, 
treatment of NPC1Fs with various concentrations of AMP-DNJ did not repair the 
defect in endolysosomal volume as measured by LysoTracker Red (Figure 4C).h  This 
is at odds with findings using B-lymphocytes from patients treated with 
miglustat243,492 where the volume of the acidic compartment, measured with 
LysoTracker red, was increased in untreated patients and normalised on therapy.  
This disparity may reflect a cell type difference or may be indicative that the effect 
is chronic (the miglustat studies used time points of days to weeks while this work 
used 24 hours).  The possibility that miglustat and AMP-DNJ have subtly different 
pharmacologies is less probable but cannot be excluded.  That AMP-DNJ corrects 
the acidification of the endolysosomal compartment when taken as a whole, while 
leaving endosomal proliferation unaffected, suggests that this drug increases 
acidification of endocytic organelles. 
                                                          
h These experiments were conducted by BSc student Lukasz Stolarczyk under my 
supervision; I thank him for his efforts. 
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Figure 4  Effect of AMP-DNJ on some endolysosomal parameters  (A) 20nM AMP-
DNJ reduces endolysosomal pH in both healthy and NPC1 deficient cells; results are 
the mean ± SEM of at least 4 independent experiments.   (B) 20nM AMP-DNJ repairs 
mistargeting of BODIPY-LacCer in NPC1 deficient cells.  (C) 1-20nM AMP-DNJ does 
not correct increased endolysosomal volume in NPC1 deficient cells; results are the 
mean ± SEM of 4 independent experiments.  White bars represent untreated healthy 
cells, black represent disease; light grey bars represent treated healthy cells, dark grey 
treated disease. 
 
Confirmation that the pH effect was dependent on the cytosolic pool of GlcCer was 
sought by using brefeldin A (Figure S2) which merges the ER and Golgi thus co-
localising ceramide and GlcCer synthase (Chapter 1, Figure 4) thereby increasing 
cytosolic GlcCer.525  In fibroblasts this tactic delivered similar reductions in 
endolysosomal pH in both control and disease cells (4.5±0.1 to 4.2±0.1 for control, 
5.4±0.3 to 4.6±0.1 for disease cells) as had been observed with AMP-DNJ (Figure 
5A).  To exclude the possibility of off-target pharmacology endolysosomal pH was 
also measured in a near-haploid chronic myelogenous leukaemia cell line (HAP1  
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Figure 5  Confirming the effect of cytosolic GlcCer on endolysosomal pH  (A) 
Brefeldin A reduces endolysosomal pH in healthy and disease fibroblasts; results are 
the mean ± SEM of at least 3 independent experiments.  (Correlation curves as Figure 
2B.)  (B) GBA2 KO in HAP cells reduces endolysosomal pH ; results are mean ± SEM 
of 4 independent experiments.  (C) Sample correlation curve for LysoSensor yellow/blue 
in wt HAP cells (white squares, r2=0.999) and GBA2 KO cells (grey squares, r2=0.997). 
White bars represent untreated healthy cells, black represent disease; light grey bars 
represent treated healthy cells, dark grey treated disease. 
 
cells).i   Consistent with previous results, CRISPR genetic knockout of GBA2 led to 
a decrease in endolysosomal pH (Figure 5B). 
 
How does cytosolic GlcCer acidify endolysosomes? 
Given that increasing cytosolic GlcCer uniformly led to increased endolysosomal 
acidification it was postulated that this lipid could activate vATPase the lysosomal 
proton pump.  Previously activation of this potein complex has been found to depend 
                                                          
i These cells (wt and KO) were a generous gift from Prof Dagmar Wachten 
(CAESAR, Bonn); the pH measurements were undertaken by my colleague 
Meenakshi Bhardwaj.  I am grateful to them both. 
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on raft-inclusion475 and on raft components, including GlcCer.515,526  Molecular 
docking was identified as a useful tool to investigate this.   
 
Attention was focussed on the interface between the membrane-bound a and c 
subunits (blue and grey respectively in Figure 3A) as any lipid binding could 
potentially bridge these two proteins and hence hold the protein assembly together.  
(Building of a model including one a and 3 c subunits was conducted as described 
in Materials and Methods.)  The ROSIE-Rosetta ligand docking protocol was used 
in preference to AutoDock to allow maximum flexibility of the proteins; the 
calculation was simplified by using just the GlcCer headgroup (Figure S3).  This 
calculation was performed at the interface between the a subunit and each of the 3 
c subunits in the model.  For each of the starting positions the 30 binding poses with 
most favourable interface score were surveyed (data in Figure S4) and in all cases 
about half oriented GlcCer correctly relative to the bilayer.  There was sufficient 
space for a GlcCer headgroup in each search space with the sugar forming H-bond 
bridges between a and c subunits on two;  representative examples are shown in 
Figure 6.  Thus cytosolic GlcCer may help assemble the vATPase complex.  (After 
this work was completed and published471 a study emerged showing a yeast vATPase 
has lipid molecules associated with it and that these lipids increase pump activity.527) 
 
From Figure 6A emerges the potentially key role of Asn437 on the a subunit which 
is conserved across the 3 human protein isoforms and in other mammals.  In C. 
elegans, which also contains GlcCer, it is conservatively mutated to Asp while in S. 
cerevisiae, which lacks this glycolipid the residue is a glycine (Figure 7A).  This point 
can be expanded by considering this protein across the yeasts,j some of which 
contain GlcCer and some of which do not.528,529  The presence or absence of GlcCer 
broadly correlates with whether or not the residue equivalent to Asn437 can 
participate in H-bonding (Figure 7B) – yeasts with GlcCer mostly have an Asp at 
this position, those without mostly have a Gly.  (Tyr386 and Gln720 (Figure 6B) are 
conserved across all mammal and yeast species examined - data not shown.)  Whilst 
this is only circumstantial evidence for the action of GlcCer in activating vATPase 
by this mechanism, it is highly suggestive when taken with the in vitro data 
presented here and previous findings in the area.475,515  The question thus arises of 
how mutant NPC1 leads to a deficiency in cytosolic GlcCer.   
 
 
 
                                                          
j I am grateful to Dr Stephen Muench (Leeds University) for suggesting this 
experiment. 
Cytosolic GlcCer may 
help assemble the 
vATPase complex 
121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6  Docking suggests cytosolic GlcCer can activate the vATPase  (A) GlcCer 
(purple) uses H-bonds (green) to bridge the a subunit (blue) and adjacent c subunit 
(chain N, grey).  (B) GlcCer (purple) uses H-bonds (green) to bridge the a subunit (blue) 
and an adjacent c subunit (chain B, grey)  (C) GlcCer (purple) uses H-bonds (green) to 
bind to the third adjacent c subunit without bridging (chain D, grey) without bridging to 
the a subunit (blue).  Subunits shown  not contacted  by GlcCer shown in white; chain 
designations taken from 5tj5.496 
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Figure 7  Key H-bonding residue is present almost exclusively in species with 
GlcCer  (A) Multi-sequence alignment of human a subunit isoforms and  homologues 
from other mammalian species, C. elegans and S. cerevisiae.  The residue 
corresponding to Asn427 (Figure 6A) is mutated to non-H-bonding Gly in S. cerevisiae 
(which lacks GlcCer) but conserved as an H-bonding residue across all other species 
(which do express GlcCer).  (B) Yeast expressing GlcCer528,529 (above the line) largely 
have an H-bonding residue at the position equivalent to Asn427 while yeast lacking 
GlcCer (below the line) largely have the non-H-bonding Gly. 
 
How do NPC cells become deficient in cytosolic GlcCer? 
The obvious explanation, given that NPC1 has been suggested as a transporter of a 
diversity of types of molecule,6,7,9,54 is that NPC1 itself can act as a GlcCer export 
protein.  This attractively simple solution would have the added virtue of solving 
another problem of sphingolipid biology.  GlcCer is made on the cytosolic face of 
the Golgi but emerges onto the topologically non-equivalent cell surface (Chapter 
1, Figure 4, stages ❺ and ❽); therefore GlcCer requires a flippase.194  Results 
presented so far in this chapter imply that NPC1 could be that protein while Chapter 
2 uncovered lipid binding sites on NPC1 aligned with both faces of the lysosomal 
membrane.  If NPC1 indeed acts as a GlcCer flippase then reduced GlcCer on the 
cell surface might be expected.  This is indeed found in CHO cells treated with 5µM 
of NPC1 blocker U18666a (Figure 8A), reflecting similar findings in NPC1-deficient 
cells.471  Intriguingly galactosyl-ceramide (GalCer) does not suffer from a similar 
defect (Figure 8B).k 
 
 
 
 
 
                                                          
k These experiments were performed by Dr Per Haberkant (EMBL); I am grateful 
for his expertise. 
A 
B 
123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8  The effect of blocking NPC1 on transport of sphingolipids to the cell 
surface.  Transport of newly synthesised GlcCer to the cell surface is reduced in NPCD 
cell culture models. The effect of 1 μg/ml of brefeldin A (BFA) and 5 μM U18666A on 
transport of GlcCer (A) and GalCer (B) in CHO cells expressed as % transport to the 
cell surface; results are mean ± SEM from at least 3 independent experiments 
conducted in triplicate. 
 
Docking of GlcCer to NPC2 and the NTD of NPC1 showed that the lipid is too large 
to fit into the cavities of these proteins (data not shown) consistent with in vitro 
findings with GalCer.261  Therefore saposin C (Chapter 1, Figure 4, stage ❾) is 
probably required to transport GlcCer from intra-luminal membranes to the 
transmembrane section of NPC1 though this role has not been explicitly 
demonstrated.530  Attempted docking of GlcCer to the SSD of NPC1 is not as 
straightforward as might be wished.  AutoDock can only handle 32 rotatable bonds 
so one of the long alkyl chains (Figure S3) used in the docking was artificially shorted 
to only nine carbon atoms in addition to the carbonyl carbon to satisfy this criterion 
(15,9-GlcCer, Figure S3).  These chains are rather easily flexible (Chapter 2, Figure 
1) adopting a huge range of conformations when unconstrained.  The presence of a 
membrane usually acts as such a constraint, but this was absent from the docking 
procedure, resulting in a diffuse set of clusters each with a small number of binding 
poses (extended data not shown for this reason).  These caveats must be borne in 
mind when considering the energetically favourable binding poses aligned to the 
luminal edge of the protein that did emerge (eg Figure 9A).  Additionally, docking 
results with GalCer gave approximately equivalent results (data not shown) which 
renders difficult an explanation of the difference in cell surface transport data (Figure 
8 and471).   
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Figure 9  Docking of GlcCer to NPC1  (A) GlcCer (purple) binds to the SSD in the 
same manner as cholesterol contacting the key Pro691 (pink, see Chapter 2, Figure 8)  
(B) GlcCer (purple) binds to the luminal pocket but only one alkyl chain can be 
accommodated; H-bonds shown in green. 
 
The putative cytosolic binding site is rather smaller than its luminal equivalent so 
the ROSIE ligand docking protocol was adopted due to its ability to allow protein 
flexibility.  Limitations in the software reduced the possible number of rotatable 
bonds still further (15,4-GlcCer (Figure S3) was used).  Whilst energetically 
favourable binding in this pocket was uncovered (eg Figure 9B), many poses were 
energetically unfavourable (Figure S5).  The large sugar headgroup forces the lipid 
away from the residues implicated in cholesterol and Sph binding (eg Asp796) and 
the second alkyl chain cannot be accommodated meaning that the protein likely 
cannot retain the lipid in its binding pocket unassisted.  Therefore the presence of a 
partner protein capable of interacting with NPC1 eg TMEM97354 or LAMP2,355 is 
probably required for NPC1 to process GlcCer in this way.  Overall this work cannot 
rule out a role for NPC1 in exporting unmetabolised GlcCer from the endolysosome 
but it offers support for the idea that is tentative at best.   
 
An alternative explanation relies on the potential role of NPC1 as a sphingosine 
export protein (Chapter 2 and54,347).  This lipid has been reported as an inhibitor of 
GBA2.531  Thus in healthy cells lysosomal metabolism releases Sph which is exported 
by NPC1 to the cytosolic face of the limiting membrane.  There it acts as an 
endogenous negative regulator of GBA2 thus increasing the amount of GlcCer 
available to activate vATPase (Figure 6).  It is even possible to imagine this system 
acting as a nutrient sensor whereby metabolic processes nearing completion result 
in reduced Sph export, reduced GBA2 inhibition, reduced cytosolic GlcCer and 
therefore reduced vATPase pumping of the protons for which there is now a reduced 
need.  In cells deficient in NPC1 this situation pertains constitutively leading to 
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increased pH as observed (Figure 2A).  Consistent with this model, supplying AMP-
DNJ, an exogenous GBA2 inhibitor, compensates for the deficiency in sphingosine 
and repairs the pH defect (Figure 4A).  There is currently no known cytosolic 
hydrolase for GalCer so this model would leave cell surface transport of this lipid 
unaffected, as was found (Figure 8 and471). 
 
Testing the sphingosine-GBA2-GlcCer hypothesis 
NPCD can arise not only from defects in NPC1, but also the soluble cholesterol 
carrier NPC2 (Chapter 2, Figure 7, stages ❶ and ❷).  As might be expected for a 
minor cause of a rare disease NPC2 deficiency has been little studied and there is 
only one exception532 to the pattern of a phenotype identical to that in cells with 
mutant NPC1.  It could be argued on the basis of Chapter 2 Figures 9 and 10 that 
NPC2 deficiency could be used as a test of the hypothesis that reduced sphingosine 
is responsible for the pH increase seen in cells lacking functional NPC1.  This is not 
entirely clear, however, as Sph would be expected to have much greater solubility 
in the aqueous and acidic lysosomal lumen than cholesterol and so it cannot be ruled 
out that Sph would arrive at the NTD of NPC1 by diffusion unassisted by NPC2.  In 
any case endolysosomal pH and the effects of GSL manipulation have not yet been 
studied in NPC2-deficient cells and so such fibroblasts were treated with AMP-DNJ 
at a variety of concentrations, and also with 50M miglustat, a concentration likely 
to inhibit GlcCer synthase (GCS)248 and thus potentially lead to a pH increase.  More 
usual GCS inhibitors such as (D)-PDMP and PPMP were deprioritised due to 
potential cell toxicity.533 
 
Endolysosomal pH had a value of 5.34±0.04 in cells with defective NPC2 (Figure 
10A) equivalent to NPC1 deficiency but significantly higher than healthy cells.  In 
contrast to mutant NPC1 cells this increase was not corrected by AMP-DNJ at any 
tested concentration (Figure 10A).  This result is less surprising than it might first 
appear.  As NPC2 acts at intralysosomal membranes deficiency in this protein is  
arguably less similar to deficiency in NPC1 than to deficiency in acid 
sphingomyelinase (aSMase) which has the same site of action and also leads to lipid 
accumulation.  We shall see later (Figure 12) that cells with defective aSMase have 
increased endolysosomal pH which does not respond to AMP-DNJ.  Cells deficient 
in NPC2 did not show altered endolysosomal pH on miglustat (Figure 10A) but were 
free of gross signs of toxicity (Figure 10C,D). 
 
 
The pH defect in NPC2 deficient cells cannot therefore result from disinhibited 
GBA2 and it is simpler, though not necessarily correct, to think that the same defect 
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Figure 10  The effect of glycolipid alterations on NPC2 deficient fibroblasts  (A) 
Increased endolysosomal pH is not changed by AMP-DNJ or miglustat; results are mean 
± SEM from at least 3 independent experiments.  (B) Correlation curve for LysoSensor 
yellow/blue in NPC2Fs; points are mean ± SEM from independent experiments (n=3, 
r2=0.996).  Cells treated with 50µM miglustat (D) appear the same as those treated only 
with vehicle (C). White bars represent untreated healthy cells, black represent disease 
and dark grey treated disease. 
 
in NPC1 deficient cells does not result from disinhibited GBA2 either.  Thus it 
becomes more likely the aberrant endolysosomal pH in these cells results from 
pathologically upregulated GBA2, as found in NPC1 KO mice.250  This will be 
discussed in more detail later. 
 
The gene for GBA2 has a nearby promoter region known to bind 124 transcription 
factors (data from the GeneCards534 database).l  61 of these transcription factors are 
also known to upregulate >50 of the 120 proteins found with increased expression 
in NPCD113 meaning that tracing the pathway from mutant NPC1 to over-expressed 
GBA2 is not easy. 
 
Another way of testing the ideas about lipids and lysosomal acidification is to 
measure lipid levels in cells.  A complication is that only changes in the cytosolic 
pool are proposed to be relevant and the technology to measure individual pools of 
lipid does not yet exist.  Thus only whole-cell quantitation is possible and if cytosolic 
                                                          
l genecards.org/cgi-bin/carddisp.pl?gene=GBA2, accessed 10th September 2019. 
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lipids are a minor population then changes may not be detectable, or may be 
swamped if changes also occur in more numerous populations.  It is also not certain 
which lipids are relevant for pH changes.  GlcSph, generated by the action of neutral 
ceramidase (nCerase) on cytosolic GlcCer, can be safely neglected.  An NPCD 
mouse model featured increased GBA2 activity and accumulation of GlcSph250 while 
a mouse model of aging also showed increased GlcSph despite decreased GBA2 
activity.535  Therefore GlcSph levels do not correlate with GBA2 action.  A 
complication does arise from the ability of GBA2 to use GlcCer as glucosyl donor 
for cholesterol thereby generating GlcChol.523  The role of this lipid, if any, in 
modulating endolysosomal pH is not known.  Appropriate caveats duly noted, 
treatment of cells with a GBA2 inhibitor would be expected to increase GlcCer, 
decrease Cer and also possibly decrease Sph generated through the action of 
nCerase.   
 
This was tested in both healthy and disease cellsm and as expected all lipids were 
present in greater quantity in cells deficient in NPC1 (Figure 11, p0.04).  Closer 
examination reveals that AMP-DNJ is likely to have off-target effects for a dose of 
20nM reduces total GlcCer in healthy cells (Figure 11A) whilst leaving the amount 
of ceramide, which is both its immediate precursor and catabolite, unchanged 
(Figure 11C).  Sphingosine, from which some ceramide is made and to which some 
ceramide is hydrolysed, (Chapter 1, Figure 4) is reduced at the same dose (Figure 
11E) reinforcing the conclusion of mixed pharmacology.  The same conclusion can 
be drawn from other doses in healthy cells where GlcCer is unchanged while both 
other lipids are increased (Figure 11A,C,E).  The non-specific effects of AMP-DNJ, 
combined with the confounding factors noted above, mean it is impossible to draw 
simple conclusions from this data. 
 
With NPC1Fs the larger sample variability makes interpretation less sure, but a 
similar picture emerges.  5-10nM AMP-DNJ generates peak amounts of both GlcCer 
and Sph (Figure 11B,F), something that would be unexpected from inhibition of a 
single enzyme.  Healthy cells also showed the largest changes in lipid levels in the 
5-10nM dose range suggesting that the literature522,523 dose of 20nM used in the pH 
experiments may be too high.  This issue will be repeatedly alluded to in the 
remainder of this chapter. 
 
 
                                                          
m Lipid quantitation was performed accoring to a previously published procedure590 
by Dr Maria Ferraz in the laboratory of Prof Hans Aerts (Universiteit Leiden) on cell 
pellets I provided.  I thank them for the generous gift of time and skills. 
Analysis of changes in 
lipid levels shows 
AMP-DNJ has more 
than one target 
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Figure 11  The effect of AMP-DNJ on cellular lipid levels.  GlcCer, Cer and Sph were 
quantitated in healthy (A,C,E respectively) and NPC1 deficient fibroblasts (B,D,F 
respectively); results are mean ± SEM from 3 independent experiments. White bars 
represent untreated healthy cells, black represent disease; light grey bars represent 
treated healthy cells, dark grey treated disease. 
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The utility of AMP-DNJ in correcting errors in cell culture models of NPC1-
deficiency is clear even though neither its mechanism of action nor the origins of 
the endolysosomal pH error are unambiguously established.  It is also unclear 
whether or not the clinical success of GBA2 inhibition can be attributed to this 
correction of endoctic defects.  It would potentially be both informative and useful 
to examine the actions of this drug in related diseases.   
 
Application to other diseases 
Niemann-Pick type A disease (reviewed536) results from a deficiency in acid 
sphingomyelinase537 (aSMase) the lysosomal enzyme responsible for hydrolysing 
sphingomyelin which thus accumulates538 in the lysosome but also at the cell 
membrane.539  Total cell cholesterol does not appear to increase,538–540 which is 
surprising given the close physical276 and physiological264 relationship between this 
lipid and SM, though errors in cholesterol handling have been reported.541,542  Total 
cell GlcCer is also unchanged538 although an increase in sphingosine has been 
reported.540,543  Despite these differences faulty endocytosis544 and wider lysosomal 
dysfunction,132 including increased endolysosomal pH,441 are found, just as they are 
in NPCD.  The impact of drug-induced GSL alterations on endolysosomal pH has  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12  The effect of glycolipid alterations on NPA fibroblasts (A) Increased 
endolysosomal pH is not changed by AMP-DNJ or miglustat; results are mean ± SEM 
from 3 independent experiments.  (B) Correlation curve for LysoSensor yellow/blue in 
NPAFs; points are mean ± SEM from independent experiments (n=3, r2=0.999).  Cells 
treated with 50µM miglustat (D) appear the same as those treated only with vehicle (C).  
White bars represent untreated healthy cells, black represent disease and dark grey 
treated disease. 
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not yet been studied and is both interesting for an understanding of cellular 
physiology and potentially useful for therapy.   
 
Fibroblasts from NPAD showed an elevated endolysosomal pH of 6.1±0.1 compared 
to healthy controls (Figure 12A) consistent with a recent literature report.441  Whilst 
GCS inhibition through 50M miglustat gave a non-significant increase to 6.9±0.7 
GBA2 inhibition with AMP-DNJ did not reduce endolysosomal pH in cells from this 
disease.  Gratifyingly miglustat did not show any gross signs of toxicity in this cell 
line (Figure 12C,D). 
 
As briefly mentioned in chapter 1, NPCD is a member of the class of lysosomal 
storage disorders which result from diverse failures of the physiology of this  
organelle but whose clinical manifestations all feature neurodegeneration.  
Mucopolysaccharidosis type IIIa (MPSIIIa, also known as Sanfilippo syndrome545) 
arises from mutant heparan-N-sulfatase, a member of a class of enzymes responsible 
for hydrolysing glycosoaminoglycans, linear carbohydrates formerly known as 
mucopolysaccharides, and the consequent accumulation of unmetabolised enzyme 
substrate.  Mucolipidosis type IV (ML-IV) is caused by mutation and therefore 
dysfunction of the Ca2+ release channel TRPML180,546 (Chapter 1, Figure 1, stage ❽) 
and results in defects in endocytosis547 and autophagy.393  TRPML1 function is 
decreased at higher pH.386  Fibroblasts from MPSIIIaand ML-IV were thus treated 
with a range of concentrations of AMP-DNJ.  GlcCer synthase (GCS) inhibitor PPMP 
(Figure S2) was also used with the expectation that this would reduce cytosolic 
GlcCer and thus increase endolysosomal pH.  This parameter has not previously 
been measured in cells from these diseases.  Preliminary data from these 
experiments, performed twice, were mixed (Figure 13).   
 
The endolysosomal pH of MPSIIIa cells was found to be 5.3, higher than healthy 
controls (Figure 13A), but was not corrected by AMP-DNJ consistent with the failure 
of a clinical trial of marketed GBA2 inhibitor miglustat in this disease.548  
Endolysosomal pH was also insensitive to PPMP (Figure 13A).  ML-IV cells had a 
higher endolysosomal pH (5.8) than healthy controls which was corrected by AMP-
DNJ treatment (Figure 13E) – perhaps consistent with the lipid quantitation data 
above (Figure 11) the largest effect was seen at 10nM where an endolysosomal pH 
of 4.6 was observed.  This effect is also consistent with the efficacy of miglustat in 
a mouse model of ML-IV.549  (Intriguingly PPMP, even at half the usual 
concentration, led to a greater reduction in endolysosomal pH (Figure 13E) though 
this may be the result of the toxicity of this agent.533)  Thus AMP-DNJ appears to 
correct elevated endolysosomal pH in cells from a disease where GBA2 inhibition 
AMP-DNJ is 
sometimes, but not 
always effective in 
LSDs with increased 
endolysosomal pH. 
The endolysosomal pH 
defect in Niemann-Pick 
type A disease does 
not respond to AMP-
DNJ 
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has been successful in vivo, but conversely apparently fails to correct the same error 
in cells from a disease where GBA2 inhibition is ineffective clincially.  The idea that 
the success of GBA2 inhibition to treat disease results from correction of endocytic 
defects is thus strengthened.  This connection was not known when this work was 
begun. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 The effect of altering glycolipids on endolysosomal pH in LSDs  
(A) In MPSIIIa increased endolysosomal pH is unchanged on glycolipid 
alteration.  (B) Correlation curve for LysoSensor yellow/blue in MPSIIIa 
fibroblasts; (r2=0.913).  . (C) In ML-IV fibroblasts increased endolysosomal pH 
is reduced on inhibition of GBA2 or GCS. (D) Correlation curve for LysoSensor 
yellow/blue in ML-IV fibroblasts; (r2=0.998).  All data are from one 
representative example (mean±SD) of two independent experiments 
conducted in duplicate.  White bars represent healthy cells, black disease and 
dark grey treated disease. 
 
Experiments in another LSD, Krabbe disease (previously known as globoid cell 
leukodystrophy), complicate the picture still further.  This disorder stems from 
deficiency in galactosylceramidase, the lysosomal enzyme responsible for the 
digestion of GalCer550 (analogous to Chapter 1, Figure 4, stage ❾).  It is widely 
believed, though not yet proved, that accumulating GalCer is hydrolysed by acid  
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Figure 14  The effect of AMP-DNJ on Krabbe fibroblasts  (A) AMP-DNJ does not 
correct increased endolysosomal pH (mean±SD) from one representative experiment 
conducted in duplicate. (B) Correlation curve for LysoSensor yellow/blue in Krabbe 
fibroblasts; (r2=0.967).  (A,B are a representative example of two independent 
experiments.)  (C) GCS inhibition produces apoptotic appearance in Krabbe fibroblasts.  
(D) Representative images from LysoTracker experiment (E) Quantitation of acidic 
compartment volume (mean ± SEM examining at least 40 cells per condition).  White 
bars represent healthy cells black represent disease and dark grey treated disease. 
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ceramidase to give GalSph (also called psychosine) which escapes the lysosome by 
an unknown mechanism and leads to damage to organelles, particularly 
mitochondria, and cell death.551  While endolysosomal pH was elevated in 
fibroblastsn from this disorder, consistent with measurements in rat oligodendrocytes 
treated with psychosine,236 treatment with AMP-DNJ did not correct it while PPMP 
again led to a reduction (Figure 14A; data is a representative example of two 
independent experiments).  This reduction may be an experimental artefact as a 
closely structurally related GCS inhibitor, (D)-PDMP (Figure S2), led to cell toxicity 
(Figure 14C).  However AMP-DNJ did correct the error in lysosomal volume (Figure 
14D,E).  Thus in Krabbe disease AMP-DNJ corrects the proliferation in endocytic 
vesicles, but not the pH defect while in NPCD the exact opposite applies (Figure 
4A,C) and it is thus an open question whether or not endocytic proliferation is 
dependent on correct acidification.  Just as the lipid quantitation data did, these 
results also point to multiple modes of action for AMP-DNJ. 
 
Application to amyloid-related diseases 
Amyloid precursor protein (APP) is a plasma-membrane resident molecule of 
unknown function.  It is cleaved by the actions of two proteases: -secretase at sites 
outside membranes and -secretase, unusually, at sites within them.  The resulting 
protein fragments, termed amyloid beta (A) and released into the cytosol, are of 
varying lengths and are named after the number of residues each contains, eg A40.  
When secreted from the cell A forms the basis of amyloid plaques, the aberrant 
accumulation of which is widely held to be responsible for Alzheimer’s disease (AD).  
A logical goal of therapy is therefore to reduce A.   
 
The reasons for the increased amounts of A in AD have yet to be unravelled 
although this is a feature shared with NPCD, both cells552 and the CSF of patients.157  
In NPCD the CSF levels can be corrected by miglustat therapy.157  Endolysosomal 
dysfunction also occurs in AD and it has been suggested that this is linked to reduced 
clearance of A (see553 and references therein).  At the same time clozapine (Figure 
S4), an anti-psychotic drug with mixed pharmacology which has been proposed to 
include GlcCer,554 has been reported to reduce A in a mouse model of AD.555  The 
pathway included p35 and cdk5 providing echoes of NPCD as dealt with in Chapter 
1, Figure 3 and surrounding discussion.  Very recently a TRPML1 agonist has been 
reported to acidify endolysosomes in AD model cells and to block the accumulation 
of A induced by LDL.556  All these lines of evidence suggested that AMP-DNJ could 
                                                          
n These cells were a gift from Prof Frances Platt (University of Oxford) to whom I 
am grateful. 
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be used to reduce the pH of endolysosomes in AD model cells and thereby to reduce 
levels of A.   
 
Due to the well-documented difficulties of growing neuronal cells in culture, 
experiments were performed in two neuroblastoma cell lines, one of which (SH-
SY5Y) had been transfected557 to overexpress APP stably.o  Preliminary experiments 
(Figure 15) showed that AMP-DNJ did indeed increase endolysosomal acidity in the 
untransfected NB7 cells (6.2 to 5.4 with 10nM, though only n=2); little if any 
reduction was observed in the SH-SY5Y cells (data not shown).  Thus the rationale 
of using AMP-DNJ to acidify lysosomes as a means of reducing A was provisionally 
and partially supported. A pH increase was not observed with GlcCer synthase 
inhibitor PPMP, as might be expected, testament to the complexity of the operating 
pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 The effect of AMP-DNJ on endolysosomal pH in neuroblastoma 
cells  (A) In NB7s endolysosomal pH is reduced on treatment with AMP-DNJ.  
(B) Correlation curve for LysoSensor yellow/blue in NB7 cells; (r2=0.961).  Data 
are (mean±SD) of two independent experiments conducted in duplicate. 
 
In order to obtain as full a picture as possible of the effect of sphingolipids on A 
production studies in these cells employed a diversity of drugs in addition to AMP-
DNJ and PPMP.  Myriocin, an inhibitor of serine palmitoyl transferase (Chapter 1, 
Figure 4, stage ❶) reduces synthesis of sphingosine and thereby, in principle, all  
 
 
other sphingolipid populations.  NPC1 blocker U18666a was also used to see if A 
would increase consistent with the higher levels observed in cell culture models and 
                                                          
o These cells were a gift from Prof Nigel Hooper (University of Manchester); I 
thank him for his generosity. 
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patients with this disease157,552 and clozapine to check consistency with the previous 
report of reduced A in an AD mouse.555  A levels were measured both in the 
media and in cell lysates; NB7 cells, which are not transfected with APP, had lower 
levels of A generally and undetectable levels of the shortest fragment A38.  After  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16  Effect of lipid alteration on secreted Aβ  NB7 (A) and SH-SY5Y (B) cells 
were treated with the indicated drugs overnight before quantitation of Aβ in the media; 
results are mean ± SEM from 3 samples. 
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a 24 hour incubation none of the drugs tested gave effects on levels of secreted A 
that were consistent across both cell type and protein length (Figure 16).p   
Whilst clozapine reduces all forms of this protein in SH-SY5Y cells it has no effect 
on A40 secreted by NB7s and even increases A42 exported by this cell line.  PPMP 
does not affect A40 in either cell line but increases A42 in both.  Neither U18666a 
nor AMP-DNJ affected levels of any form of secreted A suggesting that in these 
models endolysosomal pH is not the key determinant of how much protein is 
formed. 
To examine levels of A in cell lysates the drug panel used above was supplemented 
with (D)-PDMP, an inhibitor of GlcCer synthase, and its (L)- isomer (Figure S3).  
These two compounds are both reported to reduce A in a transfected neuroglioma 
cell line558 despite having opposite effects on GSL levels in the same cells;559 they 
are also effective in transfected CHO cells.533  Disappointingly, none of the agents 
significantly reduced A in lysates of SH-SY5Y cells, though some led to small and 
significant increases.  (Figure 17A).  (These experiments were not conducted in NB7 
cells as A is not present in measurable amounts in the lysates of untransfected cell 
lines.)  PPMP gave a large increase, though that may result from increased 
expression of APP with this compound (Figure 17B). 
 
Thus the picture that emerges of the relationship between lipids and levels of A is 
exceptionally complex.  Lipids affect endolysosomal pH (Figure 15A,C) and 
potentially other lysosomal ion fluxes (Chapter 2), APP expression (Figure 17B) and, 
in multiple ways, -secretase activity.560–562  All these factors can, at least in principle, 
affect A levels.  Thus the therapeutic goal of reducing A by altering lipid levels, 
even if it is possible, is likely to be met only by identifying and precisely targeting 
one or more crucial sub-populations of lipids.  Even if such a pool could be 
identified, selective manipulation is difficult to achieve.  AMP-DNJ is probably the 
available drug with the greatest ability to target a defined lipid population but data 
from fibroblasts (Figure 11) suggests that even this agent is not perfectly selective. 
 
 
Less well known than AD is the involvement of amyloid in Down syndrome (DS), 
the triplication of chromosome 21 on which the gene for APP is located.  Individuals 
with this condition are at vastly increased risk of developing amyloid plaques;563  
 
 
                                                          
p A quantitation assays were performed by Kate Kellett and Kate Fisher of the 
Hooper lab at Manchester university on samples I provided.  I thank them both for 
their diligence and for informative discussions of the results. 
AMP-DNJ reduces 
endolysosmal pH but 
leaves A levels 
unchanged in two 
neuronal model cell 
lines 
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Figure 17  Effect of lipid alteration on Aβ levels in cell lysates of SH-SY5Y cells 
(A) quantitation of Aβ levels in cell lysates of SH-SY5Y cells treated with the indicated 
drugs; results are mean ± SEM from 3 samples.  (B) Western blot of APP (upper panel) 
in cell lysates of SH-SY5Y cells treated with the indicated drugs; actin (lower panel) was 
used as a loading control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 The effect of AMP-DNJ on endolysosomal pH in DS fibroblasts  (A) In 
DS fibroblasts endolysosomal pH is  increased but reduced on treatment with AMP-DNJ.  
(B) Correlation curve for LysoSensor yellow/blue in DS fibroblasts (r2=0.915).  Data are 
representative examples of two independent experiments. White bars represent 
untreated healthy cells, black represent disease and dark grey treated disease. 
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endolysosomal dysfunction has also been documented564 and very recently an 
amyloid-dependent endolysosomal pH increase has been reported.565  Preliminary 
experiments (data shown are a representative example of two independent 
experiments) replicated this latter finding: endolysosomal pH in untreated cells was 
 5.8 (Figure 18A).  Furthermore the acidity was found to by GSL-sensitive as AMP-
DNJ reduces endolysosomal pH (an optimum dose of 10nM gives a pH of 5.2) while 
PPMP increases it further (Figure 18A).  The very idea that DS might be susceptible 
to drug treatment is novel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Endolysosomal pH is 
elevated in a Down 
syndrome cell line; 
AMP-DNJ corrects this 
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Open questions and future work 
 
I don't know, Sophie thought.  Surely nobody really knows.  And yet - Sophie 
thought it was a fair question. 
Jostein Gaarder 
Sophie's World 
 
The following discussion will make two assumptions.  The first is that the 
preliminary results reported above on the effects of GBA2 inhibition on 
endolysosomal pH in pathologies other than Niemann-Pick are accurate.  Whilst 
these findings are consistent with in vivo data where those are available,548,549 and 
each disease was tested twice, the experiments should be repeated until statistical 
significance is obtained.  More controversially we will also assume that neither AMP-
DNJ inhibiting GBA2 nor brefeldin A merging the ER and Golgi has any significant 
effect other than increasing cytosolic glucosylceramide.525,566  This assumption is 
incomplete (see Figure 11 and surrounding discussion) but both useful and necessary 
as the other targets of AMP-DNJ are unknown.  From these two assumptions and 
the results reported above several deductions follow. 
 
The finding that both AMP-DNJ and brefeldin A reduce endolysosomal pH in healthy 
cells (Figure 5A) implies that the regulation of this parameter by cytosolic GlcCer is 
a general, though possibly minor, pathway.  Next it is possible to divide LSDs into 
those where endolysosomal pH is normal (currently only CLN2 deficiency, Figure 
13C) and those where it is increased.  In some of these defective acidification is 
rescued by increasing cytosolic GlcCer (NPC1 deficiency and ML-IV, as well as 
Down syndrome) which in turn implies that this sub-population of lipid is reduced 
in these pathologies.  Therefore other explanations for increased endolysosomal pH 
are correspondingly less likely.  
 
Such explanations may include an association between NPC1 and components of 
the vATPase as suggested by two studies125,461 which may be impaired in the 
presence of mutant NPC1.  More difficult is the potential involvement of growth 
regulating complex mTORC1.  Cholesterol accumulation, such as occurs in NPCD, 
has variously been reported to result in mTORC1 inhibition,126 mTORC1 activation125 
and no difference in mTORC1 status.98  GlcCer is also reported to bind mTORC1517 
meaning that it may become necessary to include this complex in the account of 
action of AMP-DNJ, though the explanation offered above is simpler and therefore 
preferable.  Other secondary effects of cholesterol may be implicated.  (Consistent 
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with the argument advanced in this section about the importance of cytosolic GlcCer 
in silico modelling (Figure 3) has suggested that a direct effect of cholesterol on the 
vATPase is unlikely.)  Secondary effects could be investigated by using cells from 
patients with Wolman disease, a genetic LAL deficiency which features 
endolysosomal cholesterol accumulation.  Lysosomal pH has previously been 
reported as normal in such cells53 but with a dextran probe, the deficiencies of which 
were noted above; only the most basic quantitation of secondary lipid accumulation 
has been performed to date.567  Combining lipidomics with measurements of 
endolysosomal pH in this disease and the repair of any defect with AMP-DNJ might 
help confirm the putative key role of cytosolic GlcCer.   
 
Why is the crucial cytosolic sub-population of GlcCer reduced?  This work 
postulated a Niemann-Pick specific mechanism in which mutant NPC proteins fail 
to fulfil their roles as sphingosine exporters54,347 (Chapter 2, Figures 8-11) reducing 
the reported inhibition of GBA2 by this molecule531 and hence depleting the 
cytosolic pool of GlcCer.  The failure of AMP-DNJ to correct the pH error in NPC2-
deficient cells suggests that this pathway is incorrect and so leaves unanswered the 
question of the pathological role, if any, of sphingosine accumulation in NPCD.  
However this very failure also opens the door to a more generally applicable 
understanding of the role of GBA2 in disease. 
 
If GBA2 is not disinhibited in NPCD but its substrate pool is depleted then either 
the enzyme has become activated or its expression is upregulated.  No activation 
mechanisms are known for GBA2 and so the idea that NPC pathology leads to 
upregulation is preferred; confidence in this deduction is increased by the 
observation of such upregulation in a murine model of NPCD.250 
 
This conclusion, however, does not tell us why the cytosolic pool of GlcCer should 
be so important.  The case was made above, and suggested by previous work, that 
this sub-population,515  or at least raft components or inclusion,475,526 activates 
vATPase but this is far from being proved.  If vATPase can be isolated then GlcCer 
binding can be assessed using an ELISA assay with immobilised lipid.  Whilst this 
would evidence the fact of lipid-protein binding, it would not identify how the two 
partners interact.  Mutagenesis experiments changing the key reside Asn437 to an 
alanine could be more useful.  Assuming the mutant protein was expressed, localised 
and functioned correctly then it should prove insensitive to GSL alterations, eg those 
produced by AMP-DNJ.  The ultimate experiment would be to characterise 
structurally the protein complex with adventitious lipids intact.  This should be 
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possible using lipo-paticles followed by examination of the complex by MS and 
cryoEM.568,569   
Other pathways of AMP-DNJ action are possible.  Clearly lysosomal acidification 
depends on vATPase expression which was found to be increased by AMP-DNJ at 
both the mRNA and protein levels.471  Provocatively, Myb-binding protein 1a, a 
protein involved in transcription, has been found to bind sphingolipids in three 
independent proteomic screensq implying a possible link between GlcCer and 
numerous proteins, not just vATPase.  Mapping these pathways will be an essential 
component of future attempts to understand the impact of sphingolipid perturbations 
on the cell (compare Chapter 1, Figure 2).  A more direct link to protein expression 
is supplied with the disclosure that GBA2 localises to the ER and Golgi.570  Earlier 
work found that miglustat can prevent interaction between calnexin and the F508 
mutant CFTR channel571 thereby normalising protein expression and restoring a 
chloride current which has been implicated in control of lysosomal acidity.236  This 
miglustat study571 used a dose of 100µM which will also inhibit GCS248 requiring 
caution in the interpretation of this result.  Nonetheless it opens the possibility that 
AMP-DNJ may acidify endolysosomes by increasing expression of CFTR whose 
activity has been reported as cholesterol-dependent.572  Were this the case then we 
would expect to be able to measure an increase of CFTR expression and to find that 
a CFTR blocker573 negates the effects of AMP-DNJ.   
 
A role for GBA2 inhibitors at the ER may also invoke calcium in the explanation.  
Two independent studies have suggested that GlcCer indirectly activates the 
ryanodine receptor (RyaR) leading to increased cytosolic calcium210,574 which could 
potentially refill the depleted lysosomal Ca2+ stores in NPCD cells53–55 thereby 
normalising calcium efflux through channels such as TRPML1.  (The open 
probability of this channel increases with higher cytosolic calcium.546)  Corrected 
lysosomal calcium could restore defective endocytosis and autophagy and possibly 
be a counter-current necessary to balance endolysosomal acidification.  Consistent 
with these observations thapsigargin, an inhibitor of the sarco-/endoplasmic 
reticulum calcium pump, was found to normalise lysosomal calcium rapidly in NPCD 
cells and to relieve lipid storage.54  Expression of proteins related to calcium handling 
was found to be altered in NPCD cells.113  The question thus arises of whether AMP-
DNJ prevents GlcCer hydrolysis not at the lysosome but at the ER and the resulting 
increased GlcCer leads to calcium release which normalises lysosomal function.  
                                                          
q Per Haberkant (EMBL) and Cliff Lingwood (Sick Kids, Toronto), personal 
communications; MPharm student Zain Mohammed analysed the overlap of these 
large data sets with my guidance.  I am grateful to all of them. 
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Experiments to test this idea have thus far been unsuccessful.  If the effect of AMP-
DNJ were Ca2+-mediated we would expect it to be blocked by the cell-penetrant 
calcium-selective chelator BAPTA-AM.  When used alone this reagent unexpectedly 
led to a reduction in endolysosomal pH (data not shown) rendering it unsuitable for 
competition experiments with other drugs.  The effect of non-toxic SERCA inhibitor 
curcumin could not be assessed using LysoSensor yellow/blue due to this 
compound's strong yellow colour, an observation that will only enhance its 
reputation as interfering with assays.575  The restoration, or otherwise, of 
endolysosomal calcium by AMP-DNJ could be assessed using confocal microscopy 
loading cells with calcium probe Fura2 and lysing lysosomes with Gly-Phe-ß-
naphthylamide (GPN).54 
 
Whatever the function of the cytosolic sub-population of GlcCer it is possible 
manipulations of it might have effects in NPCD more widespread than those 
demonstrated above (Figure 5).  As noted in chapter 1 (Figure 1, stage ❸) some 
very early endocytic vesicles are formed from the plasma membrane in a manner 
dependent on both GSLs and galectin-3.21  Given that cell surface GlcCer is reduced 
in NPCD (Figure 8) we might expect disease cells to show deficiencies in this 
process, and for these to be repaired by AMP-DNJ.  Further along the endocytic 
pathway, traffic from early to late endosomes can be assessed using horse radish 
peroxidase as a fluid phase marker.61  This endocytic segment is impaired in NPCD, 
probably driven by the mislocalisation of the key protein AnxA2.27  Assessing 
whether or not AMP-DNJ corrects this defect is a worthwhile enterprise.  It is 
possible that GBA2 inhibition will have no effect on either galectin-3 or AnxA2 
dependent process which would suggest, in combination with the results in Figure 
4, that AMP-DNJ targets late, but not early, endocytosis. 
 
What the work presented here does not demonstrate is the extent of repair of the 
late endolysosomal (LEL) compartment – are these organelles normalised or merely 
adjusted?  In particular is lipid accumulation reversed?  AMP-DNJ corrects 
endolysosomal pH (Figure 4) but not necessarily cholesterol export as the NPC1 
protein is still dysfunctional.  Thus the misdistribution of lipids such as SM and PIs 
in the lysosomal limiting membrane, which accumulate through energetically 
favourable interactions with cholesterol,276,284 may not be altered and so many of the 
protein-mediated errors investigated in chapter 2 may remain uncorrected.  Whilst 
sophisticated subcellular lipidomics techniques can assess changes in specific 
lipids,43 the use of filipin as a fluorescent cholesterol marker is a simpler assay 
common in the NPCD field (eg203).  The question of whether AMP-DNJ reduces 
lysosomal cholesterol storage is thus relatively easy to address.  In addition lipid 
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accumulation can permeabilise lysosomes releasing their degradative contents into 
the cytosol131–133 (Chapter 1, Figure 3, stage ❷).  Various techniques are available 
to assess lysosomal permeabilisation576 and the impact of AMP-DNJ on this 
parameter should be investigated.   
 
Lipids in the internal membranes such as triglycerides also accumulate in NPCD43 
but probably because they are processed by hydrolases such as LAL which have low 
pH optima and high substrate flux515,577 and so their activity declines with reduced 
acidity.  Normalising pH with AMP-DNJ will therefore be expected to reduce the 
accumulation of these fats, provided their lysosomal export pathway is operable.   A 
similar case might be constructed regarding the cathepsin proteases.  Optimal pH 
for activity is 3-4 for cathD578 and 4-5 for cathB579 and cathB activity is 
correspondingly reduced in NPC1 deficient cells.74  The relatively simple experiment 
of using Magic Red to assess cathB activity74 in NPCD cells treated with AMP-DNJ 
should be revealing. 
 
Closely related to endocytosis is the process of autophagy where correct lysosomal 
acidification is also necessary89–91 and so it would be expected that AMP-DNJ 
treatment would correct the errors evident in NPCD (see Chapter 1).  This could be 
assessed by looking for a reduction in the number of vesicles positive for autophagy 
marker protein LC3-II.  A new, simpler technique using acridine orange580 may suffer 
from the pitfalls noted above with this reagent; nor is it clear how autolysosomes 
would be distinguished from acidic endocytic vesicles. 
 
What of the LSDs where pH is increased but not repaired by AMP-DNJ (MPSIIIa, 
Krabbe, NPA and NPC2 deficiency)?  From the argument presented thus far it may 
be suggested that GBA2 is not upregulated in those diseases.  This might be 
surprising as the only other LSD where GBA2 regulation has been investigated is 
Gaucher which stems from mutation of lysosomal glucosylceramidase (GBA1, 
Chapter 1, Figure 4, step ❾).  Here GBA2 was also upregulated253 explaining the 
therapeutic effectiveness of pharmacological inhibition (miglustat is approved for 
use in Gaucher) or genetic knockout581 of this enzyme.  No data on the effect of 
GBA2 inhibition on the elevated518 endolysosomal pH found Gaucher cells has yet 
been reported.   
 
The GBA2 status of diseases whose increased endolysosomal pH is unresponsive to 
AMP-DNJ could be investigated by blotting for the protein and measuring enzyme 
activity.253,510  Speculatively, this may reveal that GBA2 upregulation is a general 
feature of LSDs.  In those circumstances we would be forced to re-examine the 
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assumptions with which we began this section, and in particular the idea that 
increasing cytosolic GlcCer is the only relevant effect of AMP-DNJ.  In fact Figure 
11 and the accompanying discussion made it clear that this agent has widespread 
effects on the cellular lipid profile.  The possibility thus arises that it is these effects, 
as well as or instead of changes to cytosolic GlcCer that mediate endolysosomal pH 
changes.  This could perhaps be clarified by performing subcellular lipidomics43,180,582 
on cells from a variety of disease types with and without AMP-DNJ treatment.  Given 
the apparently crucial role of the cytosolic pool of GlcCer even organellar lipidomes 
may not offer sufficient resolution and it may be necessary to subfractionate, 
something that has been achieved for lysosomes,583 before measuring the lipid 
profile.  In the meantime the opposite responses to AMP-DNJ of the pH and 
endocytic volume defects in NPC and Krabbe cells (Figure 4 and 14) fuel the 
impression that lysosomal storage disorders are superficially similar but 
fundamentally different.   
 
Other diseases: endolysosomal pH and the effects of AMP-DNJ 
The outlook for the use of GBA2 inhibitors in Alzheimer's disease is yet more 
complicated.  As noted above manipulation of lipid sub-populations can have a 
variety of effects on the cell, some of them undesirable, like increasing APP 
expression.  The lipid quantitation data from fibroblasts (Figure 11) where AMP-
DNJ affects at least two processes suggests that precisely targeting such 
manipulations is extremely difficult.  To this should be added the differences 
between cell models (transfected glioma558 and CHO533 cells responded differently 
to PDMP than the blastoma cells used here) and the unresolved controversy over the 
relevance of transfected cells to disease in patients.  It then becomes difficult to see 
how to proceed empirically with a lipid-altering approach to AD.  Nonetheless the 
general tendency of clozapine to reduce Aß levels (Figure 16) and the suggestion 
that GSLs may mediate this compound's effects554 may offer a way forward.  
Interesting next experiments would be to measure clozapine's effects on 
endolysosomal pH and lipid levels and to quantify any changes to APP expression 
on clozapine treatment (Figure 17B shows little apparent alteration).  These 
experiments may allow us to tease out which factors are important in A reduction. 
 
Parkinson’s disease (PD) is another relatively common neurodegenerative disorder 
but here the prospects are perhaps better.  Deficiency in one copy of the GBA1 gene 
(Chapter 1, Figure 4, stage ❾) is the most common risk factor yet identified for 
PD;584 deficiency in both copies is the cause of the LSD Gaucher disease which 
features raised endolysosomal pH.518  Consistent with both this observation and the 
report of increased GBA2 activity in Gaucher,253 this disease is treated clinically with 
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miglustat.  Thus there may be pathological and treatment pathways common to both 
disease, and ultimately GBA2 inhibition may treat PD.    There are several 
intermediate questions of interest: Does one defective GBA1 gene lead to increased 
GBA2 activity?  What about other PD risk factors such as mutant LRRK2585 or 
PARK9?586  If so, is endolysosomal pH increased as it is in a PD model521?  Does 
this increase contribute to the accumulation of the toxic α-synuclein protein?  Can 
increased endolysosomal pH be corrected by GBA2 inhibition?  If so does this 
prevent, or even reduce, the build-up of α-synuclein?  These questions could be 
addressed using activity-based probes510 and the LysoSensor technology from this 
chapter in patient fibroblasts, neuroblastoma cells or iPSC-derived neurones.  
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Materials and methods 
General 
Unless otherwise stated incubation of cells was conducted at 37°C in a humidified atmosphere 
containing 5% CO2 and media were supplemented with 10% FBS (Gibco 10500-064) and 50U 
penicillin – 50µg streptomycin per mL penicillin-streptomycin (Gibco 15070-063).  Fibroblasts and 
SH-SY5Ys were grown in cell culture flasks using high glucose DMEM supplemented with 10mM 
glutamine (Gibco 41965-039), NB7s were grown in cell culture flasks in RPMI (Gibco 61870-010) 
and RAW macrophages which were grown in untreated petri dishes in RPMI.  Cells were passaged 
or media refreshed every 2-5 days.  Cells used are shown in Table S1. 
 
Table S1  Cells used in this chapter 
 
Cell type Tissue 
source 
Supplier 
Code 
Aberrant protein 
Mutation 
Gender 
and age 
of donor 
Monocyte 
macrophage 
Blood ECACC 
91062702 
- mouse 
Fibroblast Skin Coriell Institute 
GM00380 
- ♀, 35 
years 
Fibroblast Skin Coriell Institute 
GM03123 
NPC1 
Pro237Ser/Ile1061Thr 
♀, 9 years 
HAP wt Bone 
marrow 
Horizon 
- 
- No 
information 
HAP GBA2 KO Bone 
marrow 
Horizon 
HZGHC004109c001 
CRISPR KO of GBA2 No 
information 
Fibroblast Skin Coriell Institute 
GM18424 
NPC2 
Val30Met; other allele 
uncharacterised 
♀, no data 
Fibroblast Skin Coriell Institute 
GM13205 
aSMase 
Premature stop at 
Leu382; other allele 
uncharacterised 
♀, 2 years 
Fibroblast Skin Coriell Institute 
GM01739 
Heparan-N-sulfatase 
1307del9; other allele 
normal 
♀, 6 years 
     
Fibroblast Skin Coriell Institute 
GM02048 
TRPML1 
Heterozygous; exons 
missing 
♀, 2 years 
Fibroblast Skin Coriell Institute 
GM02571 
- 
Trisomy 21 
♀, 3 
months 
Neuroblastoma 
NB7 
Bone 
marrow 
See footnote o - 
Various chromosomal 
defects587 
No 
information 
Neuroblastoma 
SH-SY5Y 
Bone 
marrow 
ATCC, 
CRL-2266 
Stably over-expressing 
APP557 
♀, 4 years 
 
 
Trypsin (Gibco 25200-072) was used to remove cells from flasks except for RAW macrophages which 
required only scraping.  PBS was sterile (Gibco 10010-015) unless otherwise stated; non-sterile PBS, 
MES+ and RIPA buffers were prepared according to the formulae given below.  Protease inhibitor 
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cocktail (PIC) tablets (Pierce A32955) were suspended in 400µL ddH2O to give 25x stock solution.  
Other chemicals were obtained and used as set out in Table S3. 
 
Non-sterile PBS: 5 PBS tablets (Sigma P4417) were dissolved in 1L ddH2O with stirring.  The resulting 
solution was stored at 4°C. 
MES+: MES (3.2g, Sigma 69892) MgSO4.7H2O (177mg), KCl (5.144g) and NaCl (125mg) were 
dissolved in 600mL ddH2O with stirring to give fc values of MES (25mM) MgSO4 (1.2mM) KCl 
(115mM) and NaCl (5mM).  The solution was divided into 6 equal portions and cooled to 4°C.  Each 
portion was adjusted to a pH value in the range 3-7.5.  Buffers were stored at 4°C. 
RIPA: NaCl (876mg), Nonidet-P40 (1mL, Sigma N6507), Na-deoxycholate (500mg, Acros 
218590150) and Tris (655mg) were dissolved in 100mL ddH2O with stirring to give fc values of NaCl 
(150mM), Nonidet-P40 (1% v/v), Na-deoxycholate (0.5% w/v) and Tris (50mM).  Buffer was stored 
at 4°C and used within 1 month. 
 
Endolysosomal pH 
Procedure is for fibroblasts and is based on previous work.65,480,481  Cells were grown in one T225 
(flask a) and six T75 (flasks b-g) cell culture flasks until confluent.  Medium was removed and replaced 
with fresh; drugs were added as appropriate (see Table S2) and cells incubated overnight.  Media was 
decanted and the cells trypsinised; media was re-added and the cells centrifuged (5mins, 1500rpm).  
Media was removed and the pellets resuspended in 1mL (flask a) and 200µL (flasks b-g) of original 
medium.  LysoSensor yellow/blue DND-160 (Invitrogen, L7545, 1mM in DMSO) was added - 5µL to 
pellet a, 1µL to pellets b-g (fc 5µM) - and the samples incubated in a water bath at 37˚C for 5 minutes.  
The centrifuge tubes were filled with ice-cold non-sterile PBS and centrifuged (4˚C 5mins, 1500rpm).  
All supernatants were discarded.  Pellet a was resuspended in 3mL ice-cold non-sterile PBS and 500µL 
placed in each of six 1.5mL Eppendorf tubes (pellets a1-a6); pellets b-f were resuspended in 500µL 
ice-cold non-sterile PBS and placed in each of six 1.5mL Eppendorf tubes; all tubes were centrifuged 
(4˚C 5mins, 2000rpm).  Supernatants were discarded.  To pellets a1-a6 were added 430µL ice-cold 
MES+ of different pH values in the range 3-7.5; monensin and nigercin (each 4.3µL of a 0.1mM 
solution) were added; to pellets b-f were added 430µL ice-cold non-sterile PBS.  All tubes were 
vortexed.  2x200µL of each sample were placed in separate wells in a black non-treated 96-well plate 
pre-cooled to ice temperature.  6x200µL ice-cold non-sterile PBS were also added to separate wells.  
The plate was incubated at ice temperature on the bench for 10 minutes after monensin and nigericin 
were added.  The plate was examined by fluorescence exciting at 320 and 360nm and measuring 
emission at 451 and 520nm (cut-off values set at 455 and 515nm) using a SpectraMax Gemini 
instrument.  If needed repeat readings were taken at 10 minute intervals until an acceptable correlation 
curve (r2  0.9) was obtained.  Yellow/blue ratios for pellets a1-a6 gave the correlation curve; 
yellow/blue ratios for pellets b-g were calculated and pH values obtained by comparison with this 
curve. 
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Variations: for RAW macrophages one large (15 cm diameter) and six small (9 cm diameter) petri 
dishes were used; for NB7 and SH-SY5Y cells a centrifuge speed of 3500rpm was used.  Incubation 
time with brefeldin A was 2hours. 
 
Table S2  Drugs used in this chapter 
All solutions and dilutions were made with DMSO unless otherwise stated. 
 
Drug Mode of 
action 
Supplier, 
Catalogue 
number 
Initial 
concen-
tration 
Dilution Volume 
added 
to 
(media 
volume) 
Final  
concen-
tration 
Ref 
U18666a NPC1 
blocker 
Tocris 
1638 
1mg/mL - 10.6µL 
(5mL) 
5µM  
U18666a NPC1 
blocker 
Tocris 
1638 
1mg/mL  0.64µL 
(5mL) 
300nM 482 
AMP-DNJ GBA2 
inhibitor 
See 
footnote g 
1mg/mL 1:250 10µL 
(5mL) 
20nM a 523,588 
Brefeldin 
A 
COP-1 
blocker, 
merges ER 
and Golgi 
Sigma 
B7651 
1mg/mL - 10µL 
(10mL) 
1µg/mL  
Miglustat GBA2 
inhibitor 
Tocris 
3117 
6.4mg/mL - 10µL 
(5mL) 
50µM 248 
(D)-PDMP GCS 
inhibitor 
Matreya 
1756 
2.1mg/mL - 10µL 
(5mL) 
10µM 518 
(L)-PDMP  Matreya 
1749 
2.1mg/mL - 10µL 
(5mL) 
10µM  
PPMP GCS 
inhibitor 
Cayman 
17236 
10mg/mL - 3.8µL 
(5mL) 
15µM a  
Myriocin SPT 
inhibitor 
Sigma 
M1177 
2mg/mL - 10µL 
(5mL) 
10µM  
Fumonisin 
B1 
Cer 
synthase 
inhibitor 
Cayman 
62580 
5.4mg/mL - 10µL 
(5mL) 
15µM 589 
Clozapine GlcCer 
modulator? 
Tocris 
C444 
2mg/mL  16.3µL 
(5mL) 
20µM 554 
Monensin Na+/H+ 
ionophore 
Sigma 
M5273 
6.9mg/mL 
10mM 
1:10 b 4.3µL 
(430µL) 
10µM  
Nigericin K+/H+ 
ionophore 
Sigma 
N7143 
7.5mg/mL 
10mM 
1:10 b 4.3µL 
(430µL) 
10µM  
 
Notes: a Lower concentrations were achieved by using a reduced amount of drug solution and 
normalising the volume with DMSO.  b Dissolved and diluted in methanol 
 
Endolysosomal pH time course 
Seven petri dishes containing RAW macrophages were grown to confluence.  Medium was removed 
and replaced with fresh; U18666a (fc 300nM, see Table S3) was added 0, 15, 30, 45, 60, 120 and 
180 minutes before cells were harvested and yellow/blue ratios measured as above.  Comparison with 
the correlation curve obtained by averaging results for other independent experiments gave the pH 
values. 
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Measurement of endocytic vesicles 
Cells were placed in a Nunc 6-well plate (Thermo Scientific 140675) at ca. 50% confluence and 
incubated overnight.  Media was removed; cells were washed with 1mL PBS and fresh media (2mL) 
added.  AMP-DNJ was added at requisite concentrations and the cells incubated overnight.  Cells 
were washed with 3x2mL warm (37˚C) medium containing 0% serum ('0% medium') before adding 
1.5mL warm 1% medium containing 400nM LysoTracker red (prepared by adding 4µL LysoTracker 
red DND-99 (1mM in DMSO; Invitrogen L7528) to 10mL 1% medium).  Cells were incubated for 15 
minutes.  Medium was removed and each well washed with 3x2mL warm 10% medium for 1 minute 
each time.  After the final wash 2mL ice-cold 10% medium was added to each well.  Cells were 
examined by fluorescence microscopy using an EVOS instrument and the RFP filter; 40x 
magnification and 40% light intensity were used.  Typically 10 images per well were recorded.  For 
each image red pixels were counted in ImageJ using the Color Pixel Counter plugin with default 
settings (imagejdocu.tudor.lu/plugin/color/color_pixel_counter/start); the number of cells in each 
image was counted manually. 
 
Golgi trafficking 
Procedure is for fibroblasts and is based on previous work.41  5x100µL of cells suspended in medium 
(control or containing drug (Table S3)) were placed on a coverslip in a petri dish and incubated 
overnight.  Medium was removed and each coverslip washed with 3x100µL 0% medium.  95µL 1% 
medium containing 1.5µM BODIPY-LacCer (prepared by adding 7µL of BODIPY-LacCer (1mg/mL in 
ethanol; Invitrogen, discontinued) to 0.5mL 1% medium)  was added to each coverslip and petri 
dishes incubated for 45 minutes (pulse time).  Medium was them removed for each coverslip and the 
dish washed with 3x10mL 10% medium for 1 minute each time.  10mL of fresh 10% medium was 
placed in the dishes which were then incubated for 90 minutes (chase time).  The medium was then 
removed and 10mL ice-cold 10% medium added.  Coverslips were retrieved individually and 
examined by fluorescence microscopy using an EVOS instrument and the GFP filter.  Typically 40-50 
images were recorded.  Images were analysed manually for the presence of Golgi staining. 
Variations: for RAW macrophages BODIPY-LacCer complexed to BSA (Invitrogen B34402, 1mg 
dissolved in 1mL ddH2O) and a chase time of 60 minutes were used. 
 
Lipid quantitation 
Cells were grown until confluent, treated with drug (DMSO for controls) and incubated overnight.  
Cells were harvested, the pellets rinsed x3 with PBS and stored at -20°C.  Pellets were transported to 
Universiteit Leiden in a container packed with solid CO2 where they were analysed for lipid content 
as described.590 
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Aß assay 
Cells were grown in Nunc 6-well plates (Thermo Scientific 140675) until confluent.  Media were then 
removed, the cells washed with PBS (2x1mL) and 1mL OptiMEM (Gibco 31985-062) added.  Drugs 
were added (see Figure S2 and Table S3) and cell incubated overnight.  800µL medium was removed 
from each well, centrifuged (3mins, 3000rpm) and then 750µL placed in a 1.5mL Eppendorf 
containing 30µL 25x PIC (see above).  Samples were stored at -20°C until they were transported to 
Manchester University in a container packed with solid CO2 where they were analysed for Aß content 
as previously described.557  The remaining OptiMEM was removed from each well and cells washed 
with 2x1mL warm PBS.  200µL RIPA buffer containing PIC (see above) was added and the cells 
scraped; the suspension transferred to a 1.5mL Eppendorf and incubated at ice temperature for 30 
minutes.  The mixtures were then centrifuged (4°C, 10mins, 13000rpm), 75µL of lysate removed and 
stored at -20°C until transport and analysis as above. 
 
Multi-sequence alignment 
The human, mammalian and C. elegans sequences were downloaded from UniProt (uniprot.org) and 
aligned in Clustal Omega (ebi.ac.uk/Tools/msa/clustalo/).465  For yeast the S. cerevisiae sequence was 
subjected to a BLAST search in UniProt and the resulting 250 sequences imported to JalView where 
they were sorted according to GlcCer status528,529 (sequences from species with no GlcCer information 
were removed). 
 
Protein modelling 
Protein modelling was performed as described in chapter 2 except for the vATPase model with one 
a and three c subunits which required sequence alignment in DeepView and the project mode of 
SwissModel (swissmodel.expasy.org/).304,306,591  Details are given in Table S3. 
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Table S3  Properties of protein structures used in this chapter 
 
Protein Struc-
ture 
Model 
based 
on 
Resolu-
tion (Å) 
QMEAN- 
Brane score 
Position in 
membrane 
Ref 
vATPase 
(c subunit 
decamer) 
 5tj5 3.9 
 
 
496 
vATPase 
(a subunit 
and three c 
subunits) 
 5tj5 3.9 -5.75 
 
496 
NPC1 
(membrane 
region) 
 
 
 
 
5u74  3.34 -4.23  338 
 
 
Molecular docking 
Molecular docking was performed as described in chapter 2.  Details for the AutoDock docking of 
cholesterol to the c subunit decamer are given in Table S4.  For ROSIE-Rosetta ligand docking of the 
GlcCer headgroup to the ac3 model, the starting position was the terminal N of Lys54 of each of the 
three c subunits; for GlcCer to NPC1 the starting position was Cß of Ser666; in both cases all other 
settings were defaults. 
 
Table S4  Docking parameters for AutoDock  For more details on the procedures used to perform 
docking and calculate the grids used, see Chapter 2 Table S3 and.309,310 
 
Protein, 
region 
Grid centre Grid dimensions 
(points) 
Grid offsets 
(points) 
Residues 
with 
flexible 
sidechains 
Lipid and 
(number of 
GA runs) 
vATPase c subunit 
decamer, 
luminal face 
Phe137,  
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Figure S1  Chemical probes used in this work 
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Figure S2  Sphingolipid manipulating drugs used in this work 
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Figure S3  Natural GlcCer and short chain surrogates used for molecular docking 
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Figure S4  ROSIE-Rosetta ligand docking output for GlcCer at vATPase  Squares represent binding 
poses between the a subunit and c subunit chain N (Figure 6A), triangles represent binding poses between 
the a subunit and  c subunit chain D (Figure 6B) and circles represent binding poses between the a subunit 
and the c subunit chain B (Figure 6C).  Only correctly oriented conformations from the 30 poses with most 
favourable interface scores are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S5  ROSIE-Rosetta ligand docking output for GlcCer at the luminal pocket of NPC1  Dotted 
lines mark the boundaries of the energetic favourability for both total score and interface score.  Only 
poses in the lower left quadrant  are favourable. 
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Mitochondria 
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Chapter 1 introduced the phenomenon of mitochondrial dysfunction in NPCD and 
the idea that it results from damage caused by cathepsins escaping damaged 
lysosomes.  That chapter also surveyed the evidence for the more popular notion 
that mitochondrial insufficiency is caused by cholesterol overload and found the data 
highly suggestive but ultimately inconclusive.  This chapter will consider the idea 
that reduced mitochondrial function results not from cholesterol but from 
sphingolipids and considers the possibility that this aspect of NPCD might be treated 
by manipulating levels of this class of molecule, as chapter 3 showed was successful 
for endocytosis.  Finally it returns to the cholesterol hypothesis and proteins of the 
mitochondrial membranes. 
 
Introduction 
Basics of mitochondrial function 
The generation of adenosine triphosphate (ATP), a molecule stable to biological 
conditions and yet readily hydrolysed to release energy, occurs in the mitochondria 
by a multi-stage process involving multi-protein complexes embedded in the inner 
mitochondrial membrane (Figure 1A).  Pyruvate, derived from glycolysis in the 
cytosol, enters the mitochondria where it participates in the Krebs cycle.  At various 
points in this cycle NADH and FADH2 are produced (Figure 1, ❶ and ❷).  These 
are organic sources of hydride ion (H-) and are processed by Complex I and Complex 
II respectively.  The hydride is split into an H+ ion (proton) and two electrons (❸).  
The electrons are passed, via ubiquinone (Q), to complex III (❹) and the energy 
liberated thereby used to transport a proton across the inner membrane against its 
concentration gradient and into the inter-membrane space (❺).  An electrical 
potential is also generated by this separation of ions and is termed .  Further 
transport of electrons from Complex III to Complex IV by cyt c (❻) allows another 
proton to be exported.  Protons can then flow back into the mitochondrial matrix 
down their concentration gradient via the ATP synthase (fATPase, ❼) and the 
energy release allows the synthesis of ATP (❽).  The protons are recombined with 
the electrons in the presence of oxygen to give water (❾). 
 
If electrons escape this transport chain into the inter-membrane space they can react 
with oxygen to give, after further chemistry, hydrogen peroxide, and the superoxide 
and hydroxide radicals.  These molecules are collectively known as reactive oxygen 
species (ROS), are toxic to cells but generally rendered harmless by peroxisomes.  
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Figure 1  Mitochondrial physiology (A) Schematic of the respiratory chain, 
for details see text.  (B)  Electron micrograph of a mitochondrion taken from 
biology-pages.info/C/CellularRespiration.html (accessed 18/07/2019).  (C) 
Structure of complex I (PDB: 5txd592) proteins coloured differently.  
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Measuring mitochondrial function 
This work uses two complementary measures of mitochondrial function: oxygen 
consumption and ATP production, both experiments being performed in healthy and 
disease fibroblasts.  Oxygen consumption was measured using an OxyGraph 
machine593 (details given in Materials and Methods).  This experiment places two 
samples of ca. 106 cells in a buffer in sealed glass chambers where oxygen 
concentration can be measured using electrodes.  The cells are first permeabilised 
with digitonin causing the loss of small molecules including Krebs substrates and 
consequent decline in oxygen consumption to almost zero.  Cells are then supplied 
with a large excess of malic and glutamic acids which produce NADH, substrate for 
complex I.  Additional supply of ADP renders possible the production of ATP and 
thus oxygen consumption increases sharply, though reliant only on complex I.  
Feeding the cells with succinic acid, which produces FADH2, substrate for complex 
II, increases oxygen consumption still further.  The cells can then optionally be 
treated with rotenone, an inhibitor of complex I, to evaluate oxygen consumption 
reliant only on complex II.  Further optional treatments include mitochondrial 
uncoupler CCCP (to assess total respiratory capacity) and fATPase inhibitor 
oligomycin (which should abolish oxygen consumption almost entirely).  Whilst this 
assay has the advantage of being able to resolve any deficiencies specific to 
individual complexes, its drawbacks are the need for a large number of cells and 
relatively low throughput. 
 
ATP production was measured using a repurposed cell viability assay that assess the 
number of cells in a sample by consuming their ATP to produce a fluorescent signal 
- the amount of ATP is correlated with the number of cells present.  Thus if the 
number of cells is fixed a measure of ATP levels is produced instead (details given 
in Materials and Methods).  This assay lacks the detail of oxygen consumption (it 
cannot even distinguish mitochondrial from glycolytic function) but the use of only 
6000 cells per sample means that it can be run in a 96-well plate so the throughput 
is high.  The underlying assumption is that there are only negligible differences in 
growth rates between cell types and within the same cell type treated with different 
drugs. 
 
Fibroblasts are an appropriate cell type to study mitochondrial function 
As noted in chapter 1 all cells need to import cholesterol to mitochondria so that 
Cyp27A1 and related proteins can synthesis LXR ligands as part of the cell’s 
cholesterol homeostatic processes.  Mitochondria of steroidogenic cells also contain 
Cyp11A1 (also known as P450scc) which mediates the first committed step in steroid 
hormone synthesis raising the possibility that such cells may have a higher demand 
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for cholesterol than those from non-steroidogenic tissues.  It is therefore important 
to note that while mitochondrial dysfunction has been observed to result from NPC1 
deficiency in CHO cells138,185 it has also been found in brain,137,171 muscle,171 liver171 
and skin.55  Fibroblasts thus constitute a valid and convenient platform for the study 
of respiratory insufficiency in NPC disease. 
 
Results and Discussion 
Defining the mitochondrial defect in NPC1-deficient cells 
In accordance with previous work138 oxygen consumption was found to be reduced 
in untreated NPC1-deficient cells compared to healthy controls (Figure 2A).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Respiratory dysfunction in NPC1-deficient cells  (A) Oxygen 
consumption if reduced under all conditions tested (mean±SEM, n=4).  (B) ATP 
production is ca. 80% of healthy cells (mean±SEM of 6 independent 
experiments conducted in triplicate).  (C) Sample correlation curve for the Glo 
ATP assay (r2=0.997) carried out with each experiment as per the 
manufacturer's instructions. 
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This respiratory error was again apparent when feeding complex I alone and even 
more pronounced when feeding complex I together with complex II (Figure 2A) 
suggesting a pernicious error of mitochondrial function rather than something that 
can be localised to a particular protein complex.  This contrasts with previous work 
where, using an incomplete mitochondrial fraction, the error was localised to the 
fATPase.171  ATP production was also reduced in disease fibroblasts (Figure 2B) as 
has been found previously.138,171 
 
Which lipid is responsible? 
In chapter 1 we encountered the idea that mitochondrial dysfunction in NPCD stems 
from cholesterol overload of that organelle and observed that the direct evidence for 
this is not quite conclusive as cholesterol quantitation was performed on 
mitochondrial fractions that were pure but incomplete.138,171,181,186  (Other 
studies594,595 do not attempt to demonstrate the purity or completeness of their 
mitochondrial fractions.)  While cholesterol overload has been reported to result in 
mitochondrial dysfunction in both liver and pancreatic cells173,174 mechanisms by 
which this might lead to respiratory insufficiency have only recently been put 
forward, and on evidence which is quite slim.172,175  At the same time the build-up 
of lipids other than cholesterol raises the possibility that one or more of these might 
actually be the culprit.  Consistent with this notion are reports of deleterious effects 
on mitochondrial function of Sph596,597 (though not at pathophysiologically relevant 
concentrations) GlcSph598 and GlcCer.598  The LSD Gaucher disease, caused by an 
impaired ability to metabolise GlcCer, also features mitochondrial dysfunction599 and 
in a yeast model of NPCD respiratory defects were attributed to excess 
ceramide.600,601  These observations open the possibility that multiple lipid defects 
lead to mitochondrial dysfunction in NPCD and hence even the experimentally 
challenging180 subcellular lipidomics approach might not clarify matters. 
 
To investigate the possibility that sphingosine might poison mitochondria 
respirometry was undertaken in HEK cells where sphingosine-1-phosphate (S1P) 
lyase (Chapter 1, Figure 4, stage ⓮) had been knocked out.r  This is the terminal 
enzyme in sphingolipid catabolism which catalyses an irreversible carbon-carbon 
bond cleavage, hence its loss causes cells to accumulate both S1P and sphingosine602 
even while continuing to grow normally in culture.  This phenotype is similar to 
NPC1-deficient cells.  These Sph-enriched cells displayed lower oxygen consumption 
than the parent cells from which they were derived (Figure 3) thus possibly giving 
credence to the idea that in NPCD excess sphingosine leads to mitochondrial  
                                                          
r These cells were a gift from Dr Per Haberkant (EMBL) to whom I am grateful. 
Mitochondria are 
dysfunctional in NPCD 
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Figure 3  S1P lyase knockout in HEK cells impairs oxygen consumption  
Oxygen consumption is reduced, though not always significantly, under all 
conditions tested (mean±SEM, n=4). 
 
dysfunction.  (Attributing mitochondrial toxicity to the excess of S1P is perhaps less 
likely as a mimic of this lipid has been shown to reduce ROS in a neuronal cell 
culture603 whereas ROS increases in NPCD.138) 
 
Next the question was asked whether this was an effect specific to sphingosine, as 
is sometimes observed in other areas (eg114), or generalisable to similar molecules.  
Thus healthy fibroblasts in the OxyGraph were fed with 5µM dihydrosphingosine 
(dhSph, see chapter 1, Figure 4, stages ❶-❷) and incubated for 40 minutes.  After 
this time respiratory activity reduced to 60-70% of that present in untreated cells 
(Figure 4) thus reducing the likelihood that a specific Sph-protein interaction is 
responsible for respiratory dysfunction.  (These experiments were conducted in PBS 
as no change could be detected when adding dhSph to cells in the usual respiration 
buffer (data not shown) - this can probably be attributed to dhSph binding to the 
BSA that is present in the buffer.)  This is consistent with work in mice where 
knocking out ceramide synthase (Chapter 1, Figure 4, stage ❷) led to an expected 
increase in dihydrosphingosine as well as mitochondrial insufficiency.604 
 
These experiments may hint at a mechanism of action for these sorts of molecules.  
Previously sphingosine had been implicated in mitochondrial dysfunction through 
induction of Ca2+ errors605,606 though the possible equivalence of dhSph was not 
examined.  A simpler explanation may suffice: it may be that any amine can poison 
mitochondria - the basic portion of the molecule reacting with H+ ions in the 
intermembrane space (Figure 1A) and so reducing their concentration thus reducing 
and hence fATPase activity.  The localisation of both sphingosine kinase607 and 
monoamine oxidase608 (for which Sph is not a substrate) to mitochondria argues in  
It is plausible that 
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Figure 4  Dihydrosphingosine reduces oxygen consumption  Dosing 
healthy fibroblasts in PBS with 5µM dhSph reduces oxygen consumption under 
all conditions tested (mean±SEM, n=3). 
 
favour of this idea.  Thus it is plausible that other amines, eg GalSph that is believed 
to be responsible to toxic effects in Krabbe disease,609 also poison mitochondria.  
This raises a transport question: how does a lipid stored in the lysosome end up in 
the mitochondrion?  This is a relevant question whether the lipid is sphingosine, 
cholesterol or a different species entirely. 
 
Transport of lipids from lysosomes to mitochondria 
Mitochondria are unable to synthesise their own lipids and so must acquire them 
from elsewhere, most obviously the ER via membrane contact sites;610,611 the 
question for this study is whether lipids can also be provided from the lysosome.  In 
some pathologies this seems possible.  Thus traumatic brain injury leads to activation 
of lysosomal enzyme aSMase which acts on sphingomyelin in a metabolic process 
equivalent to Chapter 1, Figure 4, stage ❾ for GlcCer.  This hydrolase generates 
ceramide and thence sphingosine; ultimately sphingosine is increased in 
mitochondria where it disrupts normal function.612  (Previously expressed caveats 
regarding purity and completeness of the mitochondrial fraction apply here also.)  
The simplest explanation is that sphingosine generated in the lysosome is transported 
to the mitochondrion.  Studies with cholesterol have suggested that such a pathway 
does not require functional NPC1 but is mediated by NPC2185 and lysosomal 
cholesterol transport protein StARD3181,186,613 (also known as MLN64) which we met 
in chapter 2.  Thus NPC2 conveys cholesterol to the lysosomal limiting membrane 
where it presumably flips before being collected by the START domain of StARD3 
and inserted into the outer mitochondrial membrane.  (This study185 of the role of 
NPC2 is contextualised by the work cited in chapter 1 showing that various 
devices41,216,217,264,266–268 promote cholesterol export from the lysosome even in the 
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absence of functional NPC1 and makes yet more opaque the role of NPC1, as 
discussed in chapter 2.) 
 
But why can NPC1-deficient cells transport lipid to the mitochondrion not, as 
reviewed in chapter 1, to its normal destination in the ER?  Vacuole-mitochondrion 
contact sites have been described in yeast;614 and more recently the equivalent in 
human cells71 has been found to be mediated by rab7, a protein whose dysfunction 
is implicated in NPCD (see chapter 2).  This chapter will therefore assume that a key 
feature of NPCD pathology is the formation of lysosome-mitochondria MCSs.  It 
will further assume that, even in the absence of functional NPC1, significant 
amounts of cholesterol and sphingosine accumulate on the cytosolic face of the 
lysosomal membrane from where they can potentially be transported to the 
mitochondria.  This second assumption is to an extent at odds with the model of 
NPC1-mediated lipid export discussed in chapter 2 but is an appropriate paradigm 
given the paucity of our knowledge of NPC1 and the data on mitochondrial 
dysfunction in NPCD.   
 
Unlike NPC215 and the NTD of NPC1330 no StAR protein has been crystallised with 
a bound sterol so the best method for elucidating binding is through molecular 
docking using the recently published crystal structure of StARD3 (PDB: 5i9j360) 
combined with the analysis of sterol binding in StAR-like proteins.  The ROSIE 
ligand docking protocol312,615,616 allows great protein flexibility and works best with 
enclosed pockets like the one in StARD3 so this was selected.  Binding poses can 
be named according to the orientation of the cholesterol hydroxy group and 
consistent with previous work359 binding poses were found in both the 'IN' and 'OUT' 
orientations (Figure 5A).  The previous study could not distinguish between these 
two clusters of results using docking or MD, though the total simulation time of 
1.5ns may be too short.  On inspecting the 30 most favourable ROSIE binding poses 
(those with the most negative interface score) a statistically significant (p<10-5) 
preference for the IN orientation was evident (Figure 5B) as has previously been 
reported for StARD5.617  This is consistent with studies on StARD1618 (also known 
as STAR) and StARD4619 which both suggest that the 1 loop (blue in Figure 5A) 
flexes to allow lipids to enter the cavity.  Thus the StARD3 opening created by a 
flexed 1 loop could interact with the polar surface of a membrane; cholesterol 
could then leave the membrane polar-end first and enter the binding cavity and 
hence the IN orientation would arise naturally.  (An exactly similar situation pertains 
if StARD3 were to collect cholesterol from the putative luminal binding site of 
NPC1, see Chapter 2, Figure 13.)  Most cholesterol IN poses featured an H-bond  
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Figure 5  Docking of cholesterol in StARD3  (A) Docking of cholesterol in 
StARD3 (PDB: 5i9j) yields both IN (orange) and OUT (pale orange) poses; the 
Ω1 loop is shown in blue.  (B) The interface score of the cluster of IN poses 
(circles) is significantly more favourable than that of the OUT poses (squares).   
 
to Ser362 which is shown in Figure 5A and was also identified as key in the previous 
study.359   
 
After this docking work had been completed the crystal structures of three yeast 
StAR orthologuess with bound sterols were published;.620–622  the orientations of 
these bound ligands show similarities as well as differences (Figure 6A,B) to the 
results emerging from the docking experiments (Figure 5).  Most obviously all sterols 
are bound with the IN geometry (Figure 6A) supporting the idea that this is 
biologically important.359 All are bound with the methyl groups of the sterol -face 
oriented similarly (Figure 6A, though only StARD3 features a CH- interaction 
involving the sterol α-face (with Trp404, Figure 6B).  All sterols make hydrophobic  
                                                          
s These structures were found using the DALI search tool683,684 for similar protein 
structures.  I am grateful to Dr Pietro Roversi (University of Leicester) for bringing 
this technique to my attention. 
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Figure 6  Conservation of structure amongst StARD3 and related proteins  
(A) Human StARD3 with docked cholesterol is shown overlaid with S. 
cerevisiae Lam4 (PDB 6bym) and two sterol binding domains of S. cerevisiae 
Lam2 (PDB 5ys0 and 6cay) with bound sterols.  (B) Detailed view of lipid-
protein interactions with selected binding residues; StARD3 residue labels are 
edged in black; some protein structure omitted for clarity.  For details see text.  
(C) Section of overlay-based multisequence alignment of the sterol binding 
domains from (A) and (B).  For details see text. 
 
contacts with aliphatic sidechains inside the pocket (eg Val1151 of Lam2 and Val314 
of StARD3, Figure 6B).  Simple multi-sequence alignment of these four proteins 
shows the fungal structures have <20% sequence identity to StARD3 and positions 
Ser362 
Trp404 
Val1164 
Gln1149 
B 
A 
StARD3 Ω1 loop Docked cholesterol 
Yeast orthologues Bound sterols 
Val314 
C 
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residues equivalent to putative key H-bonidng residue Ser362 outside the lipid 
binding pocket (data not shown).  Thus the sequences were re-aligned based on the 
structure overlay (performed in UCSF Chimera363).  This gives an even lower 
sequence identity to human StARD3 (ca. 12% in every case) but sheds more light 
on lipid binding.  Thus Ser362 aligns with a valine in every case (Figure 6C, arrow) 
but an H-bonding residue occurs two positions further on (Figure 6C, red box; eg 
Gln1149 of Lam4) and these are found crystalographically to bind the sterol –
OH,621,622 (Figure 6B) with an intermediate water in one case.620  (Some of the 
residues aligning with position 363 of StARD3 are capable of H-bonding but their 
sidechains are positioned outside the binding pocket.)  This perhaps explains why 
the bound sterols in the crystal structures only partially overlay with  cholesterol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7  Flexibilities in StARD3 with potential functional consequences  
(A) MD simulation of a sample IN binding pose shows the Ca  atoms of the 
protein backbone (grey) experience minimal fluctations while the the Ca  atoms 
of the Ω1 loop  (blue) have considerable flexibility.  The cholesterol  (orange) 
remains stably bound suggesting loop opening alone is insufficient to provoke 
cholesterol off-load.  (B) Cholesterol unloading may be prompted by Arg351 
switching between the two conformations found in the crystal where it can form 
an H-bond (green) with key cholesterol binding residue Ser362 (conformation 
A) and ionic interactions (magenta) with Asp332 (conformation B).   
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docked to StARD3 (Figure 5A) and why the RMSD for the carbon atoms in these 
lipids compared to docked cholesterol is usually larger than the RMSD for the protein 
overall (9.40Å vs 5.81Å for 5ys0, 8.70Å vs 6.37Å for 6cay and 8.77Å vs 8.35Å for 
6bym).  Perhaps as a consequence of this the regions of yeast proteins corresponding 
to the 1 loop appear more open (Figure 6A), though these loops are still found 
important for yeast protein function.620–622  Overall, then, docking predicts a binding 
mode of cholesterol to StARD3 very similar to that found experimentally for fungal 
orthologues. 
 
In a 10ns MD simulation a sample pose of cholesterol bound to StARD3 rapidly 
underwent a small rearrangement preserving the Ser362 H-bond and then remained 
stable with minimal movement in the protein backbone (Figure 7A, video 
StARD3_5i9j_chol; protein in grey, 1 in blue, cholesterol in orange).  Also evident 
from Video StARD3_5i9j_chol and Figure 7A is 1 opening and then closing during 
the lifetime of the simulation while cholesterol remains bound; this may suggest that 
an additional trigger is needed for lipid release.  Intriguingly the crystal structure of 
StARD3360 found the Arg351 sidechain in two conformations: one forming an ionic 
interaction with Asp332 and the other (a slight majority) forming an H-bond with 
Ser362 (Figure 7).  We may thus conjecture that something about membrane binding 
triggers the re-establishment of this H-bond thereby ejecting the cholesterol 
molecule. 
 
This chapter has supplied evidence that sphingosine (Figure 3) and possibly other 
amines (Figure 4) can lead to reduced mitochondrial function while chapter 2 
repeatedly found sphingosine capable of binding to proteins in the same manner as 
cholesterol.  The question thus arises of whether the NPCD respiratory defect can 
be attributed to sphingosine transported from lysosomes to mitochondria by 
StARD3.  Here we are faced with a complication.  The pKa of sphingosine has been 
reported as 6.6 in solution348 and 9.1 in a model membrane349 meaning that it will 
likely be electrically neutral in the cytosol but protonated (and positively charged) in 
the membrane.  It is not obvious whether or not it will lose its charge on moving 
from a membrane into the lipid binding pocket of StARD3 although the geometrical 
considerations of lipids entering and leaving membranes discussed above suggest 
that Sph should adopt the same IN binding mode as cholesterol.   
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Figure 8  Sphingosine binds to StARD3 in a variety of conformations  
(A,B) Unprotonated (A) and protonated (B) sphingosine bind StARD3 (PDB: 
5i9j) in poses where the IN clusters (circles) are energetically indistinguishable 
from the OUT clusters (squares).  (C) Selected IN binding poses of 
unprotonated sphingosine in StARD3; some protein omitted for clarity, Ω1 loop 
shown in blue. 
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Figure 9  Stability of Sph binding poses in StARD3 under MD simulation  
Simulation data from starting poses 1, 2, 3 and 4 (Figure 7) are shown in (A), 
(B), (C) and (D) respectively; C (whole protein) is in grey C (1) blue and Sph 
purple. 
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ROSIE ligand docking was performed with sphingosine both neutral and protonated 
and the 30 binding poses with most favourable interface scores were surveyed.  (The 
built-in conformer generator315 used in ROSIE tends to give only very small 
variations from the initial molecular shape thus Frog2623 was used in preference.)  
Neutral sphingosine (Figure 8A) gave slightly more energetically favourable binding 
overall than protonated sphingosine (Figure 8B); for neither species was there a 
discernible differences between those poses categorised as IN and those denoted 
‘OUT' and nor was binding dominated by Ser362 - a diverse range of residues 
formed H-bonds with the lipid.  Four representative binding poses (Figure 8C) of 
neutral sphingosine were subjected to 10ns MD simulations.  RMSD analysis of the 
results for each suggested that the protein experienced limited fluctuations (Figure 
9A-D, grey) while 1 moved around much more as expected (Figure 9A-D, blue).  
Sph in poses 1 and 3 did not appear to be stable (Figure 9A,C, purple) while Sph in 
poses 2 and 4 underwent much smaller displacements from its initial position (Figure 
9B,D, purple).  An analysis of residence time (the percentage of the production 
phase the lipid forms H-bonds to a given residue, Table) led to the same conclusions 
- the H-bonds formed by poses 2 and 4 remain largely stable for the duration of the 
simulation while those in poses 1 and 3 do not persist.  Similar findings pertain to 
protonated sphingosine (data not shown). 
 
 Ile301 Asp332 Arg351 Ser362 Gly384 Asn407 
Pose 1 0 24 2 0 0 0 
Pose 2 8 0 48 59 0 0 
Pose 3 0 0 15 0 34 0 
Pose 4 0 0 0 0 68 5 
 
Thus for Sph there is no energetic difference between the biologically relevant IN 
mode and its likely irrelevant OUT counterpart, some IN poses are unstable and 
some of the stable IN poses bind the protein in a manner likely to be different to 
cholesterol, a genuine613 biological substrate.  The failure of Sph docking/MD 
experiments to converge on a single stable solution suggests the conclusion that 
StARD3 is not involved in any sphingosine-induced mitochondrial pathology even 
though such dysfunction can be artificially induced as shown above (Figure 3). 
 
Does GBA2 inhibition correct mitochondrial defects? 
The effectiveness of AMP-DNJ in NPCD mice250 suggests that the effect of GBA2 
inhibition on mitochondrial dysfunction in this disease, which has not previously 
been studied, is worthy of investigation.  (There is some evidence of benefit from a 
very small human study.140)  A necessary caution is that while A2AR agonists have  
Modelling supports the 
accepted transport 
pathway of cholesterol 
to mitochondria; 
sphingosine probably 
cannot use the same 
mechanism. 
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Figure 10  AMP-DNJ does not correct respiratory insufficiency in NPC1-
deficient cells  Neither reduced oxygen consumption (A, mean±SEM, n=4) nor 
reduced ATP production (B, mean±SEM of 4 independent experiments 
conducted in triplicate) in NPC1-deficient fibroblasts is corrected by AMP-DNJ.  
White bars represent untreated healthy cells, black bars untreated disease 
cells; light grey bars represent treated healthy cells, dark grey treated disease. 
 
corrected both lysosomal and mitochondrial errors in cells55,234 they produced only 
limited improvements in a mouse disease model238 and so translation between 
cellular and in vivo models is not necessarily straightforward.   
 
Experiments showed that incubating NPC1-deficient fibroblasts for 24 hours with 
the dose of 20nM AMP-DNJ,t which had successful rectified errors in the 
endolysosomal system (Chapter 3), did not improve the reduced oxygen 
consumption (Figure 10A).  Oxygen consumption was also unchanged in healthy 
cells under these conditions (data not shown).  Likewise ATP production remained 
deficient despite treatment (Figure 10B) and was similarly unaffected in healthy 
                                                          
t  I am indebted to the laboratory of Prof Johannes Aerts (Universiteit Leiden) for a 
gift of a generous sample of this material prepared as previously described.249,682 
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cells.  Reducing the incubation time to 4 hours in search of a more transient effect 
was unsuccessful (Figure 10B).  This strengthens the idea, advanced in Chapter 3, 
that the clinical usefulness of GBA2 inhibitors in NPCD arises from their ability to 
correct endocytic defects and adds the contribution that such drugs' failure to halt 
disease progresion completely may stem from their ineffectiveness at correcting 
mitochondrial defects. 
 
Searching for other sphingolipid effects 
Whilst the failure of GBA2 inhibition to correct mitochondrial dysfunction was 
disappointing there are compelling reasons for connecting energy production with 
sphingolipids more widely.  The lysosomal storage disorders Gaucher disease and 
Krabbe disease are both caused by a failure of sphingolipid metabolism and feature 
mitochondrial dysfunction among their cellular characteristics.551,599  The 
mitochondrial lipid transporter ABCB10 has recently been identified as a GlcCer 
binding proteinu while ceramide,624 as well as sphingosine, is toxic to this organelle.  
Thus despite the potential problems625 it was considered worthwhile to examine the 
effects of pharmacological manipulation of sphingolipids on mitochondrial function 
in both healthy and NPC1-deficient cells.  Details of the drugs and concentrations 
used are given in Table S1 and Figures S1-3. 
 
 
None of the drugs employed led to changes in ATP production in either cell type 
(Figure 11A).  Whilst perhaps surprising it is worth noting the difficulties described 
in chapter 3 of precisely manipulating defined lipid populations and that many 
sphingolipids are toxic to mitochondria so increasing the amount of one lipid at the 
expense of another may lead to no overall change.  The CBE result is perhaps 
particularly unexpected for this compound is an inhibitor of GBA1 whose 
dysfunction leads to Gaucher disease.  These results are nonetheless consistent with 
previous work that found CBE-induced mitochondrial defects only after a 10 day 
incubation.626 
 
Attempting to alter sphingolipid populations by feeding lipids to cells was similarly 
unsuccessful.  Neither GlcSph nor GalSph nor a cell-penetrant GlcCer analogue 
(AdaGlcCer) at either of its recommended concentrations627 corrected inadequate 
ATP production in NPC1-deficient cells or changed ATP production in healthy cells 
(Figure 11B).  This was a surprise as GalSph incubation is often used to simulate the 
LSD Krabbe disease and has been shown to induce mitochondrial dysfunction.609  
Thus, hypothesising that GalSph and other sphingolipids bound to protein in the 
                                                          
u Prof Cliff Lingwood (Sick Kids, Toronto), personal communication 
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Figure 11  Sphingolipid manipulations do not correct impaired ATP 
production in NPC1-deficient cells  Neither pharmacological inhibition of 
sphingolipid metabolism (A, mean±SD of 2 independent experiments 
conducted in triplicate) nor incubation with sphingolipids (B, mean±SD of 2 
independent experiments conducted in triplicate) alter ATP production in 
healthy or NPC1-deficient fibroblasts.  White bars represent untreated healthy 
cells, black bars untreated disease cells; light grey bars represent treated 
healthy cells, dark grey treated disease. 
 
media (consistent with experiments in628) these experiments were repeated in serum-
free media. Microscopic inspection of the cells revealed blebbing and fragmentation, 
features of apoptosis, in a manner that appeared to be dose-dependent (Figure 12) 
suggesting that measured ATP levels would be more likely to be a consequence of 
cell death than a less controlled disease process.   
 
The results presented thus far show that sphingolipids may be part of the problem 
of mitochondrial dysfunction in NPCD; they do not appear to be part of the solution. 
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Figure 12  
Apparent 
apoptotic 
effects of 
sphingo-
lipids on 
fibroblasts 
Healthy cells 
shown on the 
right, NPCD 
on the left 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
5µM  
GlcSph 
10µM  
GlcSph 
20µM  
GlcSph 
5µM  
GalSph 
10µM  
GalSph 
20µM  
GalSph 
20µM  
AdaGlcCer 
40µM  
AdaGlcCer 
180 
 
Inhibiting mitochondrial cholesterol import 
Given that the mitochondrial defect in NPCD had proved refractory to manipulation 
of sphingolipid levels and that, as discussed in chapter 1, mitochondrial cholesterol 
import is necessary for all cells so that Cyp27A1 and related enzymes can produce 
LXR ligands, mitochondrial cholesterol overload was reconsidered as the source of 
the metabolic defect in NPCD cells. The details of cholesterol import to mitochondria 
have yet to be worked out, but the broad outline is known (reviewed629,630) and the 
proteins involved shown in Figure 13.  (The drugs used in this section are shown in 
Figure S3 and the concentrations and solvents in Table S1.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Working model for cholesterol import to mitochondria  The 
functions of these proteins (if any) in cholesterol import have yet to be 
completely defined; see text for details. 
 
 
About ATAD3A very little is known, though this protein may act to tether the outer 
and inner membranes631 thereby facilitating cholesterol transport to the inner 
membrane where Cyp27A1 is believed to reside. 
 
StARD1 is thought to transport cholesterol from the outer to the inner membrane 
though this protein's exact location and mode of action are both unclear.  21-acetoxy 
pregnenolone (21-AcP) has been identified as an inhibitor of StARD1632 (given the 
close structural similarity of the StAR proteins 21-AcP may also act off-target to 
block StARD3-mediated lipid transport to the mitochondrial outer membrane).  
Incubation with this agent at its IC50 of 10µM did not alter ATP levels in either 
healthy or disease cells (Figure 14).  Thus the concentration was increased to 40µM 
and cells treated for either 4 or 24 hours.  At the longer time point this yielded a 
small increase in ATP levels in disease cells (79±4% of untreated healthy to 86±1%, 
HO 
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Figure 14) but a similar change in healthy cells (100 to 110±2%) questions whether 
this is through an impact on pathology or is a more general phenomenon. 
 
StARD1 requires activation by PKA to achieve full capacity633 and anchoring proteins 
(either ACBD3 or AKAP) for this cytosolic enzyme have been found in protein 
assemblies implicated in cholesterol import629 (Figure 13).  Therefore it is possible 
that a PKA inhibitor (H89 was chosen as being reasonably selective162) might reduce 
any cholesterol-induced mitochondrial toxicity.  Indeed H89 at a concentration of 
200nM (2.2x IC50 for PKA162) yielded an improvement of ATP production from 
79±4% of untreated healthy to 89±1%; a corresponding increase was not seen in 
healthy cells (Figure 14). 
 
Figure 14  Attempted correction of impaired ATP production in NPC1-
deficient cells by pharmacological manipulation of cholesterol transport 
proteins  Inhibition of PKA by H89 and ABCA1 by probucol gave increased 
ATP production in NPC1-deficient fibroblasts but not in healthy cells (mean±SD 
of at least 2 independent experiments conducted in triplicate).  White bars 
represent untreated healthy cells, black bars untreated disease cells; light grey 
bars represent treated healthy cells, dark grey treated disease. 
 
 
The success of both 21-AcP and H89 could be seen as supporting the cholesterol 
hypothesis of mitochondrial toxicity; as a control probucol, an inhibitor of cell-
surface cholesterol exporter ABCA1634 which would not be expected to increase 
mitochondrial function was also tried.  Surprisingly this agent at its recommended 
concentration of 10µM634 also gave an improvement in ATP production from 79±4% 
of untreated healthy to 96±4% (Figure 14) and a smaller enhancement (100 to 
108±4%) in healthy cells suggesting that the influence of cellular cholesterol balance 
on energy metabolism is not simple. 
 
Perhaps a surprising member of the cholesterol import machinery629,630 is  the voltage 
dependent anion channel (VDAC), an ATP release channel of the outer 
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mitochondrial membrane635 (Figure 13).  An NMR study identified cholesterol 
binding sites on the -barrel pore;636 MD simulations confirmed binding of 
cholesterol at these sites was stable and affected the structure of the protein though 
ion flux was found unchanged on lipid association.637  (An alternative approach638 
to binding site discovery using photo-activatable cholesterol analogues arrived at 
different conclusions, predicting the lipid would bind anti-parallel to the membrane 
(see Chapter 2, Figure 6.) which seems less likely.)  The computational work used a 
monomeric channel, which a later crystallographic study suggests may not be 
correct,639 while a cholesterol derivative has been reported to affect the 
oligomerisation state of VDAC;640 thus the effects of mitochondrial cholesterol on 
VDAC function remain to be clarified.  Selective inhibitors of this channel have only 
just become avaialable641 whilst activators are currently unknown rendering further 
study and potential correction of the role of VDAC in NPCD challenging. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15  Binding sites on TSPO  TSPO (grey) is embedded in the outer 
mitochondrial membrane (opaque disks); both reported ligand binding sites 
(blues overlap the CRAC cholesterol binding motif (orange, key residues 
shown).  Structure taken from PDB 2no2.642 
 
 
Translocator protein (TSPO) is a protein of the outer mitochondrial membrane which 
has been implicated in numerous CNS pathologies643,644 including Alzheimer's.645,646  
It was initially named the peripheral benzodiazepine receptor (PBR); the updated 
nomenclature was adopted to reflect the evolving view that this protein transports 
substrates into the mitochondrion, a view that nonetheless remains controversial.647  
(For this reason there have been some attempts to hijack the acronym to mean 
tryptophan-rich sensory protein.)  However there is a growing body of work that 
finds this protein involved in mitochondrial cholesterol import.629,630  TSPO was in 
fact the first protein identified with a CRAC motif.296  Chapter 2 expressed some 
skepticism regarding the general usefulness of such motifs for predicting lipid 
CRAC motif 
Ro5-4864 and etifoxine binding 
PK11195 binding 
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binding sites, but in this case cholesterol binding to TSPO was unambiguously 
demonstrated at the predicted region.648,649  (Given this binding motif lies on the 
surface of the protein the proposal that cholesterol import uses TSPO as a channel650 
is rather unlikely; molecular docking showed there is probably insufficient space for 
this without significant rearrangement of the protein's 3D structure (data not 
shown).)  Since then various TSPO ligands have been shown to provoke cholesterol 
efflux in retinal epithelial cells,651,652 macrophages653 and astrocytes and 
fibroblasts.654  Thus if mitochondrial dysfunction in NPCD is the result of cholesterol-
induced toxicity then TSPO is a target worth investigating.  This approach is also 
advocated by the implication of TSPO in mitochondrial calcium homeostasis and 
energy production.655,656 
 
Previous work has identified two ligand binding sites on TSPO, both of which 
overlap with the CRAC motif (Figure 15).  Thus mutagenesis experiments suggest 
benzodiazepine Ro5-4864 binds at an exposed site657 while PK11195 binds at a site 
within the membrane by analogy with the crystal structure of a bacterial 
equivalent.658  Etifoxine is found to bind at the same site as Ro5-4864 but with a 
higher potency than its binding inherently merits due to the phenomenon of slow-
offset kinetics.659  Incubation with the recommended concentrations660 of these 3 
drugs for 4 hours did not produce any changes in ATP levels in either healthy or 
disease fibroblasts (data not shown).  Extending the incubation to 24 hours did not 
alter this picture for 1nM PK11195 (Figure 16A) though increasing the concentration 
to 100nM did enhance ATP production (data not shown).  24 hour incubation with 
1µM Ro5-4864 produced a small increase in ATP (79±4% of untreated healthy to 
86±3%, Figure 16A) but a similar increase could be observed in healthy cells (100 
to 109±6%) suggesting this treatment may not genuinely be disease modifying.  
(Increasing the concentration of Ro5-4864 to 10µM did not further increase ATP 
production in disease cells, data not shown.)  In contrast, use of 20µM etifoxine for 
24 hours increased ATP production in NPC1-deficient cells from 79±4% of 
untreated healthy to 93±3% (Figure 16A) but only a negligible increase in healthy 
cells (100 to 105±5%).  Given that cholesterol off-load is seen with TSPO ligands 
in a variety of cell types651–654 and that sphingosine probably won't bind TSPO (at 
least not at the cholesterol binding site) due to electrostatic repulsion between the 
protonated head group and Arg156, this result argues in favour of cholesterol as the 
toxic lipid in NPCD and against sphingosine.  This is consistent with the docking/MD 
studies of StARD3 reported above (Figures 5-9). 
 
The positive results seen with etifoxine, probucol and H89 raises the question of 
whether combinations of these drugs could enhance ATP production further.  
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Unfortunately this was not found to be the case - co-incubation with etifoxine and 
inhibitors of either PKA or ABCA1 failed to increase mitochondrial function above 
the levels seen with etifoxine alone (Figure 16B). 
Figure 16  Attempted correction of impaired ATP production in NPC1-
deficient cells by TSPO ligands (A) Of the TSPO ligands tested only etifoxine 
produces an increase in ATP production in disease but not healthy cells.  (B) 
The response to etifoxine is neither blocked nor augmented selected other 
agents.  Both charts show  mean±SD (or SEM where appropriate) of at least 2 
independent experiments conducted in triplicate.  White bars represent 
untreated healthy cells, black bars untreated disease cells; light grey bars 
represent treated healthy cells, dark grey treated disease. 
 
Any of these agents may be operating at their expected targets but not by the 
predicted pathways or indeed off-target.  This is difficult to clarify pharmacologically 
for PKA and ABCA1 as selective kinase inhibition is a notoriously difficult task162 
and the ABC proteins are designed to bind a broad range of substrates.  Off-target 
pharmacology of etifoxine is easier to elucidate.  This compound binds TSPO at the 
same binding site as the benzodiazepine Ro5-4864659 (Figure 15) and structurally 
mimics this class of compounds (Figure S3).  Benzodiazepines have been suggested 
to affect A2AR binding sites661 while A2AR agonists have been reported to correct 
mitochondrial errors in NPCD cells55,234 thus it is plausible that etifoxine could be 
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acting off-target at A2AR.  However co-incubation with etifoxine and 500nM A2AR 
antagonist ZM24138555,234 did not suppress the ATP enhancement seen with 
etifoxine alone (Figure 16B) allowing the conclusion that this agent is not mediating 
its effects through A2AR agonism. 
 
The question of off-target effects was further investigated by measuring oxygen 
consumption in NPC1-deficient fibroblasts treated with etifoxine.  No increase in 
this parameter was observed whether or not respiratory complexes were fed with 
substrates (Figure 17).  This suggests that the enhancements in ATP production 
found above arose from etifoxine acting through a non-mitochondrial pathway and 
that this drug is therefore unlikely to correct any cholesterol-induced damage to 
mitochondria.  Whilst disappointing this is consistent with recent work suggesting 
that off-target effects of TSPO ligands are not uncommon.662 
 
 
Figure 17  Etifoxine does not increase oxygen consumption in NPC1-
deficient fibroblasts Oxygen consumption is unchanged after 24 hour 
incubation with etifoxine under all conditions tested (mean±SEM, n=3-4).  White 
bars represent healthy cells and black bars disease; grey bars represent 
treated disease cells. 
 
Do TSPO ligands affect lysosomes? 
While both mitochondrial and lysosomal dysfunction are widely recognised features 
of neurodegenerative disorders they have only recently started to be connected; the 
emerging links are bidirectional.  Thus knockout of lysosomal K+ channel TMEM175 
(implicated in Parkinson's disease84,457) results in not only lysosomal abnormalities 
but also reduced cellular oxygen consumption,85 while knockout of a mitochondrial 
transcription factor leads to increased endolysosomal pH and storage of 
sphingolipids.663  A genetic deficiency in mitochondrial complex I led to reduced 
expression of lysosomal proteins LAMP1 and cathepsin D a key protease664 while 
knockdown of a complex III component affects lysosomal calcium.665  Similar links 
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emerge from attempts at treatment.  Thus supplying ubiquinone (see Figure 1) to 
model cells of the LSD Gaucher disease corrected not just mitochondrial 
abnormalities but also endosomal proliferation.519  Most relevantly for the current 
study, compensation for mitochondrial errors in NPCD mice led to corrected 
sphingolipid storage in brain, though not in liver.172  Thus the wider application of 
TSPO ligands was considered worth investigating despite the failure of GBA2 
inhibition to correct respiratory errors in NPCD (Figure 10) when it had succeeded 
at the lysosome (Chapter 3). 
 
Figure 18  Effect of TSPO ligands on endolysosomal pH in NPC1-deficient 
cells  1µM Ro5-4864 significantly reduces endolysosomal pH will 20µM 
etifoxine increases it (results shown as mean ± SEM, n=3-5 export for Ro5-
4864 + etifoxine mean ± SD, n=2). 
 
Elevated endolysosomal pH was found to be corrected in NPC1-deficient fibroblasts 
treated with Ro5-4864 for 24 hours (Figure 18) just as it had been on GBA2 
inhibition.  Perhaps equally importantly etifoxine, which binds at the same site as 
Ro5-4864,659 produced a significant increase in pH and blocked the effect of Ro5-
4864.  (This antagonism may be the result of using a higher concentration of 
etifoxine.)  Thus the effects of synthetic modulators of a relatively small 
mitochondrial protein of unclear function647 extend beyond its organelle of residence 
to reactivate enervated lysosomes. 
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Open questions and future work 
 
Will my head split - or will it see?  I see half - I only see half. 
G K Chesterton 
The Innocence of Father Brown 
 
Several lines of evidence presented in this chapter support the working 
hypothesis138,171,181,186 that cholesterol is responsible for mitochondrial dysfunction in 
NPCD.   Sphingolipid manipulations failed to affect respiratory function in either 
control or disease cells (Figures 9 and 10) with the exception of excess sphingosine 
and its congener (Figures 3 and 4) for which a viable pathway to the mitochondrion 
could not be identified (Figures 7 and 8).  Conversely pharmacological inhibition of 
mitochondrial cholesterol import increased ATP production in disease cells (Figure 
13) consistent with the previous identification of an NPC1-independent transport 
pathway for this lipid from lysosomes to mitochondria.185  Whilst the question of 
mitochondrial cholesterol loading can only finally be settled by lipidomic analysis of 
a clean and complete mitochondrial fraction180 from NPCD and control cells there 
are some easier experiments that could offer partial insight.  Filipin is a natural 
product which forms a fluorescent complex with cholesterol.  NPCD cells would 
therefore be expected to show increased filipin staining co-localised with a 
mitochondrial label186 such as a fluorescently tagged antibody or MitoTracker green 
(which stains mitochondria in a -independent manner).  Fluorescent cholesterol 
analogues are another possibility but the tag can sometimes affect lipid-protein 
interactions (eg666) which may mean that results obtained with such compounds do 
not reflect biological reality.  The assumption that this mechanism is correct also 
suggests further experiments aimed at therapy.  If cholesterol transport to 
mitochondria is NPC2-dependent as suggested185 then knockdown of NPC2 in 
NPC1-deficient cells may correct the respiratory defects.  Combining effective drug 
treatments (eg H89 with 21-AcP) may lead to greater improvements than the already 
successful monotherapies (Figure 13). 
 
The cholesterol hypothesis is, however, questioned by the failure of TSPO ligands 
to correct mitochondrial dysfunction (Figures 15 and 16) when they have previously 
provoked cholesterol off-load in a variety of cell types.651–654  Assaying these 
compounds for cholesterol efflux or accumulation in lipid droplets might illuminate 
this apparent difficulty;652,654 asking whether the effect changes on knockdown of 
cell surface cholesterol exporters such as ABCA1 would add another layer of detail. 
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This work has not attempted to address the reasons for the putative toxicity of 
cholesterol at mitochondria.  To the hypotheses tentatively advanced thus far172,175 
we may add the recent discovery of the BK channel at the inner mitochondrial 
membrane (reviewed667,668), including that of fibroblasts,669 and the coupling of this 
channel to the respiratory chain.670  We encountered this channel on the lysosome 
in chapter 2 together with the extensive evidence of its impaired function in the 
presence of excess cholesterol.372–375  Thus if NPC1-deficient cells overload their 
mitochondria with cholesterol that is transported to the inner membrane then the 
flow of K+ out667 of the inter-membrane space and into the matrix (Figure 12) will 
be impaired.  This will affect the voltage across the inner membrane making export 
of protons across it harder and thereby leading to reduced fATPase activity, reduced 
oxygen consumption and reduced ATP synthesis as observed.  Consistently, BK 
openers inhibit ROS production.671  It would thus be interesting to test the effect of 
BK channel activators on mitochondrial function in NPCD.  Endolysosomal pH is 
another parameter worth investigating as BK is also localised to lysosomes369,370 and 
channel agonism has corrected the endocytic defects in this disease.384  Some BK 
channel openers are cytotoxic672 so it is important to choose agents from this class 
that do not exhibit this property. 
 
The opposite effects of Ro5-4864 and etifoxine on endolysosomal pH (Figure 17) 
suggest they are mediated through the same protein.  It might be considered 
surprising that ligation of a protein in the mitochondrion could affect such a 
fundamental property of the lysosomes, but is consistent with the growing evidence 
cited above of bidirectional links between these organelles.  The alternative 
explanation is that both compounds affect a currently unknown, possibly lysosomal, 
target.  This issue can be investigated by testing whether the effects persist on 
genetic knockdown of TSPO.  As noted above (Figure 12) TSPO is part of a multi-
protein complex with PKA.  PKA is reported to activate the CFTR chloride channel235 
which may have a role in lysosomal acidification.236  The intermediacy of these two 
proteins could be tested by incubating cells with combinations of etifoxine, H89 (to 
inhibit PKA)162 and CFTRinh172 (to inhibit CFTR).573  Any effects could be confirmed 
by genetic knockdown of the relevant protein. 
 
Chapter 2 showed that AMP-DNJ corrected not only lysosomal acidification but also 
mistargeting of an endocytic marker.  It will therefore be interesting to find out if 
TSPO ligands have the same effect, and if they can correct the endolysosomal 
volume defect that AMP-DNJ left unchanged (Chapter 3, Figure 4). 
 
The presence of the BK 
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Materials and methods 
General 
For general methods and details of cells used see chapter 3. 
 
ATP production assay 
Cells were placed in a white cell-culture treated 96-well plate (Corning 3610) at a density of 6000 
cells per well and incubated overnight.  Medium was removed, cells washed with 100µL sterile PBS 
per well and 100µL fresh media containing drugs or sphingolipids added at concentrations shown in 
Table S1.  Three wells were used for each treatment.  The plate was incubated for 4 or 24 hours.  
After this time 100µL of the Promega Cell-Titer Glo reagent (catalogue number: G7570) which had 
been thawed in the dark for at least two hours was added.  The plate was gently shaken for 2 minutes 
and allowed to stand for a further 10 minutes before measuring the luminescence at 560nm using a 
GloMax plate reader. 
As per the manufacturer's recommendation each plate also contained 3 wells each of 100µL aqueous 
ATP solution at concentrations of 10-5, 10-6 and 10-7 M.  Adding 100µL Glo reagent to these invariably 
gave luminescence readings linearly correlated with concentration with r2 > 0.95. 
 
Oxygen consumption assay 
Cells were either treated or untreated depending on the experiment.  Approximately 106 cells were 
harvested, counted and centrifuged (1500rpm, 5 minutes) the pellet resuspended in 2mL MiR05 
buffer (see below) and placed in the OxyGraph machine (oroboros.at/?Oxygraph).  The cells were 
allowed to come to equilibrium (indicated by stabilised oxygen consumption) before drugs and 
substrates were added as per Table S2.  After each addition oxygen consumption was allowed to 
stabilise before a reading was taken. 
MiR05 buffer:593 to 100mL ddH2O was added lactobionic acid (35.83g, Acros 167111), the solution 
adjusted to pH 7 with aqueous KOH solution and diluted to 200mL with ddH2O.  120mL of this was 
added to 500mL ddH2O containing EGTA (190mg, Sigma E3889, fc 0.5mM), anhydrous MgCl2 
(286mg, Sigma M8266, fc 3mM), taurine (2.502g, Sigma T0625, fc 20mM), KH2PO4.7H2O (2.622g, 
fc 10mM), HEPES (4.77g, Sigma H3375 fc 20mM), sucrose (37.65g, fc 110mM) and BSA (1g).  The 
volume was adjusted to 1L with ddH2O and the pH adjusted to 7.1 using aqueous KOH solution; 
lactobionic acid fc 60mM.  Buffer was split into 50mL aliquots and stored at -20°C until needed when 
an aliquot was thawed and subsequently stored at 4°C. 
 
Docking 
100 or 200 conformers of neutral and protonated sphingosine were generated as a single sdf file 
using Frog2.623  This file was submitted to the ROSIE-Rosetta ligand docking protocol311,312 with a 
starting position of CZ2 of Trp404 of StARD3 (PDB: 5i9j;360 QMEAN score 0.91, see Chapter 2 Table 
S1 for output).  1000 structures were generated; all other settings were defaults.  Results were triaged 
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by interface energy score and total energy score followed by more detailed assessment of the structure 
of the most favourable as described in the main text. 
 
Molecular dynamics 
This was performed as described in chapter 2 except for the use of neutral sphingosine which was 
parameterised using CgenFF320,673 giving very few adverse penalty scores (Figure S1); the calculated 
values for charges and angles behind all of these were considered acceptable on close inspection so 
the parameter file was used without modification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 CGenFF penalty scores for unprotonated sphingosine  For details see text 
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Table S1  Drugs used in the ATP production assay 
All solutions and dilutions were made with DMSO.  Solutions were stored at -20°C. 
Drug Mode of 
action 
Supplier, 
Catalogue 
number 
Initial 
concen-
tration 
Dilution Volume 
added 
to 
(media 
volume) 
Final  
concen-
tration 
Ref 
Myriocin SPT 
inhibitor 
Sigma 
M1177 
2mg/mL - 10µL 
(5mL) 
10µM  
Fumonisin 
B1 
Cer 
synthase 
inhibitor 
Cayman 
62580 
5.4mg/mL - 10µL 
(5mL) 
15µM 589 
(D)-PDMP GCS 
inhibitor 
Matreya 
1756 
2.1mg/mL - 10µL 
(5mL) 
10µM 518 
(L)-PDMP  Matreya 
1749 
2.1mg/mL - 10µL 
(5mL) 
10µM  
PPMP GCS 
inhibitor 
Cayman 
17236 
10mg/mL - 3.8µL 
(5mL) 
15µM  
CBE GBA1 
inhibitor 
Cayman 
15216 
4mg/mL - 10µL 
(5mL) 
50µM 518 
AMP-DNJ GBA2 
inhibitor 
See 
footnote f 
1mg/mL 1:250 10µL 
(5mL) 
20nM a 523,588 
GlcSph  Sigma 
43659 
4.6mg/mL - 10µL 
(5mL) 
20µM a 518 
GalSph  Sigma 
D9256 
4.6mg/mL - 10µL 
(5mL) 
20µM a  
AdaGlcCer GlcCer 
mimic 
Matreya 
1945 
12.7mg/mL - 10µL 
(5mL) 
40µM a 627 
21-AcP StARD1 
blocker 
Sigma 
A3750 
1.9mg/mL - 10µL 
(5mL) 
10µM 632 
21-AcP StARD1 
blocker 
Sigma 
A3750 
7.5mg/mL - 10µL 
(5mL) 
40µM  
Ro5-4864 TSPO 
ligand 
Sigma 
C5174 
1.6mg/mL 1:10 b 10µL 
(5mL) 
1µM  
Etifoxine TSPO 
ligand 
Sigma 
SML0272 
3mg/mL - 10µL 
(5mL) 
20µM 660 
PK11195 TSPO 
ligand 
Sigma 
CO424 
1.8mg/mL 1:100  10µL 
(5mL) 
100nM  
Probucol ABCA1 
blocker 
MP 
Biomedicals 
156271 
2.6mg/mL - 10µL 
(5mL) 
10µM  634 
H89 PKA 
inhibitor 
Tocris 
2910 
8mg/mL 1:100 10µL 
(5mL) 
300nM 
(2.2x 
IC50) 
162 
ZM241385 A2AR 
antagonist 
Tocris 
1036 
2.4mg/mL 1:28 10µL 
(5mL) 
500nM 55 
ATP Assay 
standard 
Sigma 
A26209 
5.6mg/mL 1:1000 - 10-5M  
 
a Lower concentrations were achieved by using a reduced amount of drug solution and normalising the 
volume with DMSO. 
b Stored as single use aliquots. 
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Table S2  Drugs used in the O2 consumption assay 
Substances were Solutions were divided into aliquots; the working aliquot was stored at 4°C, 
the remainder were stored at -20°C until needed. 
 
Drug Mode of 
action 
Supplier, 
Catalogu
e number 
Concen-
tration 
Solvent Volume 
added 
to 2mL 
MiR05 
Final  
concen-
tration 
Digitonin Cell perme-
abiliser 
Sigma 
D141 
10mg/mL DMSO 1µL 4µM 
(L)-malic acid Complex I 
substrate 
Sigma 
M1000 
107mg/mL Water 5µL 2mM 
(L)-glutamic 
acid 
Complex I 
substrate 
Sigma 
G1626 
374mg/mL Water 10µL 10mM 
ADP fATPase 
substrate 
Sigma 
A5285 
245mg/mL Water 5µL 1.2mM 
Succinic acid Complex II 
substrate 
Sigma 
S2378 
270mg/mL Water 20µL 10mM 
Rotenone Complex I 
inhibitor 
Sigma 
R8875 
0.059mg/m
L 
Ethanol 1µL 0.05µM 
Oligomycin fATPase 
inhibitor 
Sigma 
O4876 
4mg/mL Ethanol 1µL 2.5µM 
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Figure S1  Chemical structures of sphingolipids used to treat cells 
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Figure S2  Chemical structures of drugs affecting sphingolipid metabolism 
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Figure S3  Chemical structures of other drugs used in this chapter 
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Integration 
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Chapter 1 introduced the cellular manifestations of Niemann-Pick type C disease as 
originating with mutations in a protein of late endosomes and lysosomes and with 
pathology not limited to those organelles but rather spreading to ER, mitochondria 
and nucleus.  This widespread dysfunction calls for an integrated approach which 
was not possible at the start of this work as links between different aspects of the 
disease were largely unclear.  This chapter attempts to connect the various disease 
aspects studied here with very recent work and so to articulate such a synthesis 
asking also how it illuminates future treatment approaches. 
 
Summary of findings 
The accumulation of cholesterol in the late endolysosomes (LELs) of NPCD cells 
triggers the secondary storage of other lipids.  Chapter 2 used computational tools 
to suggest that one of these lipids, sphingosine, might accumulate because it is a 
substrate for the NPC proteins. This chapter also examined how other lipids might 
interact with proteins key to the functions of LELs and found numerous lipid-protein 
interactions with likely negative functional consequences.  The implication of this is 
that successful treatment of NPCD probably requires a reduction in LEL cholesterol; 
how that can be achieved clinically is currently unclear. 
 
Chapter 3 examined inhibition of GBA2, the only approved treatment of NPCD 
available at this time; it found that the treatment restores key endocytic functions 
included LEL pH.  This effectiveness was postulated to arise because GBA2 is 
upregulated in NPCD for unknown reasons; inhibition restores normal function, in 
particular enriching the depleted pool of glucosylceramide on the cytosolic face of 
membranes and so, perhaps, activating vATPase.  GBA2 inhibition was found 
ineffective in some related disease but provisionally useful in others. 
 
Chapter 4 studied respiratory dysfunction in NPCD and found that it was not 
corrected by GBA2 inhibition, perhaps explaining why such a treatment approach is 
only partially clinically effective.  The idea that sphingolipid manipulations more 
generally could correct respiratory defects in NPCD was not upheld by experiment.  
While the support it offered was only qualified, this chapter did not contradict the 
widely held, though unproved, hypothesis that cholesterol overload poisons 
mitochondria.   
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More recent work 
 
And you see it all, and you've worked it out 
And you see it all, and you want to shout 
REM 
Aftermath 
 
Since the completion of the work contained in this thesis two papers have been 
published that offer significant insight into the disease process.  The first of these674 
showed that cholesterol transfer occurs at ER-endosome contact sites and that 
NPC1-deficiency results in a reduction in these contacts and a corresponding 
increase in endosome contacts with mitochondria.  In principle this potentially 
explains almost every aspect of the disease.  If there are fewer contacts between 
endosomes and the ER then there will be a reduction in cholesterol at the ER causing, 
indirectly, the translocation of SREBP to the nucleus and increases in genes related 
to cholesterol synthesis and uptake (Chapter 1, Figure 2).  However, communication 
between LELs and ER is bidirectional as the ER is the source of the Ca2+ required 
for endolysosomal calcium refilling.52,56  Adequate LEL calcium is necessary for 
correct endocytosis (Chapter 1, Figure 1), functional autophagy,93 lysosomal genetic 
regulation via calcineurin and TFEB (Chapter 1, Figure 2) and possibly correct 
lysosomal acidification.  Reduced endosome-ER contacts therefore impair all of 
these processes.  In exact contrast, increased endosome-mitochondria contacts will 
likely overload the respiratory centre with cholesterol, postulated to be toxic to its 
normal function.  Seen in these terms it is quite possible that defective NPC1 protein 
leads not to reduced cholesterol export but to its misdirection away from the ER and 
to the mitochondria.  If mitochondria have a lower capacity for processing 
cholesterol than does the ER, then congestion will result leading ultimately to 
lysosomal storage of cholesterol.  Thus this study674 found that some disease 
manifestations could be corrected by forcing an endosome-ER tether, which adds to 
the already extensive list of means noted in Chapter 1 for normalising cholesterol 
export from lysosomes of NPC1-deficient cells.41,216,217,264,266–268   
 
The second paper675 studied yeast NPC1 orthologue ncr1 which it showed was 
responsible for the export of ergosterol from the vacuole.  Structural work showed 
the NTD in a conformation not previously observed for NPC1, but correctly oriented 
to deliver a sterol to a site intermediate between NTD and SSD; ergosterol was found 
in this site in the crystal (Figure 1).  This 'tunnel' site is formed from the MLD and 
CTD (Chapter 2, Figure 7) and so is consistent with other work338 suggesting the 
CTD is necessary for cholesterol export (it does not necessarily contradict another  
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Figure 1  Two views of S. cerevisiae ncr1 (PDB: 6r4l)  (A) Full length protein 
showing the NTD (blue), the ergosterol molecule (orange, ringed) in the tunnel 
binding site and Pro622 (pink) the yeast equivalent of Pro691 to mark the SSD.  
(B)  There appears to be nothing obstructing the movement of ergosterol 
(orange) from the tunnel binding site where it was found in the crystal to the 
SSD marked by Pro622 (pink). 
 
study339 arguing that cholesterol export requires dimerisation of NPC1).  The idea 
expressed in Chapter 2 that the relay mechanism of cholesterol export is a way of 
getting the lipid through the highly polar glycocalyx that lines the inside of the 
lysosomal limiting membrane is very much supported by this new study.  Very recent 
work established LIMP-2 as an alternative lysosomal cholesterol exporter which 
appears to have a similar hydrophobic tunnel.676  The structure of ncr1 (PDB: 6r4l) 
suggests that the questions raised in Chapter 2 about the function of the non-SSD 
TMHs present in NPC1 are not entirely appropriate.  The small luminal loops of 
NPC1 are likely to be necessary to hold the MLD and CTD in place, the function of 
the TMHs is to secure the loops.  Figure 2 shows an updated version of the 
cholesterol export narrative introduced in Chapter 2 Figure 7. 
 
Thus NPC2 binds to the MLD of NPC1 (Figure 2, ❶) and delivers cholesterol to the 
NTD (Figure 2, ❷) before rearrangement of the protein allows transfer to the tunnel 
site (Figure 2, ❸).  From here there are at least two possibilities.  A larger 
rearrangement may open a channel through the middle of NPC1 allowing cholesterol 
to traverse the protein (Figure 2, ❹) and presumably be collected by a cytosolic 
carrier.  This has previously been suggested by analogy with a similar protein460 and 
also on computational grounds,346 though Chapter 2 noted serious reservations about 
the latter study deriving from the likely inaccuracy of the protein structure used.  If 
cholesterol follows this pathway in the manner shown (rather than rotating inside 
the protein) then it will emerge tail-first from NPC1 and therefore probably enter  
A B 
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Figure 2 Cartoon of cholesterol export by the NPC system  NPC1 co-
operates with NPC2 and possibly ABCA1 to export cholesterol from the 
lysosome.  For details see text. 
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the lipid-binding cavity of any cytosolic carrier protein tail first.  This imposes 
constraints on the identity of that protein - it almost certainly cannot be a StAR (see 
Chapter 4) and perhaps cannot be an Aster, despite the reported interaction of a 
member of this family with NPC1,674 as they appear to bind cholesterol with the 
same geometry as the StAR proteins.677  It could be ORP5 though conflicting results 
have been reported on NPC1-ORP5 interaction.109,674  (Depending on just how much 
conformational flexibility NPC1 has this alternative opens the possibility that the 
protein may export molecules larger than cholesterol, such as glucosylceramide, 
though the issue of how such lipids are transported to NPC1 when they are too large 
for NPC2 is a problem.)  The second possibility (Figure 2, ❺) is that cholesterol 
moves from the tunnel site to the SSD (the binding sites appear to be aligned 
correctly to allow this, Figure 1B) where it would likely bind approximately as 
calculated in Chapter 2 before diffusing away from the protein and into the 
membrane (Figure 2, ❻).  On this model the completion of cholesterol export is 
regulated by ABCA1 which, it is largely unappreciated, localises to endosomes678 as 
well as the cell membrane.  Furthermore, detailed investigations suggest that ABCA1 
is not, as is usually assumed, a cholesterol transporter; rather cholesterol movement 
is a secondary effect resulting from the ability of ABCA1 to translocate ('flip') other 
lipids, particularly sphingomyelin (SM).129,678,679  Consistently, cholesterol 
distribution in membranes was recently found to be dependent on SM molecules 
with a rather specific chain length.680  Thus we may hypothesise that endosomal 
ABCA1 flips SM and cholesterol follows (Figure 2, ❼) driven by the energetically 
favourable interactions276 between the two.  This might also explain why ATP 
production increases on blocking ABCA1 with probucol (Chapter 4, Figure 13).  
Tentatively, this also offers another alternative mode of action for AMP-DNJ.  If 
ABCA1 flips GlcCer as well as sphingomyelin, and if cholesterol can follow GlcCer 
as much as sphingomyelin (both reasonable assumptions but currently untested) then 
GlcCer on the cytosolic face of the lysosomal membrane can regulate post-NPC1 
cholesterol transport.  It follows that increasing this pool of lipid with AMP-DNJ will 
increase cholesterol export with the consequent relief of lysosomal pathology as 
found in Chapter 3. 
 
This narrative still leaves some questions unanswered.  Figure 2 omits the putative 
cytosolic facing binding site for cholesterol and the possible collection of the lipid 
from there by StARD3 (Chapter 2, Figures 8 and 12) as these currently lack direct 
validation from in vitro lab experiments.  It is worth noting that endosome 
mitochondria contacts were found to be dependent on StARD3674 so further 
investigations may support this as a third route of cholesterol export.  Perhaps more 
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significantly for the work reported here the issue of sphingosine (Sph) is unresolved.  
The accumulation of Sph in lysosomes of cells deficient in NPC154,114,347 suggests 
either that this is a secondary effect of cholesterol storage or that Sph can use the 
same export machinery as cholesterol.  Chapter 2 favoured the second hypothesis 
but designing an experiment to distinguish these two potential mechanisms will be 
hard.  In any case the pathological consequences of sphingosine accumulation are 
currently unclear.  Perhaps most importantly the reasons for the aberrant contact site 
populations674 discussed above have not yet been clarified.  It is currently no more 
than speculation to think that this contact site error can be explained, by some 
unknown mechanism, by the role of the MLD and CTD in forming the tunnel binding 
site, though the regulation of lysosomal proteins461 (including cathepsin D) by this 
part of NPC1 might be the beginnings of a coherent story. 
 
The contact site findings also offer us a new way of thinking about pharmacological 
treatment.  If the principle defect in NPCD is endolysosomes contacting the wrong 
organelle then the task of therapy is to reduce those contacts and re-establish correct 
ones.  This suggests that AMP-DNJ is only partially successful because, though it 
has benefits for the lysosome (Chapter 3, Figure 4), it does not sufficiently disrupt 
lysosome-mitochondria contacts.  Such contact disruption may be achieved by first 
identifying the proteins involved – early studies have identified rab7 in human cells71 
and the Vam6-Vps39 pair in yeast614 (see also681) – and then asking how to disturb 
their interactions with partner proteins.  Whether such a tactic would be enough to 
provoke the endolysosome into re-establishing contacts with the ER is unclear.  
While the claim to see all of NPC biology is certainly premature and possibly wildly 
optimistic it is also true that further studies along these lines may lead both to 
successful treatment and to solving the mystery of NPC1. 
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